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This section

provides a medium through which Canadian
surgeons can declare themselves, briefly and in
formally, on the day-to-day affairs of surgery.

MODERN TREATMENT OF BONE TUMOURS
Our understanding of bone tumours has
shown a steady increase and consequently
our ability to treat them rationally and
successfully has made noteworthy progress
as is indicated by the series of papers from
the fourth annual conference on the clinical
application of basic sciences that appear in
this issue of the journal. During the early
days of modern surgery, the management of
bone tumours was hampered by lack of
knowledge. The clinical, radiologic and
microscopic criteria that were developed
and the various tumour entities that were
delineated just before and after World War
II resolved much of the previous confusion
and made possible a satisfactory classifica
tion of bone tumours that provides a basis
for investigators and clinicians to communi
cate their results to one another. The classi
fication presented by K. K. Unni in this
issue (page 504) is the one generally ac
cepted and it is not likely to be appreciably
modified in the future.
Progress has also been made in under
standing the etiology of some of the malig
nant tumours of the osseous system. It has
been recognized for some time that ionizing
radiation can cause malignant disease. Trau
ma as an etiologic factor has long been
suggested by the clinical history of some
cases and experimental work now indicates
that a viral etiology is not outside the realm
of possibility. However, it must be recog
nized that the experimental work that has
been carried out so far is important more
because of its future promise than for any
actual assistance it has been to the patient
suffering from malignant disease. The
existence of experimental models has pro
vided a more solid foundation for the modern
approach to therapy by permitting the estab

lishment of controlled situations that would
not be possible in clinical practice.
A better understanding of the host re
sponse to tumours has provided exciting and
convincing evidence that there are indeed
defence mechanisms for the destruction of
tumours or the limitation of their growth.
This had been suggested many years ago and
now appears to be established as fact. Once
more there can be hope that a better under
standing of these processes will allow more
rational manipulation of the natural defences
and perhaps better therapeutic results.
Finally, the combination of newer meth
ods of therapy, immunologic and chemothe
rapeutic, together with aggressive surgical
resection and often replacement with either
custom-made parts or allografts, give hopes
for the future. Surgical extirpation of malig
nant tissue remains the best means of cure.
Aggressive surgery for metastases combined
with chemotherapy to prevent the develop
ment of further spread of the tumour has
in some centres obtained gratifying results.
Where surgical ablation of the tumour would
otherwise lead to unacceptable loss of func
tion of a limb, replacement with a prosthe
sis or a graft has also given early promise.
Several facts have become apparent in
assessing the present status of the manage
ment of bone tumours. In the first place,
such tumours are rare. If real progress is to
be made in their management, regionaliza
tion of facilities must be accepted in order
that sophisticated therapy can be made
available to all. This is the only way in
which meaningful data can be obtained
about the results of therapy. Secondly, it is
nO longer possible for one individual to
supply the total management of all aspects
of bone tumours. A multidisciplinary ap-
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tumours but are actually quite different from
lesions of other parts of the body. A second
hope is that we may be able to form a true
assessment of the effects of the types of
therapy described in the following articles,
both on the tumour and on the individual.
Only time will tell whether aggressive sur
gical resection accompanied by replacement
of the resected part will give long-term
satisfactory results.
R. L. C ruess , m d , frcs [c]
Professor and chairman,
Division of orthopedic surgery,
McGill University,
Montreal, PQ.
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proach is mandatory in order to bring the
greatest expertise to each individual pa
tient. Finally, it must not be forgotten that
the quality of life of the survivor after he
has received treatment for cancer is of great
importance. This area is frequently neglected
and must be taken into account in order
that the patient and his medical team may
make rational decisions.
The papers published in this issue pre
sent many aspects of the status of presentday therapy of some selected tumours. It is
hoped that future work will give us a better
understanding of the etiology of not only
malignant disease but some of the lesions of
the musculoskeletal system that are called

GLIMPSES OF SURGICAL HISTORY:
R FOR RELIGION AND ROYALTY
DAVID A. E. SHEPHARD

In his caves and forest haunts, primitive man
attributed disease to human possession by
demons. The remedy was to cast out the evil
spirit through the agency of the good —
priests and kings. Thus were early medicine
and surgery shaped by RELIGION and
RO YALTY.
In Babylon and ancient Egypt priests and
physicians were as one; temples served the sick
as well as God. But the priest-physicians served
medicine in another way: they kept alight the
lamp of medical learning in the corridors of
time, which were swept by the winds of magic.
In time, however, it was the religious view
that disease reflected divine purpose, with the
intellectual emphasis solely on theological
matters, that made the lamp flame weakly.
Until scientific learning was accepted as fruit
ful, heretics and heathens kept the lamp
aburning. Today, hospital chaplains are there
fore welcome cohealers with surgeons and
other physicians.
Kings and emperors were healers too: the
“royal touch” for scrofula demonstrated one
aspect of the divine right of kings — though
the father of English surgery, Richard Wise
man (1622-76), showed what mere mortal
surgeons could do for citizens who did not
have the benefit of the royal touch. William

Ill of England, too, was aware that the royal
touch had suggestive rather than divine
powers: to the few citizens he did touch he
expressed the good advice, “God grant you
better health and more sense,”
Royal rulers have influenced medicine and
surgery in various ways. Some Chinese em
perors were investigators as well as editors
and authors. Shen Nung, about 3000 BC,
was one such: he experimented on himself
with drugs and poisons and compiled The
Great Herbal, an English edition of which was
published as recently as 1911. Hwang Ti, about
2500 BC, wrote the Nei Ching, in which he
stated that “all the blood in the body is under
the control of the heart.. . . The blood current
flows continuously in a circle and never stops.”
In the West, kings and queens supported
medicine by patronizing the medical profes
sion: the first royal medical college was
formed in 1551, after Henry VIII had granted
letters patent to Thomas Linacre. The sur
geons’ royal college in England was formed
in 1800, the Company of Barber Surgeons in
1540.
But monarchs, who were also mortals,
needed medical care. Thus we find expressions
such as a la reine attached to anesthesia. And
no doubt Simpson, when anesthetizing Queen
Victoria, called on the double powers of reli
gion and royalty to help him in his courtly
task — and the queen herself on her own re
markable powers.
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SELF-ASSESSMENT
SESAP II QUESTION

609. The roentgenogram shown above demonstrates changes in the distal end of the
femur of an 18-year-old girl. A diagnosis is established by biopsy.
If there is no evidence of distant metastases, the treatment of choice for this patient is
(A)
(B)
(C)
(D)
(E)

hemipelvectomy
disarticulation of the hip
irradiation and chemotherapy
irradiation followed by midthigh amputation
midthigh amputation alone

For this incomplete statement select the one completion that is BEST from those noted
above.
For the critique of Item 609 see page 575 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Syllabus:
Surgical Education and Self-assessment Program No. 2.)
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MODERN CONCEPTS OF BONE TUMOUR TREATM ENT

INTRODUCTION

H. K. UHTHOFF, MD, FRCS[C]* and J. E. HARRIS, MD, FRCP[C], FAC Pt

progress in the diagnosis and treat
ment of malignant tumours of bone has
markedly improved the prognosis in disease
once thought to be fatal, especially in
younger persons. It is not so long ago that
surgical intervention was considered by
many to be practically futile, and survival
of a patient for more than 5 years was
grounds for doubting the original diagnosis.
Better treatment can be achieved only
through a clear understanding of the basic
principles involved, and therefore the divi
sion of orthopedic surgery, University of
Ottawa, in collaboration with the service
of oncology and in association with the
Royal College of Physicians and Surgeons
of Canada, organized in May 1977 an ap
plied basic science course entitled “Modern
Concepts of Bone Tumor Treatment”.
An outstanding faculty of internationally
known experts came to Ottawa to discuss
refined methods of diagnosis and diverse
modalities of treatment. It became clear
from their presentations that in treating pa
tients with malignant disease a multidisci
plinary approach is mandatory. This pro
duces results so gratifying that for the first

R ecent

*Chief, department of orthopedic surgery, Otta
wa General Hospital, Ottawa, Ont.
tDirector, laboratory
General Hospital.

of

immunloogy,

Ottawa

Reprint requests to: Dr. H. K. Uhthoff, Chief,
department of orthopedic surgery, Ottawa General
Hospital, Ottawa, Ont. K IN 5C8.

time one dares to speak about cure of ma
lignant bone tumours. Moreover, when
surgery is indicated, the use of prostheses
makes it possible to avoid the mutilation
that once would have resulted from exten
sive resection of tissue. In large part these
advances have been made possible through
early postsurgical intervention with new
programs of adjuvant chemotherapy. The
introduction into clinical use of agents such
as doxorubicin (Adrianmycin) and the grow
ing experience with high-dose methotrexate
therapy followed by citrovorum factor
rescue have provided effective treatment in
patients who have minimal residual disease
following surgical resection of bone tu
mours. For the first time, too, beneficial
chemotherapy has become available for pa
tients with bone tumours who have disse
minated disease. The influence of these wel
come developments is becoming evident in
the increased duration of disease-free in
tervals and prolongation in patients’ survival.
This new and exciting area in the treatment
of cancer by chemical agents is considered
in detail in the papers that follow. New in
sights into the etiology and immunology of
bone tumours and their possible application
to future programs of chemotherapy or
chemoimmunotherapy also receive attention.
We are grateful to all the participants in
the symposium for their outstanding con
tributions and to the coeditors of the Cana
dian Journal of Surgery for enabling us to
publish many of the papers presented.
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BONE SARCOMAS: ETIOLOGY AND IMMUNOLOGY*
JOSEPH G. SINKOVICS, MD, FACP,t HARIKISHAN THOTA, PhD,t JIMMY
J. ROMERO, BS and RUTH WALDINGER, RN
The etiology of skeletal sarcomas is found in
exogenous agents (irradiation, oncornavirus) act
ing in a peculiar setting of host factors. Patients
with skeletal sarcomas react immunologically to
autologous and allogeneic sarcoma cells, but
reactors can be found among the healthy persons
with or without exposure to patients with sar
comas. Various modalities of immunotherapy are
available to increase the patient's immune reac
tivities in general or to sarcoma cells in partic
ular, but immunotherapy of skeletal sarcomas
has not yet brought about clear-cut and sub
stantial benefits in addition to or beyond the re
sults of conventional treatment.
L'etiologie des sarcomes du squelette se retrouve dans certains agents exogenes (irradia
tion, virus oncorna) agissant a I'interieur d’un
ensemble particulier de facteurs endogenes. Les
patients souffrant de sarcome du squelette reagissent immunologiquement a des cellules sarcomateuses autologues et allogenetiques, mais
les repondants peuvent etre retrouves parmi les
personnes saines, avec ou sans contact avec
des patients atteints de sarcome. Divers modes
d'immunotherapie sont disponibles pour augmenter chez le patient la reponse immunologique non specifique, ou specifique aux cellules
sarcomateuses en particulier, mais I’immunotherapie des sarcomes du squelette n'a pas
encore procure de benefices evidents ou substantiels, ajoutes ou superieurs aux resultats du
traitement conventionnel.
T he etiology of skeletal sarcomas profound

induced by viruses in man (as they are in
mice) it should be possible to identify crossreactive sarcoma-specific antigens and to
use these to monitor the host’s immune
reaction to the tumour, quantitate the tu
mour burden and offer a prognosis for the
disease. Such antigens may also be useful
for immunotherapy.
E tiology

Overlapping Features of Sarcomas
Tumours originating in the mesenchymal
cells of osseous or cartilaginous structures
cannot be regarded as distinct from sar
comas originating in soft tissues. These
tumours exhibit overlapping features as the
undifferentiated mesenchymal cells of ori
gin reach various degrees of differentiation
towards connective tissue (fibroblasts), fat
tissue (lipocytes), muscle (striated and
smooth muscle myocytes), and cartilage and
bone (chondrocytes and osteocytes). Two
examples of this overlap are osteocytic and
chondrocytic tumours originating in soft
tissues1"5 and chondrocytic elements in
metastatic soft tissue sarcomas such as cystosarcoma phylloides.4
Induction by Radiation

The etiology of sarcomas is unknown.
Trauma is often recorded as preceding sarcomagenesis. Since bone infarcts have been
shown to give rise to osteogenic sarcomas in
*From the section of clinical tumor virology and man,5 trauma cannot be dismissed as a
immunology, department of medicine, The Uni
possible etiologic factor in the development
versity of Texas System Cancer Center, M. D.
Anderson Hospital and Tumor Institute, Houston, of sarcomas. On the other hand, one may
TX.
surmise that trauma is coincidental and that
Supported by the Kelsey-Leary Foundation of subclinical sarcoma existed before the in
Houston and by Biomedical Research grant no.
jury.
RR511-14, allot. BR-04.
The best documented physical factor in
Presented at the conference “Modern Concepts
of Bone Tumor Treatment”, Ottawa, Ont., Mav sarcomagenesis in man, especially in the
12 and 13, 1977.
etiology of osteogenic sarcoma, is ionizing
tInvited guest lecturer of the Royal College of
radiation either in the form of bone-seeking
Physicians and Surgeons of Canada.
radionuclides or external irradiation.5' 6
t Deceased.
Numerous reports of radiation-induced sar
^ P ™ 1; requests to: Dr. J. G. Sinkovics, Section
ot clinical tumor virology and immunology, de- comagenesis in man have been published.
partment of medicine, M. D. Anderson Hospital
In some, massive doses of irradiation
and lumor Institute, Houston, TX 77030, USA.
(13 000 rad for retinoblastoma), in others
ly influences the immunology of the hosttumour relationship. If these tumours are
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minimal doses of irradiation (800 rad for
bursitis)7 resulted in the later development
of osteogenic sarcoma. Postirradiation osteo
genic sarcomas originate in extraosseous tis
sues: in the peritoneum and abdominal
cavity after radiotherapy for colonic, uterine
cervical or ovarian carcinoma;8* '*’ and at
the base of the brain (suprasellar) after ra
diotherapy for pituitary tumours.10 The de
velopment of true osteogenic sarcoma may
follow successful radiotherapy for Ewing’s
sarcoma.11 Therapeutic irradiation can also
give rise to chondrosarcomas.12*13
Host Factors

The most remarkable host factors influ
encing sarcomagenesis in man are von
Recklinghausen’s disease, Paget’s disease,
Albright’s syndrome, Ollier’s disease and
Maffucci’s syndrome.14*13 The association
of osteogenic sarcoma with Paget’s disease
is remarkable. The incidence of osteogenic
sarcoma in the general population of West
ern countries occurs in two peaks: the first
occurs in the 2nd decade, the second in
more advanced age groups. The second peak
of incidence may be correlated with Paget’s
disease. In Japan, where the incidence of
Paget’s disease is very low, the second peak
of osteogenic sarcoma is absent.14 Paget’s
disease has recently been attributed to a
slow virus infection inasmuch as possible
subviral structures were observed in the
nuclei and cytoplasm of osteoclasts from
patients with osteitis deformans.10 Paget’s
disease alone has been considered to be a
malignant disease of osteoclasts17 and it is
somewhat responsive to treatment with
mithramycin, actinomycin D and, sympto
matically, to salmon calcitonin. Chondro
sarcomas frequently arise from enchondromas of Ollier’s disease.13 However, the
most important factors in sarcomagenesis
may be viral and immunologic.
Oncornaviruses

Oncornaviral etiology for human sarco
mas (including osteogenic sarcoma) may be
considered on the basis of a number of ex
perimental data. The most important of
these are the phenomena of antigenic con
version and focus formation.18-20 When
cell-free filtrates of human sarcomas are
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inoculated into cultures of normal human
fibroblasts, some of these fibroblasts begin
to express new antigens that were not pre
sent in uninoculated fibroblasts; these anti
gens react in immunofluorescence tests with
antisera directed towards human sarcoma
cells. Furthermore, some of the inoculated
fibroblasts undergo a change in their growth
pattern and relation to neighbouring cells;
these “transformed” fibroblasts assume a
rounded shape and pile up on each other,
disregarding contact inhibition and thus
growing in foci.21 These changes can be
explained best by the transfer from sarcoma
cells to the fibroblasts of an oncogenic viral
genome. Genome fragments of oncornavi
ruses have been actually demonstrated in hu
man sarcoma cells,22 but a fully character
ized virus strain has not been isolated from
human sarcomas. The sighting of oncor
navirus particles or possible subviral struc
tures23 in an occasional sarcoma cell or in
a tissue culture cell line derived therefrom
is the weakest argument for viral etiology
in so far as nononcogenic endogenous on
cornaviruses also exist in both normal and
tumorous tissues.
Strong supporting evidence for the on
cornaviral etiology for human sarcomas (in
cluding osteogenic sarcoma) comes from the
animal world. Not only avian species carry
well-known oncogenic viruses, but small
mammals, New World monkeys and apes
also yield well-characterized oncogenic on
cornaviruses; most of these viruses cause
leukemias and lymphomas, but true oncor
navirus-induced soft tissue and skeletal
sarcomas have been identified in mice, rats
and lagothrix (woolly) monkeys. Most of
the sarcomagenic viruses of animals are in
complete and cannot code for the synthesis
of the viral envelope in the host cells. There
fore, although the viral genome is present
in the host cell, no mature virions are
formed; that is, most of these sarcomas are
nonproducers of virus. Coinfection with
leukemia viruses contributes the viral ge
nome fragment necessary for the synthesis
of viral envelopes. Host cells coinfected with
sarcoma and leukemogenic oncornaviruses
release fully mature, enveloped sarcomagenic
viruses. Among the attempts to apply this
principle for the rescue of a hidden human
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sarcoma virus, one of the most remarkable
is the inoculation of cultured human sar
coma cells with human leukemia cells. In
teresting cell transformations and antigenic
changes occur in these cultures, 24 but
neither the visualization nor the isolation or
identification of a human sarcoma virus has
so far been accomplished.
Other evidence for the possible viral
etiology of human sarcomas derives from ex
periments in hamsters. The incidence of
“spontaneous” osteogenic sarcomas in most
hamster colonies is exceedingly low. How
ever, after the inoculation of filtrates from
human osteogenic sarcomas, several ham
sters developed osteogenic sarcomas. 25 Sera
from patients with osteogenic sarcoma re
acted immunologically with the hamster
osteogenic sarcomas; thus it can be implied
that these tumours were induced by a hu
man osteogenic sarcoma virus. 26
I mmunology

and

I mmunotherapy

Immune Assays Claimed to be TumourSpecific
A strong argument for the immunosurveillance of the host against tumour cells is
to be found in the increased incidence of
leukemias, lymphomas and some other tu
mours in naturally immunodefective indi
viduals or in immunosuppressed recipients
of organ transplants. With the exception of
Kaposi’s sarcoma, sarcomas are not among
those tumours whose incidence has been
recorded as increasing in immunoincompetent individuals. Nevertheless, strong evi
dence for both antibody- and cell-mediated
immune reactions against both soft tissue
and skeletal sarcomas in man has been do
cumented. The antibody-mediated reactions
are immunofluorescence,15’ 18’ 27- 2S com
plement fixation with soluble sarcoma an
tigens,31’ 32 agglutination of erythrocytes
coated with a soluble osteogenic sarcoma
antigen 33 and potentiation or blocking of
lymphocyte-mediated cytotoxicity.20’ 21> 34
The cell-mediated reactions are lymphocyte
proliferation in response to exposure to sar
coma cell membranes or soluble sarcoma
antigens, 33"35 lymphocyte- or macrophagemediated cytotoxicity15’ 20’ 34’ 36 and re
lease of migration inhibitory factor after
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exposure of lymphocytes to sarcoma anti
gens. 37 However, the question of what the
human sarcoma-associated antigens are is
still unresolved and controversial. Are these
antigens truly cross-reactive? And to what
extent? Among soft tissue sarcomas only?
Among soft tissue and skeletal sarcomas
with the exception of Ewing’s sarcoma? And
what is the meaning of the immune reactions
to these antigens in clinical terms? That is,
can these immune reactions be intensified
by immunotherapy to the benefit of the
host? The existence of virus-related or
virally coded human sarcoma antigen has
not so far been proved; instead, a wide re
activity to Forssman and embryonic anti
gens expressed by human sarcoma cells has
been demonstrated in the general popula
tion and in patients with various tumours,
among them soft tissue and skeletal sar
comas. 38"40 The reactivity of healthy in
dividuals exposed to sarcoma-bearing pa
tients is most conspicuous. 41'43 The exist
ence of a unique soluble osteogenic sarcoma
antigen has been demonstrated by absorbed
xenoantisera: antisera were produced in
rabbits immunized with extracts of human
osteogenic sarcoma; and it was demon
strated that the sera, after extensive absorp
tion with normal tissues, reacted with osteo
genic sarcoma extracts in vitro and with
osteogenic sarcoma cells in vivo, 44
General Immunocompetence
The general immunocompetence of pa
tients with sarcomas can be assessed in vivo
by skin tests to various recall antigens and
to primary antigens, such as dinitrochlorobenzene (DNCB) or keyhole limpet hemocyanin, and in vitro by antibody or by lymphocyte-blastogenic response to various anti
gens. It has been claimed that primary skin
sensitization to DNCB correlates with
clinical stage and prognosis, 45 but patients
with advanced melanomas or sarcomas may
retain their ability to react to this primary
antigen or to recall skin test antigens.46’ 47
Patients with soft tissue sarcomas yielded
lymphocytes reactive to phytohemagglutinin
(PHA); however, reactivity to concanavalin
A has been claimed to be reduced.48' 40
The immune reactivity of patients with
osteogenic sarcoma still remains controver-
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sial. One group50 has claimed that the lym
phocytes of these patients cannot distinguish
autologous osteogenic sarcoma cells from
normal fibroblasts, but reactivity to PHA is
intact. Another group51 detected a profound
defect in the reactivity of lymphocytes from
patients with osteogenic sarcoma to PHA;
the lymphocytes of patients with soft tissue
sarcomas reacted normally.51 These “non
specific tests” failed to correlate with the
clinical course of 50 patients with soft tissue
and skeletal sarcomas, but lymphocytemediated cytotoxicity as expressed against
cultured allogeneic sarcoma cells correlated
well with the patients’ clinical course.47
Experience with a Cytotoxicity Assay
Immunologic studies of human tumours
had a difficult beginning in our laboratories.
The results of lymphocyte-mediated cyto
toxicity assays, set against primary cultures
or early passages of sarcoma cells during
the second half of the 1960s were disap
pointing. Primary and early cultures con
tained too many fibroblast-like cells that
grew out well even when cytotoxicity to
wards small numbers of presumably neo
plastic cells was noticed. Thus the overall
view of the cultures did not express whether
or not cytotoxicity occurred.52 In one
study53 some preparations of lymphocytes
were found to be nonselectively cytotoxic
against a battery of different tumour cells
(this report contains the earliest description
of nonselectively cytotoxic human lympho
cytes). Though only a few healthy lympho
cyte donors were tested, reactors were found
among them.54 However, when, in 1968, a
patient with chondrosarcoma was found who
repeatedly yielded lymphocytes highly and
selectively cytotoxic to autologous tumour
cells but not to autologous fibroblasts,15- 55
it became possible to design an assay, first
in a Leighton tube and later in Lab Tek
chamber/slide cultures that quantitatively
measured lymphocyte-mediated cytotoxicity
against established human tumour cell lines;
this assay also measured serum factors
synergistic with (potentiating), or antago
nistic to (blocking), cytotoxic lympho
cytes.20, 30, 34 The interpretation of re
sults obtained with this assay was difficult,
because extensive cross-reactions between
unrelated human tumour cell lines56 and
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reactivity to human tumour cells in healthy
persons57 were also found. These nonselective immune reactions may be mediated
by “natural killer cells” or may be the re
sult of true tumour immunity that is unex
pectedly prevalent in the human population
on account of frequent exposure to tumour
viruses of low pathogenicity or frequent re
jection of incipient subclinical tumours.
Since these immune reactions were meas
ured against established allogeneic human
tumour cell lines, more trivial explanations,
such as immune reactivity to HLA, blood
group, Forssman, embryonic and bovine
protein antigens expressed by the target
tumour cells, are also possible. The overall
reactivity of patients with sarcomas, how
ever, was more frequent and stronger to
wards cultured sarcoma cells than towards
cultured carcinoma cells.58
Correlation of lymphocyte-mediated cy
totoxicity and its blocking or potentiation by
serum factors with the clinical course of the
patients was not always clear. Excellent
correlation was found in a few selected pa
tients, among them a patient with chondroblastic osteogenic sarcoma,59 and another
with a small round cell tumour with high
glycogen content (this tumour was first
thought to be a rhabdomyosarcoma, but was
established later to be an extraosseous
Ewing’s sarcoma).20 In other patients con
tradistinctions between the clinical course
and the cytotoxicity assay were evident.60
These could be attributed, among other
factors not clearly understood, to the growth
of sarcomas without the expression of
tumour antigens in the immunoreactive hu
man host.60
Tables I to III present a review of our
limited experience with lymphocyte-me
diated cytotoxicity assays as applied to the
evaluation of patients with bone sarcomas.
In these tabulations cytotoxicity measured
against carcinoma, melanoma, soft tissue
sarcoma, chondrosarcoma and Ewing’s sar
coma cell lines is expressed. These human
tumour cell lines, which were established in
our laboratories, have been described pre
viously.30, 54, 61 Unfortunately these pa
tients were not extensively tested against a
bona fide osteogenic sarcoma cell line for
the following reasons: cell line no. 2322
established in our laboratory was believed
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to have been derived from a patient with
chondroblastic osteogenic sarcoma; several
patients were tested against this cell line.
However, the tissue diagnosis in this case
was later revised to chondrosarcoma grade
3 (i.e., a tumour with numerous mitotic
figures). Accordingly, patients tested against
this cell line are listed in Tables I to III as
tested against chondrosarcoma (including
another bona fide chondrosarcoma cell line
of ours, no. 2454). An alleged human os
teogenic sarcoma cell line obtained from an
other laboratory was briefly introduced in
our assay system but was found to be con
taminated with mycoplasma and therefore
its use was discontinued (results obtained
with this cell line are omitted from Tables
I to III). Thus, these assays lack data ob
tained with osteogenic sarcoma target cells,
so that the interpretations offered should be
viewed as preliminary and incomplete. Pa
tients with chondrosarcoma (Table I) ap
peared to retain lymphocyte-mediated cy
totoxicity towards carcinoma cells not dif
ferent from the degree of cytotoxicity ex
pressed by healthy donors.57 Strong cyto
TABLE I.—C ytotoxic L ymphocytes

toxicity towards soft tissue and chondrosar
coma cells was expressed equally well.
Table II contains similar data; many pa
tients with osteogenic sarcoma retained lym
phocytes cytotoxic to carcinoma cells at
about the same level as that observed in
healthy individuals57 and though there is no
clear distinction, based on lymphocyte-me
diated cytotoxicity, between soft tissue and
chondrosarcoma target cells, strong reactions
(I reactions) were more numerous against
chondrosarcoma than against soft tissue
sarcoma cells.
Table III suggests that patients with
Ewing’s sarcoma form a unique group.
Lymphocyte-mediated cytoxicity was over
whelming towards our established Ewing’s
sarcoma cell line no. 1846;30 reactivity to
wards carcinoma cell lines was weak and
towards soft tissue and chondrosarcoma
cell lines was moderate. These data appear
to be in agreement with the existence of at
least one common human sarcoma antigen
(among many sarcoma-associated antigens)
and warrant the immunologic separation of
Ewing’s sarcoma from the classic bone sarof

21 P atients

with

C hondrosarcoma

Cytotoxicity mediated, by
Lymphocytes

Target tumour cells
Carcinoma/malignant melano
ma cell lines...........................
Soft tissue sarcoma cell lines. .
Chondrosarcoma cell lines. . . .

St-0
17
3
6

i

Serum and lymphocytes

i + 1/
no. blood
samples
tested CTX, %
/

6 3 9/26
2 5 7/10
10 10 20/26

35
70
77

Sl-0

i

14
2
6

5
4
6

i + 1/
no. blood
samples
I
tested CTX, %
7 12/26
3 7/9
14 20/26

46
78
77

St = stimulatory to growth of target cells; O = growth of target cells neither inhibited (< 25%) nor sti
mulated ( < 25% ); i = inhibition of growth (cytotoxicity), 25-50%; I = inhibition of growth (cytotoxicity)
> 51%; CTX = cytotoxicity.
TABLE II.—Cytotoxic L ymphocytes

of

19 P atients

with

O steogenic Sarcoma

Cytotoxicity mediated by
Lymphocytes*

Target tumour cells
Carcinoma/malignant melano
ma cell lines...........................
Soft tissue sarcoma cell lines. .
Chondrosarcoma cell lines . . . .
*For abbreviations, see Table I.

Serum and lymphocytes

i + 1/
'
no. blood
samples
tested CTX, %

St-0

i

I

10
2
9

7
4
5

1 8/18
2 6/8
15 20/29

44
75
69

St-0

i

11
1
8

4
4
5

/

i+I/
no. blood
samples
tested CTX, %

5 9/20
2 6/7
15 20/28

45
86
71
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TABLE III.—C ytotoxic Lymphocytes

of

14 P atients

with

499

E wing’s S arcoma

Cytotoxicity mediated by
Lymphocytes*

Target tumour cells
Carcinoma/malignant melano
ma cell lines...........................
Soft tissue sarcoma cell lines. .
Chondrosarcoma cell lines. . . .
Ewing’s sarcoma cell lines.......

St-0

i

/

14
6
6
0

3
0
3
3

0
4
2
6

Serum and lymphocytes

i + //
no. blood
samples
tested CTX, %
3/17
4/10
5/11
9/9

18
40
45
100

St-0

i

i + //
no. blood
samples
I
tested CTX, %

12
4
5
1

4
2
4
2

1
4
2
7

29
60
54
90

5/17
6/10
6/11
9/10

*For abbreviations, see Table I.
TABLE IV.—I mmune R eactions of a P atient with C hondroblastic Osteogenic Sarcoma
tured S arcoma (Sc) and C arcinoma (C c) C ell L ines

Sample
a ...................................................
b ...................................................
c ...................................................
d ...................................................
e ...................................................
f ....................................................
g ...................................................
h ...................................................

Target cell
lines tested
------------------Attacker
Type No.
cells
Sc
Sc
Cc
Cc
Sc
Sc
Cc
Cc

3
3
1
1
2
2
1
1

No. of
tests

L
SeL
L
S eL
Ly
Se Ly
Ly
Se Ly

11
11
5
5
8
8
3
3

% reduction
of target
cells, mean
47
57
12
24
0
54
—33*
10

to

C ul 

Significance
(Student’s
t test)
a vs. c, P < 0.05

e vs. g, P < 0.05

“Growth stimulation instead of inhibition.
L = leukocytes, Ly = lymphocytes; Se = serum.

comas (chondrosarcoma and osteogenic
sarcomas).
Table IV summarizes the results of
serially performed assays with the leukocytes
and lymphocytes obtained from a patient
with chondroblastic osteogenic sarcoma
who had an unusually long clinical
course.r’4' 59 The leukocytes or lympho
cytes of this patient reacted against sarcoma
cells better than against carcinoma cells; the
patient’s lymphocytes stimulated the growth
of carcinoma cells. Despite immune reac
tions displayed toward sarcoma cells and
despite the intensification of these immune
reactions after immunotherapy,”’4 this pa
tient succumbed to recurrent and metastatic
disease. The same fate befell a similar pa
tient whose sarcoma-directed immune re
actions increased after immunotherapy but
failed to arrest clinical progression of the
disease.62 In a young girl with osteogenic
sarcoma metastatic to the lungs, sarcoma
cells were distinguished from carcinoma
cells by the in vitro assay, and serum factors
potentiating lymphocyte-mediated cytotox
icity towards bone sarcoma cells were evi

dent; despite this favourable reaction pattern
she succumbed to advancing disease resist
ant to doxorubicin (Adriamycin) (Table V).
Table VI summarizes the test results in two
elderly men with metastatic chondrosarco
ma. In one patient chondrosarcoma and
carcinoma cells were clearly distinguished,
whereas in the other the reaction to chon
drosarcoma and carcinoma cells in the in
vitro assay was equal- Despite advancing
TABLE V.— I mmune R eactions of a P atient
with Osteogenic S arcoma to C ultured Sarcoma
and C arcinoma C ell L ines
Target cell
lines tested

Attacker
cells*

% reduction of
target cells,
mean

Osteogenic and
chondrosarcoma. . . . . L
Se L
Ly
Se Ly

83
73
14
41

Squamous carcinoma. . . L
Se L
Ly
Se Ly

36
44
—17f
10

*For abbreviations, see Table IV.
(Growth stimulation instead of inhibition.
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disease their lymphocytes exercised good
cytotoxic function towards allogeneic cells
in vitro. Patients with Ewing’s sarcoma
appeared to react vigorously towards soft
tissue sarcoma cells. In 1972 one patient
with a primary tumour in the right foot
metastatic to lungs and skull entered com
plete remission after radiotherapy and
chemotherapy with vincristine, cyclophos
phamide and actinomycin D, but in 1973
recurrent disease was resistant to doxoru
bicin and dimethyl-triazeno-imidazole car
boxamide. The leukocytes and lymphocytes
of this patient were highly reactive towards
various soft tissue sarcoma cells (Table VII)
but not towards carcinoma cells; a serum
factor potentiating lymphocyte-mediated cy
totoxicity toward sarcoma cells was opera
tional. Another young man with Ewing’s
sarcoma also yielded leukocytes or lym
phocytes reactive to sarcoma cells (including
Ewing’s sarcoma cell line no. 1846) but not
to a squamous carcinoma cell line. A serum
factor blocking lymphocyte-mediated cyto
toxicity towards the sarcoma cell lines was
demonstrated in correlation with progressive
disease (Table VII).
Similar immune reactions were detected
in family members of patients with skeletal
sarcomas, including Ewing’s sarcoma; four
families were studied (Kay HD, Thota H,
Sinkovics JG: Unpublished data). However,
some healthy blood donors also displayed
such reactions.57 One patient with Paget’s
disease reacted vigorously to cultured os
teogenic sarcoma cells, and one patient with

a giant cell tumour of the lumbar vertebrae
that became malignant after radiotherapy
and excision displayed a complete lack of
reactivity towards osseous and soft tissue
sarcoma cells (Kay HD, Thota H, Sinkovics
JG: Unpublished data).
In conclusion, antibody- and cell-medi
ated immune reactions both in autologous
and allogeneic settings are evident in pa
tients with skeletal sarcomas, but the rela
tion of these immune reactions to the pa
tients’ clinical course is unclear. Similar im
mune reactions are also detectable in
healthy individuals with or without known
contact with sarcoma-bearing patients.

Immunotherapy
Immunotherapy in patients with skeletal
sarcomas has not been rewarding, but it
holds promise for further development. The
following modalities of immunotherapy
have been applied: nonspecific immunostimulation with Coley’s toxin for Ewing’s
sarcoma and osteogenic sarcoma;63 active
tumour-specific immunization with x-irradiated tumour cells64 or tumour cell ly
sates65' 66 for osteogenic sarcoma in parti
cular; adoptive immunization with lympho
cyte transfer from donors who rejected a
transplanted tumour allogeneic to the tu
mour donor;67 transfer factor68’ 60 and in
terferon.70 Anecdotal case histories strongly
suggest that nonspecific immunostimulation,
especially with endotoxin-containing pre
parations, may be marginally beneficial in
the treatment of sarcomas in general,63

TABLE VI.'—I mmune R eactions of T wo P atients (W and B) with C hondrosarcoma
S arcoma (Sc) and C arcinoma (Cc) C ell L ines
Target tumour
cells tested
Attacker
cells*

No. of
tests

% reduction
of target
cells,
mean

Type

No.

a ...................................................

Sc

4

L

6

W 69
B 90

b ................................. ................

Sc

4

Se L

6

W 51
B 98

Sc

1

Ly

1

B 71
W 22
B 89

Sample

c ................................. ................

Cc

2

L

4

d ................................. ................

Cc

2

S eL

3

W 39
B 97

Cc

1

Ly

1

B 47

*For abbreviations, see Table IV.

to

Cultured

Significance
(Student’s
t test)
a vs. c, P < 0.01
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TABLE VII.— I mmune R eactions of T wo P atients (W and J) with E wing’s Sarcoma
Sarcoma (Sc) and C arcinoma (Cc) C ell L ines
Target tumour
cells tested
Sample
a ................................. ................

Type
Sc

Attacker
No. cells*
4

No. of
tests
12

L

% reduction
of target
cells,
mean
W

Sc

4

Se L

11

d ................................. ................

4
Sc

4

10

Ly
Se Ly

8
7

52
83

b vs, f, P < 0.001

18
41

c vs, d, P < 0.01

J
W
J

48
18

d vs, h, P < 0.05

W

29
19

e vs. g, P < 0.02

W
W

e ................................. ................

Sq Cc 1

L

t .................................. ................

Sq Cc 1

Se L

e.................................. ................

Sq Cc 1

Ly

5

h ................................. ................

Sq Cc 1

Se Ly

4

w -7 5 f
4
J

Ov Cc 1

L

1

w

14

Ov Cc 1

Se L

1

w

13

Ov Cc 1

Ly

1

w

2

Ov Cc 1

Se Ly

1

w

3

J
6

Significance
(iStudent’s
t test)
a vs. c, P < 0.001
a vs. e, P < 0.01

J
c .................................

C ultured

58
78

J
b ................................. ................

to

W -1 0 f
26

J

w

J

0
4

*For abbreviations, see Table IV. Sq Cc = squamous carcinoma; Ov Cc = ovarian carcinoma.
tGrowth stimulation instead of inhibition.

but tumour-specific immunotherapy with or
without nonspecific immunization has so
far failed to alter significantly the course
of skeletal sarcomas. 6 4 This is in contrast
with modest success claimed in the chemoimmunotherapy 71 and immunotherapy7 2 of
soft tissue sarcomas. Transfer factor appears
to have some effect in the suppression of
pulmonary micrometastases of osteogenic
sarcoma, but it is controversial whether this
effect is tumour-specific. One group 0 8
claims osteogenic sarcoma-specificity of
their transfer factor preparations, whereas
others0'-’ failed to confirm osteogenic sarco
ma-specificity in the effects of transfer fac
tor. Early results for the suppression of
subclinical micrometastases of osteogenic
sarcoma by large doses of human interferon
are also promising, 70 but a precise com
parison of treated and untreated groups of
patients as to prognostic factors (tissue subtypes of osteogenic sarcomas; locations of
primary tumours both in the bone, that is

whether intramedullary or parosteal, and in
the skeleton, for example, whether prox
imal or distal, extremity or torso) is needed
before final conclusions can be accepted.
The authors thank Mr. Jerry Cabiness for his
assistance in the lymphocyte-mediated immune
assays.
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CLASSIFICATION OF BONE TUMOURS*
KR1SHNAN K. UNNI, MB, BSt
Primary tumours of bone can be classified con
veniently into distinct groups based on the ap
pearance of the tumour cell, or its product, or
both. Almost all the groups have benign and
malignant counterparts. However, malignant bone
tumours usually do not arise from benign tu
mours. Although the cell of origin in many
tumours is unknown, the classification described
in this paper refers to well-defined clinicopathologic entities, so that the behaviour of a given
tumour can be anticipated. This classification
is accepted the world over and provides a “com
mon language” for those who treat patients with
bone tumours.
Les tumeurs osseuses primaires peuvent etre
commodement classifies en groupes distincts
a partir de la morphologie de la cellule tumorale
ou de son produit, ou des deux. Presque tous
les groupes ont des contreparties benignes ou
malignes. Toutefois, les tumeurs osseuses malignes n'originent habituellement pas d'une tumeur benigne. Bien que la cellule d’origine de
plusieurs tumeurs demeure inconnue, la classi
fication decrite dans cet article couvre des
entites clinicopathologiques bien definies, de
sorte que le comportement d'une tumeur donnee puisse-t-etre anticipe. Cette classification
est acceptee universellement et elle offre une
“langue commune” a ceux qui traitent des pa
tients atteints de tumeurs osseuses.

The classification of bone tumours used at
the Mayo Clinic1 is essentially the same as

the one proposed by Lichtenstein,2 and the
one adopted by the World Health Organiza
tion8 and used by the Armed Forces Insti
tute of Pathology.4 The classification is
based on the cytologic characteristics of the
tumour cells, or the product of the tumour
*From the department of surgical pathology,
Mayo Clinic and Mayo Foundation, Rochester,
MN.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont., May 12
and 13, 1977.
1'Consultant, department of surgical pathology,
Mayo Clinic and Mayo Foundation; instructor in
pathology, Mayo medical school, Rochester, MN.
Reprint requests to: Dr. K. K. Unni, Department
of surgical pathology, Mayo Clinic and Mayo
Foundation, Rochester, MN 55901, USA.

cells, or both (Table I). Although the cell
of origin of a given bone tumour cannot al
ways be determined, the classification re
fers to well-defined clinicopathologic en
tities and is both practical and comprehen
sible. This does not mean that malignant
tumours arise from their benign counter
parts; they hardly ever do.
H e m a t o po ie t ic T um ours

Tumours of bone-marrow origin are the
most common bone tumours in our files.
Myeloma predominates, but does not usual
ly require surgical intervention. A patient
with a “solitary” myeloma may survive for
several years without disseminated disease.5
Malignant lymphoma, like myeloma, may
originate in bone or may be part of a dis
seminated process. This differentiation is
clinically important because the probability
of survival for patients with “primary” lym
phoma of bone is approximately twice that
for patients with a similar bone tumour and
disseminated disease.6
It is usually easy to make a histologic
diagnosis of myeloma based on the charac
teristics of the cell. Abundant blue cyto
plasm and an eccentrically situated nucleus
with clumped chromatin are the main fea
tures. Malignant lymphoma usually has a
mixed cell population, consisting of reti
culum cells (histiocytes) and lymphocytes in
different stages of maturation.
C hondrogenic T um ours

Osteochondroma, which usually arises in
the metaphyseal region of long bones, is
characterized by a stalk made up of bone
covered by a cartilage cap. Like the epi
physeal plate the cartilage cap has cells
arranged longitudinally. The cartilage cells
“mature” towards the stalk to produce bone.
Enchondroma is seldom treated surgically
because it is rarely symptomatic. Most enchondromas requiring surgery are in the
small bones of the hands and feet, where
they often produce pathologic fracture. Ty
pically, they have a benign radiologic ap
pearance.
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TABLE I.—Classification

Type

of

B one T umours

by

H istologic T ype

Benign

Malignant

—

Myeloma
Malignant lymphoma

Hematopoietic

505

Chondrogenic

Osteochondroma
Enchondroma
Chondroblastoma
Chondromyxoid fibroma

Chondrosarcoma
Primary
Secondary
Dedifferentiated
Mesenchymal

Osteogenic

Osteoid osteoma
Osteoblastoma

Osteogenic sarcoma
Conventional
Osteoblastic
Chondroblastic
Fibroblastic
Telangiectatic
Well-differentiated
Parosteal
Periosteal

Unknown origin

Benign giant cell tumour
Benign (fibrous)
histiocytoma

Malignant giant cell tumour
Ewing’s tumour
Adamantinoma
Malignant (fibrous)
histiocytoma

Fibrogenic

Fibroma

Fibrosarcoma

Desmoplastic fibroma
—

Notochordal

Chordoma

Vascular

Hemangioma

Hemangioendothelioma
Hemangiopericytoma

Lipogenic

Lipoma

Liposarcoma

Neurogenic

Neurilemmoma

Neurofibrosarcoma

The cells are arranged in small clusters
within lacunar spaces. The chondrocyte has
a small inconspicuous nucleus; double-nu
cleated cells are uncommon.
Chondroblastoma occurs characteristical
ly in the epiphyseal areas of young persons
and is characterized by mononuclear cells
with a sprinkling of benign giant cells. Chon
droblastomas are differentiated from benign
giant cell tumours by the presence of islands
of cartilage or of peculiar “guttate” calci
fication between the tumour cells.
Chondromyxoid fibroma, which is prob
ably related to chondroblastoma, occurs
typically on the metaphyseal side of the epi
physeal plate and, radiologically, has a
benign appearance. Histologically, the le
sion is tabulated and has a chondroid or
myxoid background. Within this background
are stellate-shaped cells. The cells are more
tightly packed towards the periphery of the
lobules.

Chondrosarcoma is the most common
malignant tumour of the chondrogenic
group. It is predominant in adults and is
usually situated in the metaphysis where it
arises from within the medullary cavity.
Generally, the radiologic appearance sug
gests erosion at the endosteal surface of
bone. Well differentiated chondrosarcomas
can be extremely difficult to differentiate
from enchondromas. Chondrosarcomas are
more cellular than enchondromas. The
nuclei are larger than normal, and doublenucleated cells are prominent. The poorly
differentiated chondrosarcoma is relatively
easy to diagnose histologically because of
the presence of bizarre nuclei and many
double-nucleated cells. Secondary chondro
sarcomas are those that arise within a pre
existing benign condition, most commonly
within an osteochondroma. The true in
cidence of malignant change in an osteo
chondroma is difficult to assess, but is
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diagnosed on the basis of increased thick
ness of the cartilage cap (particularly in an
adult) and cytologic changes of malignancy
in the cartilage cap.
Dedifferentiated chondrosarcoma is a
well-recognized entity.7 Generally it devel
ops in adults in the axial skeleton. It con
sists of a well-differentiated chondrosar
coma, usually situated within the medullary
cavity, and a highly undifferentiated spindle
cell tumour that may have the characteristics
of either a fibrosarcoma or an osteogenic
sarcoma.
Mesenchymal chondrosarcoma is charac
terized by islands of cartilage that appear
benign, interspersed with a highly malignant
small cell tumour reminiscent of Ewing’s
tumour or malignant lymphoma, or some
times of a hemangiopericytoma. The lesion
may occur within the bone or in soft tis
sues. Most patients with mesenchymal chon
drosarcoma die of metastatic disease; how
ever, the clinical course may be unpredict
able, and patients occasionally survive for
20 years from the time of diagnosis.®
O steo g en ic T umours

Osteoid osteoma and osteoblastoma are
the prototypes of benign osteoid-producing
tumours. They resemble each other his
tologically, having a nidus of irregular in
terconnecting bony trabeculae with inter
vening osteoblastic activity. The osteoid
osteoma characteristically produces pain,
particularly at night, that is relieved by acetylsalicylic acid. Osteoblastoma may or may
not produce such symptoms. Osteoid oste
oma occurs predominantly in the long bones.
An area of sclerosis usually surrounds the
nidus. The osteoblastoma tends to occur in
the axial skeleton and may not be asso
ciated with reactive sclerosis. A benign
osteoblastic lesion is called “osteoid oste
oma” if it measures less than 1.0 cm in
greatest dimension and is called “osteo
blastoma” if it measures more than 2 cm.9
Osteogenic sarcoma is the malignant
counterpart of osteoid-producing tumours
of bone. Intramedullary osteogenic sarcoma
usually originates in the metaphyseal region
of the long bones in adolescents; it is parti
cularly common in the lower end of the
femur. The lesion is an anaplastic tumour
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of high-grade malignancy with a great po
tential for metastasis. Osteogenic osteosar
coma can be classified conveniently into
osteoblastic, chondroblastic and fibroblastic
varieties, depending on the predominant dif
ferentiation of the tumour matrix.10 The
osteoblastic form has a malignant spindle
cell stroma, with fine, lacelike osteoid be
tween the spindle cells. The chondroblastic
form has a predominantly cartilaginous
matrix, with spindle cells towards the peri
phery of cartilage lobules where osteoid,
sometimes in small amounts, is common.
The fibroblastic form consists of spindle
cells with a small amount of osteoid.
In addition to these three varieties of
osteogenic sarcoma there are several welldefined clinicopathologic entities. Some of
these, such as the osteogenic sarcoma pre
sent in Paget’s disease of bone and osteosar
comas that arise after irradiation of bone,
differ from conventional osteogenic sarcoma
only because of the clinical setting. How
ever, osteogenic sarcoma of the jaw differs
from conventional osteogenic sarcoma be
cause it occurs in an older age group and
is less likely to be associated with distant
metastases; patients usually die of recurrent
tumour.
The telangiectatic type of osteogenic sar
coma is a purely lytic, highly destructive
lesion found in young people. Grossly, the
lesion appears as a blood-filled space. His
tologically, it contains septa separating
blood-filled spaces, such as those present in
aneurysmal bone cysts. Benign giant cells
are usually abundant. However, the cells
forming the septa are highly malignant;
these septal cells contain pleomorphic nu
clei and abnormal mitotic figures. It is im
portant to recognize this form of osteogenic
sarcoma as a distinct variety for two rea
sons. First, the lesion is sometimes mistaken
for a benign lesion, and second, the prog
nosis seems to be worse than that in con
ventional osteogenic sarcoma.11
Another distinct type of intramedullary
osteogenic sarcoma is the well-differentiated
form. Radiologically, the lesion appears to
be relatively nonaggressive. However, close
sciutiny reveals foci with a destructive
tendency; in this way the lesion may be dif
ferentiated from fibrous dysplasia. Histolo
gically, the lesion is well differentiated. Spin-
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die cells of varying size and shape contain
hyperchromatic nuclei and usually produce
a large amount of collagen. Mitotic figures
are difficult to find and osteoid production
may be minimal or abundant. The tumour
has a low potential for metastasis, but cure
is never attained by incomplete excision.
In addition to osteogenic sarcoma of
high-grade malignancy, two distinct types
of osteogenic sarcoma — parosteal and
periosteal — may occur on the surface of
bones.
Parosteal osteogenic sarcoma has been a
well-recognized entity for some time.12 The
lesion usually occurs in adults and involves
the lower end of the femur posteriorly. Radiologically, it appears to be heavily ossified
and is attached to the underlying bone by
a broad base. Involvement of the underly
ing medullary canal should be eliminated radiologically and grossly before parosteal
osteosarcoma can be diagnosed. Histolo
gically, the lesion is extremely well differ
entiated, having a spindle cell stroma of
well-differentiated cells. Mitotic figures are
difficult to find. The lesion usually produces
large amounts of osteoid, forming almost
normal bony trabeculae. It has minimal
metastatic potential, but is locally aggressive
and, if treated inadequately, will recur.
Periosteal osteogenic sarcoma develops
in young persons and usually involves the
upper tibial metaphysis. Radiologically, a
small radiolucent mass is visualized with
bony spicules radiating perpendicularly from
the underlying bone.13 As in parosteal os
teogenic sarcoma, involvement of the under
lying bone marrow has to be eliminated be
fore periosteal osteogenic sarcoma can be
diagnosed. Histologically, the lesion is
moderately undifferentiated and is often
predominantly chondroblastic. It has a
higher metastatic potential than the paro
steal type. However, the prognosis seems to
be better than that in conventional osteo
genic sarcoma.
T um ours

of

U n k n o w n O r ig in

Benign giant cell tumour usually occurs
in adults. Radiologically, it appears to be
purely lytic arising at the end of bone and
extending into the articular cartilage; it is
a lytic destructive lesion and may be mis
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taken for a malignant tumour. Histological
ly, giant cell tumours are highly distinctive;
they consist of a combination of mononu
clear stromal cells and benign giant cells
scattered evenly throughout the tumour.
The nucleus of the giant cell resembles that
of the mononuclear cell and it may be dif
ficult to differentiate one cell from the other.
Mitotic figures within the stromal cell may
be abundant; however, the cells lack atypia.
We have found that it is not possible to
anticipate biologic behaviour by grading
benign giant cell tumours according to the
appearance of the stromal cells. A malignant
giant cell tumour is defined as a sarcoma
arising in a portion of the bone th at pre
viously contained a benign giant cell tu
mour. The malignant tum our usually appears
several years after a benign tumour has
been treated. There often is a history of
prior irradiation to a benign tumour.
Ewing’s tumour is the commonest malig
nant bone tumour of unknown origin. It
occurs most frequently in young children,
but has been noted in all age groups. The
lesion may occur in any portion of the bone,
but the shaft of the bone is usually involved.
Histologically, the tumour is characterized
by a monotonous proliferation of small
round cells. The nuclei have a “ groundglass’’ appearance, and the cytoplasmic bor
ders of the cells are indistinct. The individual
cells lack pleomorphism.
A positive periodic acid-Schiff (PAS)
stain has been described as the most im
portant criterion for the diagnosis of Ewing’s
tumour.14 However, a positive PAS stain
merely indicates the presence of glycogen
within the cytoplasm of tumour cells and,
although a positive result is useful for the
diagnosis of Ewing’s tum our, a negative re
sult does not preclude the diagnosis. Rarely,
a Ewing’s tumour that in all other aspects
is typical has cells with a greater degree of
pleomorphism that are tw o to three times
the size considered usual in classic cases.
These have been referred to as large cell
Ewing’s tumours. They constitute 5 to 10%
of all Ewing’s tumours. It appears that this
distinction between a classic Ewing’s tu
mour and a large cell Ew ing’s tumour has
no clinical significance.
Adamantinoma is also considered a tu-
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mour in which the cell of origin is unknown.
Histologically, the lesion resembles the clas
sic ameloblastoma of jaw bone, having epi
thelioid-appearing cells in clusters distri
buted within a spindle cell stroma. Gen
erally the lesion occurs in adults; it tends
to involve the tibia. Usually adamantinoma
occurs in the midportion of the shaft and
involves a large segment of bone. The
tumour is locally aggressive, but has limited
metatastic potential.
Malignant fibrous histiocytoma15 has
been a common designation for bone tu
mours in recent years. The exact status of
such a tumour is obscure because many
osteogenic sarcomas and fibrosarcomas con
tain zones that resemble this entity. Never
theless, a few malignant tumours and even
a few benign neoplasms of bone possess the
features assigned to this tumour.
F ibrogenic T umours

Fibroma is a term used by most radio
logists to denote a lesion that is situated
in the metaphysis of long bones in young
persons- When the lesion is small and in
volves only the cortex, the term “fibrous
cortical defect” is used. Histologically, both
the fibroma and the fibrous cortical defect
show loosely arranged spindle cells with a
scattering of benign giant cells; foam cells,
in addition, are not uncommon. The spindle
cells characteristically are arranged in a
“storiform” pattern. The small lesions heal
as the skeleton achieves maturity. Desmo
plastic fibromas, which are locally aggres
sive fibrogenic lesions occurring within the
bone, are rare. They have small spindle cells
with an abundant collagen stroma. In this
respect, they resemble desmoid tumours
of soft tissues.
Fibrosarcoma is the malignant counter
part of the fibrogenic tumour. It is an un
common tumour and develops predominant
ly in young adults. Cytologically, the lesion
has spindle cells with varying degrees of
atypia; they produce large or small amounts
of collagen. Fibrosarcomas may be well
differentiated or poorly differentiated and
the clinical behaviour can be predicted from
the cytologic appearance.
N otochordal T umours

Chordoma arises from the remnants of
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the notochord within the spinal column. We
know of no benign tumours of notochordal
origin. About two thirds of chordomas oc
cur in the sacral region, almost one third
occur in the region of the clivus, and the
remainder are distributed along the rest of
the spinal column.
Chordomas are lobulated tumours with
a chondroid or myxoid background. The
cells are round or spindle shaped and are
arranged in a single file within the myxoid
stroma. Some of the cells have abundant mu
coid cytoplasm and are called physaliphorous cells. Some chordomas are associated
with large amounts of low-grade chondrosar
coma, and such tumours are referred to as
“chondroid chordomas”. Surprisingly, chon
droid chordomas have a better prognosis
than do conventional chordomas.
V ascular T umours

Hemangioma is rarely treated by surgery.
It usually is found incidentally at autopsy.
In the skull, particularly, the lesion tends
to produce a “sunburst” radiologic appear
ance.
Hemangioendothelioma is another malig
nant vascular tumour. It may be well differ
entiated or poorly differentiated. Histolo
gically, this tumour is diagnosed by the
presence of vascular spaces, which are
usually anastomosing. The vascular spaces
are lined by abundant endothelial cells with
atypical nuclei, which are large and of irreg
ular shape. The poorly differentiated heman
gioendothelioma may have large areas of
spindle cell tumour and may be difficult to
differentiate from fibrosarcoma. In approx
imately one third of cases, hemangioendo
theliomas involve multiple bones, usually
of the same limb.10
Hemangiopericytoma is composed of
small spindle cells arranged in clusters
around vascular spaces. The lesion is an
extremely rare primary tumour of bone;
little is known about its biologic behaviour.
L ipogenic

and

N eurogenic T umours

These are uncommon primary bone le
sions. The only ones in our files at the
Mayo Clinic are the benign lipomas and
neurilemmomas.
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As can be seen from our classification,
the cell of origin of some of these tumours
is uncertain. For the others, we assume the
cell of origin from the histologic appearance
of the cells or from the tumour cell product.
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MALIGNANT TUMOURS OF BONE: CLINICAL ASPECTS
AND NATURAL COURSE*
CRAWFORD J. CAMPBELL, MD, FACS
An accurate pathological diagnosis must be made
prior to treatment of a primary malignant bone
tumour. Consideration must be given to the
clinical and radiologic aspects as well as the
histology. Both benign and malignant tumours
occur more frequently in certain decades. A
search should be made for precursor lesions
such as Paget's disease. The presenting mani
festations of pain, a mass and dysfunction are
not specific for tumours. Laboratory tests may
be helpful, especially in distinguishing tumours
from infections and metabolic diseases. Metas
tasis is usually via the blood stream to the lungs
and bones. The low survival rate following
amputation for osteosarcoma and radiation
therapy for Ewing's sarcoma has been improved
by chemotherapy. The lower-grade tumours such
as aggressive giant cell tumour and low-grade
chondrosarcoma can often be treated success
fully by resection and insertion of an autograft,
an allograft or a metallic implant.
Un diagnostic pathologique precis doit etre
rendu avant d'entreprendre le traitement d'une
tumeur osseuse maligne primaire. On doit considerer les aspects cliniques et radiologiques
aussi bien que histologiques. Les tumeurs aussi
bien malignes que benignes surviennent plus
frequemment au cours de certaines decades de
la vie. On devrait faire la recherche de certai
nes lesions precurseurs telles que la maladie
de Paget. Les symptdmes tels que la douleur,
une masse ou un dysfonctionnement ne sont
pas specifiques aux tumeurs. Les epreuves de
laboratoire peuvent etre utiles, principalement
pour distinguer les tumeurs des infections et
des maladies metaboliques. Les metastases
essaiment habituellement par la circulation san
guine vers les poumons et les os. Le faible
taux de survie suite a I'amputation pour un
osteosarcome ou a I'irradiation pour un sarcome
d'Ewing a ete ameliore par la chimiotherapie.
Les tumeurs devolution lente telles que la tu
meur agressive a cellules geantes et le chondrosarcome devolution lente peuvent souvent
etre traitees avec succes par resection et in-

*From the orthopedic surgical service of the
Massachusetts General Hospital, department of
orthopedic surgery, Harvard Medical School.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa. Ont., Mav 12.
13, 1977.
Reprint requests to: Dr. C. Campbell, Massachu
setts General Hospital, Boston, Mass. 02114 USA.

sertion d'une autogreffe, d’une aliogreffe ou
d’un implant metallique.

A n accurate pathological diagnosis in a case
of bone tumour can be made only after a
careful consideration of the clinical aspects
and radiologic and histologic features. The
purpose of this paper is to describe some of
the clinical manifestations that have caused
the patient to seek medical aid, and those
that the primary physician may expect to
find. The patient usually complains of pain,
a mass, or dysfunction, of short or long dura
tion. Some lesions are found fortuitously on
examination for a nonrelated complaint.
The age of the patient is important, since
both benign and malignant tumours usually
occur more frequently in certain decades
(Table I). Since many systemic diseases,
such as inflammatory, metabolic, hemato
poietic and metastatic disease may cause
bone or joint pain, extremely careful history
taking and physical examination are man
datory.
The history of an injury, or relation to
athletic activity, may lead to the discovery
of a stress fracture or focus of myositis ossi
ficans. Finding the cause of the pain, which
is the most common presenting complaint,
can be a real challenge. Bone pain may vary
greatly in intensity and nature, from sharp
and well localized to dull and aching or
throbbing, and it is often worse at night.
The pain may appear to arise from the
neighbouring joints. However, none of these
features is specific for tumours. Great care
should be taken to look for a deep-seated
mass and to note the range of motion of
joints, the function of muscles and tendons
and the status of the neurologic and vascu
lar structures. The primary care physician
has to judge which of his patients requires
radiologic study and other tests. A good rule
to follow is that persistent pain involving
the skeletal system calls for radiologic exam
ination; obviously the location of the pain
will determine the area to be investigated.
In taking the history, making the exam
ination and in further investigations, the
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TABLE I.—P resenting S ymptoms

Tumour

Peak
incidence,
decade

and

Most
common
location

S igns

in
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M ore C ommon B one S arcomas

Pain* Mass* Functionf

Biochemistry
investigation
recommended

Duration of
symptoms,
mo

Osteogenic
sarcoma

2

About knee

+

±

±

Serum alkaline
phosphatase
(usually elevated)

Juxtacortical
osteogenic sarcoma

3, 4

Distal end of
femur (posterior)

+

+

±

_

> 6
> 6

< 6

Chondrosarcoma

4-6

Trunk; proximal
ends of femur
and humerus

Fibrosarcoma

2-4

About knee

+

±

±

Ewing’s sarcoma

2

Pelvis; humerus;
femur

+

±

±

Urinary vanillyl Often > 6
mandelic acid
(VMA) an d /o r
catecholamines (to
rule out neuro
blastoma)

Reticulum cell
sarcoma

3-6

Trunk; pelvis;
femur; humerus

+

±

±

Urinary VMA
and/or catechola
mines (to rule out
neuroblastoma)

> 6

Giant cell tumour

3, 4

Epiphyseal end
of long bone;
about knee

+

±

±

Serum calcium and
alkaline phospha
tase (to rule out
hyperparathyroid
osteoclastoma)

> 6

+

±

±

—

—

Often > 6

* + = present; ± may or may not be present,
f ± = may or may not be limited.

physician should search for precursor le
sions. It has been well documented that
osteogenic sarcoma, fibrosarcoma and, less
commonly, chondrosarcoma and giant cell
tumour occur in association with Paget’s
disease of bone, that they may occur after
irradiation and that they can develop in
fibrous dysplasia, osteogenesis imperfecta,
the margins of infarcts, bone cysts and
draining sinuses.1!' Chondrosarcoma can
develop in any benign tumour of cartilage.
1. 4, o - i 1

The routine laboratory tests are usually
not helpful. Determination of serum calcium
and phosphatase values may aid in the dif
ferential diagnosis of some tumours from
hyperparathyroidism, Paget’s disease and
metastatic carcinoma. Measurement of the
serum and urinary protein concentrations is
necessary if myeloma is suspected, and the
concentrations of urinary vanillylmandelic
' acid or catecholamines, or both, are usually

elevated in metastatic neuroblastoma. H e
matologic investigation, which should in
clude study of the bone marrow, or biopsy
is essential in myeloma, neuroblastoma, leu
kemia and malignant lymphomas. The biopsy
should be planned carefully so that a repre
sentative sampling of the tissue of the tu
mour is obtained. Before making a diagnosis
the pathologist must take into consideration
the clinical and radiologic findings.
Treatment of these malignant tumours
consists of ablation or destruction of the
primary growth, radiation therapy (in
Ewing’s and reticulum cell sarcoma), chemo
therapy (in Ewing’s sarcoma and osteogenic
sarcoma) and careful follow-up (Table II).
If amputation is necessary an attempt to
mitigate the psychologic impact on the pa
tient and his family by tactful discussion
beforehand is essential. Every effort should
be made to provide immediately a weight
bearing prosthesis for the lower limb to
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TABLE II.—G eneral M anagement of M ore C ommon M alignant T umours
M etastases and P rognosis
T umour

of

Most common
metastases

Preferred treatment

B one , Sites

5-year survival,
approximate, %

Osteogenic sarcoma

Surgical ablation; with
chemotherapy

Lung, bones

15
45

Juxtacortical osteogenic
sarcoma

Surgical ablation (occasionally
chemotherapy)

Lung

50 +

Chondrosarcoma

Surgical ablation

Lung (often late)

50

Fibrosarcoma

Surgical ablation

Lung

15

Ewing’s sarcoma

Radiation (lesion); with
chemotherapy

Lung, bones

5
50

Reticulum cell sarcoma

Radiation; chemotherapy

Lymph nodes,
bone, lung

G iant cell tumour

Surgical resection; radiation

Lung

TABLE I I I —G uideline

for

F ollow-up

of

of

40
(20 at 10 yr)
95

M alignant T umours

of

B one .

For first 2 yr
Procedure
Chest
Radiography..............................
Whole lung tomography or
computed tomography.........
System review...................................
Physical examination.......................

Every mo.

Every 3 mo.

For bone
pain

For systemic
symptoms

Annually
for life

X

Bone
R adiography.............................
Isotope scanning.......................
Study of lymph nodes and liver . ..
Ancillary tests (as indicated)..........

permit early ambulation. The physician and
the paramedical personnel should adopt a
positive approach and hopeful outlook.
Although most bone tumours metastasize
through the blood stream, some, such as
reticulum cell sarcoma, may spread to the
lymph nodes. If metastases occur, they usual
ly do so within 2 years, but in the case of
some tumours, such as chondrosarcoma, the
interval may be prolonged to many years.
There is evidence that chemotherapy in os
teogenic sarcoma and Ewing’s sarcoma may
delay the development of metastases.
The results of pulmonary resection in
osteogenic sarcoma and giant cell tumour
have been sufficiently successful prior to the
use of chemotherapy to warrant great care
in the search for metastases to the lung.12
The evidence strongly suggests that chemo

X

X

X

X

X

X

X

X

X

X

X

X

X
X
X
X

therapy may lengthen the time before the
appearance of metastases and reduce their
number. Spanos and colleagues13 reported
a 5-year survival rate of 28% in their pa
tients with metastatic osteogenic sarcoma
who were treated by pulmonary resection;
they suggested that posteroanterior stereo
scopic views of the chest be obtained every
month and whole lung tomograms every
3 months. Computed tomography is a more
sensitive test for early metastasis than lung
tomography and might very well replace it
in the 3-month follow-up check.
Every physician who treats patients with
bone tumours should have a protocol to be
followed in each case. My guideline for
follow-up is shown in Table III.
The need for correlation with radiologic
study and an appropriate biopsy is obvious
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if an accurate diagnosis is to be made in
cases of bone tumour. Ablation of the
primary tumour and appropriate chemo
therapy must be followed by careful re
habilitation and thorough follow-up for the
duration of the life of the patient.
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SURGICAL MANAGEMENT OF MALIGNANT BONE TUMOURS*
THEODORE R. MILLER, MD, FACSt
The evolution of treatment for osteogenic sarco
ma at the Memorial Sloan-Kettering Cancer Cen
ter is reviewed. The possible control of micrometastases by chemotherapy and the excision
of macrometastases at single or multiple tho
racotomies by the thoracic surgeon have added
greatly to the salvage rate of this tumour. Inten
sive chemotherapy has made possible en bloc
resection of bones involved by tumour, with
preservation of the limb. Despite advances, how
ever, amputation or en bloc resection is still
necessary to control the primary tumour.

Kettering Cancer Center. Le controle des micrometastases rendu possible par la chimiotherapie, et I'excision des macrometastases lors
de thoracotomies simples ou multiples par le
chirurgien thoracique, ont grandement ameliore
le taux de survie de cette tumeur. Une chimiotherapie intensive a rendu possible la resection
en bloc de I’os atteint, tout en permettant de
conserver le membre. Toutefois, en depit des
progres, I’amputation ou la resection en bloc
sont encore necessaires pour controler la tu
meur primaire.

On passe en revue revolution du traitement du
sarcome osteogene pratique au Memorial Sloan-

T h e eventual elimination of cancer will come

*Presented at the conference “Modern Concepts
of Bone Tumor Treatment”, Ottawa, Ont., May
12 and 13, 1977.
t Senior attending surgeon, bone tumor service,
Memorial Sloan-Kettering Cancer Center, New
York, and clinical professor of surgery, Cornell
University medical college, New York, NY.
K

Reprint requests to: Dr. T. R. Miller, 137 E
36th St., New York, NY 10016, USA.

from its prevention, not from its treatment.
At present we can only attempt to control
the disease once it has developed. Treat
ment is in a constant state of change, just
as the art of surgery is steadily improving.
In spite of occasional retreats, as in the
management of breast cancer, progress is
definitely being made. The idea that a small
cancer requires a lesser operation than a
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large cancer can be defended, but still can
not be applied to most tumours.
The magnitude of the problem in osteo
genic sarcoma and in Ewing’s sarcoma stems
from the fact that only 203 cases of osteo
genic sarcoma and 86 cases of Ewing’s sar
coma occur annually in the United States.
The scarcity of material makes it difficult to
accumulate any large series of cases.
A review of past experience is always
helpful in rationalizing our present ap
proaches and in enabling us to look with a
clear and open mind into the future. I shall
attempt to review briefly the history of the
clinical management of the malignant bone
tumours at Memorial Sloan-Kettering Can
cer Center over the past 50 years, and bring
that experience up to date with a descrip
tion of our present concept of management.
The late William B. Coley was the first
chief of the bone tumour service at our in
stitution, and was probably one of the earli
est physicians to practise immunotherapy.
At a time when amputation was the only
effective method of treatment, he admin
istered toxins of a mixture of organisms in
increasing doses to the patient postoperatively in an effort to improve the salvage rate.
The value of this agent (Coley’s toxin) has
not always been recognized and has even
been condemned by some prestigious organ
izations as a “quack approach to cancer
therapy” . Prompted by our more recent in
terest in immunotherapy, a review of some
of his case histories shows that this treat
ment had definite value. Reticulum cell sar
coma responded well to this form of the
rapy. Since the immunotherapeutic concept
became popular there has been widespread
experimentation with the use of Bacillus
parvum and bacille Calmette Guerin. Coley’s
toxin fell into disuse around 1940 and the
only treatment again remained surgical abla
tion with the rather poor salvage rate of 16
to 18% for the osteogenic sarcomas and 7
to 9% for Ewing’s sarcoma.
No treatment of any tumour, and in par
ticular a bone tumour, can be evaluated un
less it is based on accurate pathological
diagnosis. The refinements in this field with
the use of histochemistry and electro-micro
scopy have been followed with great interest
by those entrusted with the management of

Vol. 20

this group of tumours. Aspiration biopsy
can be accurate in 85% of cases provided
the aspirator furnishes the pathologist with
a clot. Surgical biopsy, however, is some
times necessary for accurate classification.
The belief that biopsy should be done be
tween tourniquets has long since been aban
doned, since it has been shown that most
cancer patients have free-floating malignant
cells in the blood stream.
Many attempts have been made to grade
bone tumours, from the viewpoints of both
histology and morbid anatomy. This group
of tumours tends to disseminate through the
blood vascular system so that the usual
methods of staging are not applicable. These
tumours rarely involve lymph nodes or the
liver, except by contiguity; they metastasize
to the lungs almost exclusively.
Other diagnostic methods such as angio
graphy, xeroradiography and the study of
alkaline phosphatase concentration in both
the tumour and blood stream have all
increased diagnostic refinement. Bone scan
ning with radionuclides has been helpful in
the earlier diagnosis in these tumours, which
frequently give rise to pain before radiologic
evidence is present.
An additional method, comparing the al
kaline phosphatase concentration in the
blood aspirated from a painful bony area
with the concentration in peripheral blood,
has been described by Woodard and Marcove.1 Blood taken from the tumour or
from a suspected metastasis will have a
much greater alkaline phosphatase concen
tration than peripheral blood or normal
bone.
While many of these tumours are radio
sensitive, osteogenic sarcoma has never, in
our experience, been cured by radiotherapy
alone. From 1935 to 1941, 114 cases of
osteogenic sarcoma were seen and 69 were
treated with therapeutic doses of irradia
tion.2 None was cured during this time.
Various methods of altering the milieu in
which the tumour was treated were at
tempted. Diathermy was given in the pre
treatment period to increase the circulation
and hence the sensitivity of the tumour
to irradiation. These tumours have been
treated under conditions of hypoxia as well
as hyperoxia, but still no cures were ob-
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tained. To date, in 1977, 1697 cases of
osteogenic sarcoma have been seen at our
institution and not one patient treated by
irradiation alone has been cured.
In the early years, it was noted that ade
quate amputation as treatment of the primary
tumour was almost never followed by local
recurrence, but in a series where subtro
chanteric amputation was done for tumours
of the lower femur, the salvage rate fell
from 19% to a dismal 5% , owing to local
recurrence and pulmonary metastases. The
latter complication is the cause of death in
this group of tumours. Resection of solitary
pulmonary metastases from other tumours
had been performed sporadically in those
cases where a long interval had elapsed be
tween the primary treatment and the appear
ance of the metastasis. This produced an
occasional cure. With the advances in anes
thesia, a renewed interest in this approach
has been vigorously pursued by Beattie and
his staff with considerable success.:i r’ Mul
tiple secondary lesions have been removed
from one or both sides of the chest by wedge
resection. It is interesting to note that the
lymph nodes of the bronchial tree and me
diastinum are rarely involved, and there
fore subtending node dissections are not
necessary in the thorax. Amputation alone
has yielded a universal salvage rate in osteo
genic sarcoma between 17 and 19% .8 The
addition of surgical removal of pulmonary
metastases has raised this figure to around
35% .4
The use of therapeutic doses of radio
therapy after the fashion of Sir Stanford
Cade,-' followed by amputation after a suit
able waiting period, seems only to be a meth
od of identifying those patients with occult
pulmonary metastases. Because of the fail
ure of this method to demonstrate steriliza
tion of the tumour in any of the amputated
specimens, Higinbotham and colleagues
began to administer necrotizing doses of ir
radiation (1000 R daily to a total of 12 000
to 14 000 R) to the tumour, making sure to
protect the skin necessary for surgical flaps.7
Amputation was done as soon as the pa
tient began to show signs of toxicity from
the necrosed tissue. Ninety-seven patients
were treated in this fashion before the meth
od was abandoned. There was no improve
ment in salvage over early amputation, and
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practically none of the tumours had been
sterilized by this large dose of ionizing ra
diation.
Cryotherapy, using liquid nitrogen to pro
duce repeated freezing of the primary tu
mour or metastasis, has been helpful in
temporarily controlling pain and speed of
growth. Conventional chemotherapy in vari
ous forms has also been tried with little or
no success. Both of these agents have been
tried in the treatment of primary and second
ary tumours.
In 1963, because of the failure of the
above methods, Marcove and colleagues9’ 0
and I started to use an autogenous tumour
antigen after amputation of the tumour-bear
ing bone. This was suggested by the observa
tion that pulmonary metastases seemed to
appear later in the course of the disease in
those cases of osteogenic sarcoma in which
there was a long interval between the ap
pearance of symptoms and the amputation,
as compared with those cases in which diag
nosis was early and treatment prompt. This,
combined with the fact that the parents and
siblings of a child with osteogenic sarcoma
often have antibodies against the child’s
tumour, suggested an immunologic approach.
Amputation was carried out as soon as the
diagnosis was made, and tissue cultures were
prepared using portions of the child’s tu
mour. The cells were then harvested and
inactivated, and three different types of
antigen were made: (a) an ultraviolet cellfree extract (UV vaccine), (b) a gamma-irra
diated suspension of cells from the culture
(gamma vaccine) and (c) a gamma-irradiated
suspension of cells from the tissue culture of
the patient’s own tumour (TC vaccine). The
last was prepared immediately before each
administration of the antigen. The others
were stored at -60°C until used. Each vac
cine was given subcutaneously weekly for
as long as possible, or until pulmonary me
tastases appeared. All patients were younger
than 21 years of age and had true osteogenic
sarcoma originating in the distal femur. None
had had evidence of metastases for at least
8 weeks after amputation. Results were com
pared with those from a retrospective series
of patients fulfilling the same criteria, treated
at our institution between 1945 and 1946.
Of 12 patients who received the UV vac
cine, metastases had not developed in 4, 5
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years or longer after the amputation, where
as in the control group only 27 of 154 pa
tients remained free of disease. A fifth pa
tient who had resection of a solitary pul
monary metastasis was free of disease 7
years after amputation and 5 years after tho
racotomy, giving an apparent cure rate of
42%, compared with 17% in the control
group. Of the five patients who received the
TC vaccine, metastases had not developed
in 4 in the follow-up period of 20 to 31
months. Survival times up to 3 years in sev
eral of the vaccine-treated patients who
eventually died of their tumour reflect a
slower progression of the disease due to
enhanced immunity. In the gamma-vaccine
group, 15 of 17 patients had metastases be
fore 21 months after amputation and their
course was much the same as in the control
series.
During this period of experimentation
with tumour antigens (1963 to 1970), the
reports appeared of the remarkable results
of chemotherapy with high-dose metho
trexate and citrovorum factor rescue. We
then began to use these agents. Chemothe
rapy in osteogenic sarcoma, because of the
necessarily high dosage, requires consider
able expertise to prevent an inordinately
high morbidity and mortality, particularly in
patients who are treated prophylactically.
During these years, occasional attempts
at en bloc resection have been made in lowgrade osteogenic sarcomas such as the parosteal type and in low-grade chondrosarco
mas confined locally. These attempts have
met with some success. Marcove,8’ 0 with
increasing boldness, has extended the indi
cations and operative techniques for en bloc
resection with prosthetic replacement and
preservation of the limb. This method, com
bined with high-dose methotrexate chemo
therapy to control the micrometastases and
with the removal of multiple secondaries
in the lungs by thoracic surgeons, has shown
great promise in increasing the salvage rate
among these unfortunate young people.
During the last 3Vi years, Marcove8'10
has performed this type of surgery on 59 pa
tients. Of these, 21 had total femoral re
section with replacement involving the hip
joint and knee. Twenty of these femoral
resections were performed for osteogenic
sarcoma of the lower femur. Most of the
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others were for chondrosarcoma or other
benign and malignant tumours of the shoul
der girdle, ordinarily requiring interscapulothoracic amputation. (The Tikhoff-Linberg
amputation is useful for cases of tumour
around the shoulder girdle.) The remainder
of the 59 cases were chondrosarcomas of
the upper femur or the fibula, and osteoge
nic sarcoma and chondrosarcomas of the
upper humerus.
The first total femoral resection was for
chondrosarcoma and the patient subse
quently died of pulmonary metastases.10
The other 20 cases were of carefully se
lected osteogenic sarcoma involving the
distal femur. Of the 14 patients still living,
13 are without disease and 11 of these
still have the limb intact. Of the six who
died, four died of pulmonary metastases
after pulmonary resection, one died of
pulmonary metastases after amputation
for local recurrence in the limb, and one
died after hemipelvectomy for metastases
in the proximal lymph nodes. Of the
nine patients who underwent amputation,
two had local recurrence, three had severe
infection requiring amputation (two of these
had had heavy irradiation before the femoral
resection) and two required amputation be
cause of fracture of the metallic prosthesis.
One patient, although free of disease, re
quested amputation because the preserved
limb did not come up to his expectations.
One other patient had an amputation be
cause of recurrence in the local lymph
nodes.10
En bloc resection must still be regarded
as experimental and great caution should be
used in selecting the cases: (a) the tumour
must be confined to the bone or soft tissue
involvement must be minimal; (b) the pa
tient must receive prophylactic chemotherapy
for 6 weeks before the operation and must
resume chemotherapy as soon as the wound
is healed;11 and (c) the patient must agree
to amputation in case of failure. In evaluat
ing the results it should be noted that the
leg tends to be stiff, with little or no flexion
at the hip, but somewhat more at the knee.
The patient must wear a stiff-leg brace postoperatively, and while the leg is good in
appearance its function and sensation are
impaired.
In summary, chemotherapy and pulmo-
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nary resection, in addition to amputation
and en bloc resection, seem to have ex
tended the lifespan of patients with osteo
genic sarcoma. The salvage rate has been
increased from 19 to 35% . It must be em
phasized, however, that it is still necessary
to amputate or resect the primary tumour en
bloc. In order to achieve this degree of
salvage the bulk of the thoracic metastases
must be resected when present.
Ewing’s sarcoma, judged by our experi
ence, presents largely a radiotherapeutic and
chemotherapeutic problem, because the
cases that we see in our clinic come to us
late. However, amputation has a place in the
management of Ewing’s sarcoma if the pa
tient is seen early enough. Amputation is a
safer method to relieve the body of the dis
eased bone, since the late effects of radiation
such as fracture, arrest of growth, and ra
diation sarcoma are possible complications.
The patient must be kept under careful con
trol for the rest of his life. The late effects
of chemotherapy are still not evident.
Fibrosarcoma of bone should be treated
by amputation of the entire bone because the
tumour tends to involve the whole marrow
cavity. The concept of skip areas in osteo
genic sarcoma has never been generally ac
cepted; even so, it is our impression that
anything less than total amputation of a
tumour-bearing bone is inadequate. There
has been a tendency in performing en bloc
resection to amputate through a femur con
taining an osteogenic sarcoma in its distal
portion, and, with a prosthesis, conserve the
ability to abduct the thigh.
In performing an amputation, we con
sider that malignant tumours of the lower
femur require hip-joint disarticulation; those
of the upper femur, hemipelvectomy; those
of the tibia and fibula, above-knee amputa
tion; those of the bones of the forearm, up
per-arm amputation; and those of the upper
humerus, interscapulothoracic amputation.
We have had no experience with the use
of the transfer factor or interferon, though
it seems that these two modalities, if proved
useful, would produce a minimal morbidity,
comparable to our experience with tumour
antigens.
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The radicalism of treatment in chondro
sarcoma depends upon the grading of the
tumour. A grade 3 tumour (International
Histological Classification12) should never
be treated by en bloc resection, but grades
1 and 2 may be treated by a lesser amputa
tion or en bloc resection, or both- Large
chondromatous tumours of the pelvis are
almost always malignant and can rarely be
treated by any measure short of hemipelvec
tomy. As in osteogenic sarcoma of the
pelvis, those lesions involving the wing of
the ilium require a resection of the wing
of the sacrum, since these tumours tend to
cross the joint and recur in that location.
R eferences
1. W oodard HQ, Marcove RC: Comparison
of chemistry of blood from bone and peri
pheral veins. Clin Orthop 66: 254, 1969
2. Cade S: Cancer of bones. Postgrad Med J 17:
157, 1941
3. Marcove RC, Mike V, Huvos AG, et al:
Vaccine trials for osteogenic sarcoma. Pre
liminary report. CA 23: 74, 1973
4. M artini N, Huvos AG, M ike V, et al: Mul
tiple pulmonary resections in treatment of
osteogenic sarcoma. Ann Thorac Surg 12:
271, 1971
5. M artini N, Bains MS, Huvos AG, et al:
Surgical treatment of metastatic sarcoma
to lung. Surg Clin North Am 54: 841, 1974
6. M arcove RC, Southam CM, L evin AG, et
al: Autogenous vaccines in treatment of
osteogenic sarcoma. Contemp Surg April
1973
7. F rancis KC, P hillips R, N ickson JJ, et al:
Massive preoperative irradiation in treat
ment of osteogenic sarcoma in children;
preliminary report. Am J Roentgenol Ra
dium Ther Nucl M ed 72: 813, 1954
8. M arcove RC, Lewis MM, Huvos AG: En
bloc upper humeral interscapulo-thoracic
resection— Tikhoff-Linberg procedure. Clin
Orthop 124: 219, 1977
9. M arcove RC, J ensen MJ: Radical resection
for osteogenic sarcoma of fibula with
preservation of limb. Clin Orthop 125:
173, 1977
10. M arcove RC, Lewis MM, R osen G, et al:
Total femur replacement. Compr Ther 3:
13, 1977
11. R osen G, M urphy ML, Huvos AG, et al:
Chemotherapy, en bloc resection, and pro
sthetic bone replacement in treatment of
osteogenic sarcoma. Cancer 37: 1, 1976
12. Schajowicz F, A ckerman LV, Sissons HA:
Histological typing of bone tumours, in
International Histological Classification of
Tumours No. 6, Geneva, WHO, 1972

518

THE CANADIAN JOURNAL OF SURGERY

Vol. 20

PLACE OF RESECTION IN THE MANAGEMENT OF
PRIMARY BONE TUMOURS*
CRAWFORD J. CAMPBELL, MD, FACS
A primary malignant sarcoma of bone in an ex
tremity must be removed so that it will not recur
locally. Amputation will accomplish this in most
cases but a prosthesis is required. In carefully
selected cases of malignant giant cell tumour,
low-grade chondrosarcoma, low-grade fibrosar
coma, parosteal osteogenic sarcoma and adam
antinoma, resection with insertion of an auto
graft, allograft or metallic implant has been
successful. More recently implants have been
used following resection of the more malignant
tumours such as osteosarcoma, high-grade fibro
sarcoma and high-grade chondrosarcoma, but
further time is required to determine the prob
lems secondary to chemotherapy, other compli
cations, the length of time for rehabilitation, and
the quality of life after this procedure as com
pared with the more conventional amputation
with early prosthetic fitting.
Un sarcome osseux malin primaire d'un membre peut etre enleve de fagon a empecher une
recidive locale. L’amputation peut accomplir
ceci dans la plupart des cas mais une prothese est requise. Dans certains cas soigneusement choisis de tumeur maligne a cellules
geantes, de chondrosarcome devolution iente,
de fibrosarcome devolution Iente, de sarcome
osteogenique parosteal et d'adamatinome, une
resection avec insertion d en e autogreffe, dene
allogreffe ou d e n implant metallique a reussi.
Plus recemment, des implants ont ete utilises
a la suite de la resection de tumeurs plus malignes telles que I’osteosarcome, le fibrosarcome
devolution rapide et le chondrosarcome devo
lution rapide, mais un plus long recul est requis
pour determiner les problemes secondaires a
la chimiotherapie, les autres complications inherentes, le temps necessaire a la readaptation,
et la qualite de la vie apres cette intervention
comparativement a I'amputation plus conventionnelle avec ajustement d'une prothese.

*From the orthopedic surgical service of the
Massachusetts General Hospital, department of
orthopedic surgery, Harvard Medical School.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont.. May 12
13, 1977.
Reprint requests to: Dr. C. J. Campbell, Massa
chusetts General Hospital, Boston, Mass. 02114

A blation by amputation has usually been
considered the procedure of choice in some
of the frankly malignant tumours of bone
such as osteogenic sarcoma and the more
malignant fibrosarcoma and chondrosar
coma.1 On rare occasions when the patient
or family will not permit amputation, re
section without entering the tumour, as sug
gested by Phemister- and Enneking,:i can
give comparable results. Interest has been
revived in resection rather than amputation,
with consideration for the desire to “keep
one’s own leg rather than wear a prosthe
sis”. By meticulous attention to chemo
therapy before and after the resection of
some osteogenic sarcomas, spectacular re
suits have been obtained. Metallic wholebone implants have been inserted by Marcove and colleagues,4 metallic half-bone
implants by Watts and colleagues (personal
communication, 1977) and allografts by
Mankin and colleagues.” These methods are
actually in the experimental stages since
much more information must be available
before the morbidity, the degree of re
habilitation and the quality of life following
such formidable procedures can be com
pared with what is possible after amputa
tion with early prosthetic fitting.
On the other hand, some tumours of
low-grade malignancy can be resected, so
that the function of the limbs is preserved.
Examples of these have been described by
many a u t h o r s .4"1# Some of the tumours
in this category are giant cell tumour, lowgrade chondrosarcoma, low-grade fibro
sarcoma, parosteal osteogenic sarcoma,
adamantinoma and, occasionally, aggressive
recurrent benign lesions such as desmoplas
tic fibroma, chondromyxoid fibroma and
benign epiphyseal chondroblastoma. If a
limb can be preserved with good function,
such a result is usually worth the time and
effort required. We believe that the follow
ing principles enunciated by Phemister,®
Ottolenghi14 and Henderson and Dahlinin
should be observed:
1. An adequate biopsy specimen should
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Fig. lb

be obtained. If possible, the biopsy wound
should be placed so that the subsequent
operation will extirpate the site and tract
of the wound. If the diagnosis can be made
accurately by frozen section, the wound
should then be sutured, the skin sterilized
and the wound excluded from the operative
field; there should be a change of drapes,
gowns, instruments and gloves before recon
struction is done.
2. En bloc excision to include the biopsy
wound should be performed.
3. The tumour should not be entered.
There are many bones or portions of
bone that can be resected leaving little
residual functional disability so that no re
construction is necessary. These include the
clavicle, scapula, ribs and portions of the
fibula, ulna and pelvis.
R esection
Fig. lc
Fig. 1.—(a) Lytic lesion of distal end of radius
in 33-year-old man, who had had several episodes
of pain following minor trauma. Cortex is pene
trated medially and dorsally. Biopsy showed giant
cell tumour, (b) Fifteen months after curettage
and bone grafting there is massive recurrence with
invasion of soft tissue. Pathological examination
showed giant cell sarcoma, (c) Four years after
reconstruction with 20-cm tibial autograft. Graft
has firmly united to navicular and lunate bones.
Sixteen years after operation this patient had 25°
flexion and 15° extension of wrist and was work
ing as furniture mover.

A number of major factors must be con
sidered to reach a decision on the feasibility
of resection for primary bone tumours.
Choice of Cases for Resection

Giant cell tumour, chondrosarcoma and
fibrosarcoma may be resected if they are
of low-grade malignancy,5- n . 13, i e so
may selected cases of adamantinoma and
parosteal osteogenic sarcoma.17- 18 Patients
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with benign aggressive tumours that have
recurred, such as desmoplastic fibroma,
chondrosarcoma, chondromyxoid fibroma
and aneurysmal bone cyst, and patients with
benign tumours located in bones in which
excision will not cause functional impair
ment are also candidates for resection. Oc
casionally an osteogenic sarcoma or a fibro
sarcoma or chondrosarcoma of high-grade
malignancy that is confined within a bone,
or is in a bone that can be excised without
appreciable functional disability, may be re
sected.4- 3
Choice of Cases for Resection and
Bone Graft

Consideration must be given to the loca
tion of the lesion, its size and its relation
to important soft tissue structures. Tomo
graphy, computed tomography, arteriography
and other radiographic and scanning pro
cedures are sometimes helpful in deline
ating the margins of the lesion. The joint
surfaces and structure of the bone that is
to remain following resection are important.
As already mentioned some bones can be
excised totally without impairing function;
in others local excision of the tumour leaves
a cavity or defect that can be simply filled
with grafted bone. The large defect remain
ing after a massive resection can be satis
factorily bridged by an autograft taken from
the tibia,7- n- 10 pelvis3- 13 or fibula,12 or
by a well-fitted allograft (Fig. 1). When a
joint is involved it can be bridged by an
autograft (arthrodesis) or preserved, albeit
altered, by use of an allograft.3- 41- 13
Choice of Graft

Consideration should be given to the
quality of the bone in deciding between the
use of autograft and allograft and to the
amount and contours of cortical and can
cellous bone required to ensure strength and
osteogenesis.3- 6- 7- 1213 In filling a
cavity such as that left after curettage of
a solitary bone cyst, insertion of autografts
or allografts gives good results. In filling
large defects following massive segmental
resections, I have preferred large autografts
taken from the posteromedial surface of the
proximal end of the tibia. Serious complica
tions have been few3- 7- 13- 1(i and with a
combination of cortical and cancellous bone
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there has been excellent union, replacement
and remodelling of the transplant.
In an attempt to preserve the joint the
use of cadaver bone and cartilage allo
grafts3- 41- 14 is being investigated. This
method has been successful for lesions about
the knee joint and is being used for the
shoulder, wrist and ankle. The fairly high
rate of complications, including joint in
stability, and the precarious state of the
articular cartilage mean that this method
will require careful analysis for many years
before the final results can be ascertained.
Defects have been remedied with artificial
material such as metal or plastic held in
place with methylmethacrylate cement. Al
though these materials give immediate struc
tural stability and often excellent joint func
tion in the young, active person, they are
likely to loosen, fracture, or otherwise fail.
Nevertheless they are the most successful
replacement for defects of the hip. Wholebone resection for osteogenic sarcoma with
a total femur and full-joint prosthetic re
placement has been done, but the resulting
morbidity, complications and functional sta
tus of the limb need further scrutiny.4
In the selection of surgical management
for primary sarcomas of bone each patient
should be treated individually. The location
of the tumour, its pathology and biologic
behaviour, and the effects of any drugs used
in its control are extremely important. One
must also consider the patient’s functional
needs, the psychologic impact on the patient
of the proposed operation, the length of
time required for rehabilitation, the family
setting and the patient’s financial status be
fore arriving at a decision. Expertise in
diagnosis, treatment and rehabilitation
should be available in any institution where
patients with primary sarcomas of bone are
treated.
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EN BLOC RESECTION FOR OSTEOGENIC SARCOMA*
RALPH C. MARCOVE, MDt
Preservation of a limb without sacrifice of the
principles of cancer surgery is desirable in young
people with osteogenic sarcoma. At present am
putation is generally regarded as the only wellestablished curative treatment for this condition.
To determine whether en bloc resection with
intensive chemotherapy is a realistic alternative
to radical amputation and chemotherapy, 43 pa
tients who underwent en bloc resection for
osteogenic sarcoma of the distal femur (20 pa
tients), proximal tibia (11 patients), shoulder
girdle (11 patients) and fibula (1 patient) were
studied.
After tumour resection, chemotherapy and
pulmonary resection 32 (74%) of the 43 patients
are alive and 29 (67%) have no evidence of dis
tant disease. Of the 38 patients without metasta
tic disease at the time of admission (5 were ad-

Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont. May 12,
13, 1977.
(Chief, bone tumor service, Hospital for Joint
Diseases, and clinical associate professor of sur
gery, Cornell University Medical Center, New
York, NY.
Reprint requests to: Dr. Ralph C. Marcove, 517
E 71 St., New York, NY 10021, USA.

mitted with pulmonary metastases) 24 (63%)
are alive without evidence of disease and with
out having had postoperative metastases.
Chez les personnes jeunes souffrant de cancer
osteogenique il est souhaitable de conserver le
membre sans toutefois sacrifier les principes
de la chirurgie anticancereuse. Presentement
I'amputation est generalement consideree comme le seul traitement curatif bien etabli de
cet etat pathologique. Afin de determiner si la
resection “en bloc" associee a une chimiotherapie intensive constitue une alternative realiste a I’amputation radicale et a la chimiotherapie, on a etudie 43 patients qui ont subi une
resection “en bloc” d’un sarcome osteogenique
du femur distal (20 patients), du tibia proximal
(11 patients), de la ceinture scapulaire (11 pa
tients) ou du perone (1 patient).
Apres resection de la tumeur, chimiotherapie
et resection pulmonaire, 32 (74%) des 43 pa
tients sont vivants et 29 (67%) ne presentent
aucun signe de maladie disseminee. Des 38
patients exempts de metastase au moment de
I'hospitalisation (5 avaient des metastases pulmonaires), 24 (63%) sont vivants sans mani
festation de I? maladie et sans avoir eu de
metastase postoperatoire.
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P reservation of a limb without sacrifice of
the principles of cancer surgery is desirable
in young people with osteogenic sarcoma.
At present amputation is generally regarded
as the only well-established curative treat
ment for this condition, 1-6 When the tumour
is close to a joint, amputation usually in
cludes excision of a part of the adjacent
joint bone as well as the involved bone to
include both the area of potential capsular
local spread and possible intraosseous skip
areas of tumours. In cases of lesions of the
distal femur, which have the lowest rates
of cure, the whole bone is usually removed.7
To determine whether en bloc resection
with intensive chemotherapy is a realistic
alternative to radical amputation and chemo
therapy,8 14 43 patients who underwent en
bloc resection for osteogenic sarcoma were
studied. The femur was the site of the tu
mour in 20 patients, the tibia was affected
in 11, the shoulder girdle in 11, and the
fibula in 1. This paper is a preliminary re
port of the results obtained.

■4

A 4

M aterials and M ethods

In all patients the following investigations
were carried out: routine physical examina
tion and laboratory determinations, standard
anteroposterior and lateral radiographs of
the involved bone as well as skeletal survey,
bone scanning and chest tomography, and
biplane arteriography of the area of osteo
genic sarcoma (Fig. l) .ir>* 1(i The findings
were evaluated to determine size, location
and resectability of the tumour and the soft
tissue component, as well as the presence of
metastatic disease or skip areas. In children
with lesions of the distal femur, orthoroentgenographic scanning of the lower extremi
ties and other appropriate studies deter
mined the degree of skeletal maturity and
projected growth curves. The objectives and
potential risks of the protocol were care
fully explained to the patients and their
families. The presence of pulmonary metastases was not necessarily a contraindication
if the lesions were considered surgically re
sectable17’20 or responsive to chemothe
rapy, or both.14’ 21' 22 The advisability of
use of an ischial weight-bearing brace postoperatively was discussed with the parents
and patient before operation. Upon com-

Fig. lb
Fig. 1.—Osteogenic sarcoma of (a) distal fe
mur and of (b ) scapula. Arteriograph demon
strates resectability of lesions.

pletion of these investigations we proceeded
with the resection of the sarcoma.
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D istal F e m u r

Twenty-six patients with lesions of the
distal femur were considered for replace
ment surgery.23 Amputation was required
in five because of the size of the tumour,
and in one because a tumour pseudocapsule
was encountered at operation. There re
mained 20 patients (age range, 11 to 21 yr)
who underwent en bloc resection of the
tumour and replacement with a metal total
femur-knee prosthesis; 3 had pulmonary
metastases at the time of admission.
About 8 weeks were needed for con
struction of the prosthesis. During this time
the patient received chemotherapy consist
ing of vincristine, doxorubicin (Adriamycin)
and high-dose methotrexate with citrovorum
factor rescue. Our regimen for the admini
stration of chemotherapy has been described
elsewhere.14' 21’ 22 When the prosthesis
was ready the patient was re-evaluated; if
the protocol criteria were still valid, replace
ment was performed. Immediately after re
placement the patient was placed in a long-

Fig. 2.—Ischial weight-bearing brace with pel
vic band used after total femur and knee replace
ment.
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leg ischial weight-bearing brace (at first
with a pelvic band). An active range of
movement and ambulation was started as
the clinical situation allowed. The pelvic
band was removed after about 6 weeks (Fig.
2). Then, after sufficient postoperative
wound healing, adjuvant chemotherapy was
resumed. The regimen consisted of biweek
ly cyclophosamide, vincristine and high-dose
methotrexate with citrovorum factor rescue
for five cycles. 14> 21*22
O pe r a t iv e T echniq Oe

In performing the biopsy in previously
untreated patients a lateral approach had
been selected to correspond with the pro
posed site of the subsequent surgical inci
sion. The biopsy scar and tract are excised
and, through a long Gibson skin incision,
posterior and anterior approaches are made
to the hip. The incision is carried along the
greater trochanter and the lateral aspects of
the femur distal to the knee and then curved
slightly anteriorly over the lateral tibia to
a point 4 cm distal to the tibial tubercle. The
incision is deepened and as the area of
tumour is approached an ample margin is
left on the femur, so that the tumour is
never made visible. If a tumour pseudocap
sule is seen the operation is discontinued and
with fresh instruments amputation is per
formed at a higher level. The knee is re
moved en bloc with the distal femur. The
patellar tendon is left intact and the patella
is split coronally so that the inner half is
removed with the specimen and the outer
half remains in continuity with the remain
ing quadriceps mechanism. The tibia is
reamed to accept the stem of the total knee
prosthesis and methyl methacrylate is in
troduced into the tibia after a trial insertion
of the prosthesis. The gluteal muscles are
attached with heavy silk through preformed
holes to the prosthetic shaft proximally, and
the groups of medial and lateral thigh mus
cles are attached to each other.. The distal
hamstrings are often transferred anteriorly to
act as knee extensors and to provide a deep
layer below the skin incision. The wound is
carefully checked for hemostasis (cautery is
generally not used). Hemovac suction en
sures drainage. The wound is flushed with
antibiotic solutions during and immediately
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after surgery and antibiotics are prescribed
before and after operation. The legs are
kept elevated postoperatively (Fig. 3).

Results
Duration of follow-up in these 20 patients
ranged from 2 to 35 months. At the time of
writing 13 of the 20 patients are alive and
free of disease; 1 is alive with disease.
Nine of the 17 patients admitted without
metastases are still free of disease.
Of the three patients admitted with pul
monary lesions, one is alive with no appa
rent metastatic disease 24 months after re
placement (she had a second pulmonary me
tastasis and thoracotomy 7 months after re
placement surgery); the remaining two pa
tients died with widespread metastases 21
and 30 months after replacement.
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Six patients underwent thoracotomy; three
are alive without disease. In one patient
chemotherapy reduced the size of the pul
monary nodule so that it was not found at
subsequent exploratory thoracotomy.
Seven patients had amputations: three for
infection, two for local recurrence, one for
breakage of the prosthesis and one for ra
diation necrosis (a dose of 6600 rad had
been administered before replacement). Of
this group three are alive and free of disease;
one had infection, one had local recurrence
and one had breakage of the prosthesis.
Range of motion usually improved with
time; ankle and foot motion usually was
quite good. At first, walking was possible
only with crutches, but patients could man
age later with a cane. Without the use of a
cane a gluteus maximus limp was evident
unless an ischial weight-bearing brace was

v
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used. Patients were instructed to wear the
ischial weight-bearing brace with quadrila
teral socket and to treat the extremity much
the same as a “polio leg”.
L e s io n s o f t h e § h o u l d e r G ir d le

Eleven patients (age range, 8 to 63 yr)
who had osteogenic sarcoma of the upper
portion of the humerus, scapula or clavicle
underwent a Tikhoff-Linberg procedure; one
had pulmonary metastases at the time of
admission.24
The Tikhoff-Linberg procedure (en bloc
upper humeral interscapulothoracic resec
tion) is an alternative to radical ablation for
neoplasms of the shoulder girdle.25' 31 It
is indicated mainly when the neoplasm does
not involve the axillary artery or the brachial
plexus, lymph nodes are negative and the
tumour is not fixed to the chest wall. Primary
tumours of bone, as well as soft tissue tu
mours adjacent to bone, can be treated by
this method. A forequarter amputation5’ 31
is a better operation if lymph nodes are in
volved. Only five patients received chemo
therapy, including the patient who had three
thoracotomies. Chemotherapy was begun 3
weeks after operation, and was administered
according to our protocol.14- 21> 22
Operative Technique
The initial incision is made over the
medial two thirds of the clavicle; it is ex
tended from the region of the coracoid
process distally along the medial border
of the arm overlying the neurovascular
bundle. The incision is so placed that the
biopsy scar and tract are excised with the
specimen. Providing it is free of tumour,
the neurovascular bundle is mobilized. The
musculocutaneous and radial nerves can
be identified and usually preserved. If the
lesion involves the soft tissue at the level
of the proximal humerus in the vicinity of
the nerves the radial and musculocutaneous
nerves may have to be sacrificed. In one
patient even the ulnar nerve was removed.
The posterior skin incision originates at
the junction of the lateral and middle thirds
of the clavicle and is carried distally over
the middle of the scapula to its angle- The
inferior angle of the scapula is mobilized
and the vertebral border is dissected from
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the chest wall in much the same way as
for a forequarter amputation. If the lesion
involves the scapula, a wide soft tissue
margin must be preserved. The skin flap
from the initial incision is raised over the
proximal humerus, leaving the deltoid muscle
intact with the specimen in upper humeral
lesions. When much of the humerus is re
moved, excessive shortening can be avoided,
and better elbow power for flexion provided,
by a humeral prosthesis or Kiintscher nail
replacement fixed into the proximal soft
tissues or the clavicle stump (Fig. 4). Some
patients are more comfortable if a greater
amount of clavicle is removed and the nail
is fixed into the soft tissue. Closure is rou
tine; hemovac suction is used. A postoper
ative sling and swathe or Valpeau dressing
is applied- Hand and elbow movement is
encouraged early postoperatively.
Results
Follow-up ranged from 2 to 37 months.
Of the 11 patients 7 are alive without evi
dence of disease.
The patient who was admitted with pul
monary metastases underwent subsequent
thoracotomies at 2, 7 and 13 months after
resection. He has no apparent disease 3
months after his last operation.
Four patients died. One was admitted
with pulmonary metastases (radiation osteo
genic sarcoma from previous Hodgkin’s dis-

Fig. 4.—(a) Preoperative radiograph of osteo
genic sarcoma of humerus in 11-year-old. (b)
Postoperative radiograph showing Kiintscher nail
inserted after resection to maintain length o f arm.
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ease) and died of widespread metastatic dis
ease 6 months after resection. Surgery in
this patient was palliative only. Another pa
tient died 7 months after resection with
widespread disease and a local recurrence.
The remaining two patients died of wide
spread metastases.
The result in the one patient with local
recurrence could not have been improved
by a forequarter amputation since the same
tissue planes at the insertion of the levator
scapulae muscle would have been disturbed.
Six (66%) patients never had evidence of
metastatic disease.
One patient, who is alive without disease,
received vaccine (lysed cell) therapy postoperatively 3 years ago.
Of the five patients who received chemo
therapy all are free of disease.
Wrist and hand function was normal in
patients who underwent operation. In pa
tients with radial nerve palsy, a cock-up
splint was used and tendon transfers were
done 2 years later. The surgical deformity
was usually corrected by a small amount of
shoulder padding under clothing, but a plas
tic filler is better.
L esions

o f the

P roximal T ibia

Eleven patients (age range, 11 to 24 yr)
with osteogenic sarcoma of the proximal
tibia underwent en bloc resection and total
long-stem knee replacement. One patient
had metastatic disease on admission. After
resection and replacement the patients were
started on the chemotherapy protocol.1114 .21
Operative Technique
A posterior medial incision is made and
the neurovascular bundle identified. The
anterior tibial artery and other interosseous
perforating vessels are ligated at their orig
in. The vessels of the popliteal fossa are
also ligated, preserving the main arterial
trunk. The fibula is removed en bloc along
with the upper tibia. The total knee and
distal femur are also removed en bloc, keep
ing a margin of normal tissue around the
tumour. Care must be maintained to
preserve cutaneous nerves. If a tumour of
the upper tibia has extended into the skin,
this area, of course, must be sacrificed.
The long-stem Guepar knee (with solid
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shafts) is cemented into the distal tibia and
proximal femur.
Results
The follow-up in this group ranged from
4 to 23 months. Eight (72) patients never
had evidence of metastatic disease. Two pa
tients are alive with disease after thoraco
tomy, one at 16 and one at 20 months after
resection. One patient died 3 months after
resection with pulmonary metastases and
local recurrence. In retrospect she should
not have undergone resection because her
lesion was too large. Amputation was done
in one patient at his request because of ex
cessive numbness of his foot (too many
cutaneous nerves had been sacrificed).
L esions

of the

F ibula

One patient, a 15-year-old girl, had osteo
genic sarcoma of the right fibula. She had
received a direct blow below the right knee,
resulting in continued mild discomfort and
swelling, 3 weeks before admission. The
right knee joint had a full range of motion.
Clinically, the lateral popliteal nerve was
intact. Arteriography demonstrated that the
tumour was resectable. She was started on
the chemotherapy regimen14’ 21’ 22 and
after a frozen section biopsy confirmed the
presence of osteogenic sarcoma, she under
went en bloc resection of the fibula.
Because of persistent fluid collection, re
sumption of chemotherapy was delayed until
2 months after operation. Vincristine and
methotrexate with citrovorum factor rescue
were administered according to our adju
vant chemotherapy protocol,14- 21*22 for 1
year.
Operative Technique
A long skin incision is made from above
the knee joint to the ankle, leaving a seg
ment of skin directly overlying the tumour.
Skin flaps are developed anteriorly and
posteriorly. The tumour is not exposed and
a 2-cm layer of healthy tissue is left over
the tumour. The lower fibula is disarticulated
at the ankle mortice. Using an osteotome,
a section of tibia above and medial to the
tibiofibular joint that includes part of the
lateral tibial condyle, is removed en bloc
with the specimen. Thus the whole of the
fibula is removed together with the tumour.

i
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tibiofibular joint and a wide surrounding
zone of muscles; the common peroneal
nerve and two of the three lower limb ar
teries are ligated. A long-leg plaster cast is
applied with the ankle in the neutral posi
tion for 6 weeks.
Results

The patient was free of disease for 2Vi
years and walked without a limp with the
use of a drop-foot brace. Stress films showed
no instability of the ankle joint. Then a
nodule developed inside the upper tibia.
The remainder of the upper tibia was re
moved en bloc and a Guepar total knee with
long-stem prosthesis was inserted. She con
tinues well and there is good stability of
the ankle joint, contributed to by the resi
dual capsule as well as the lateral ligaments.
Summary

In all, 43 patients were treated for osteo
genic sarcoma of the extremities by en bloc
resection and chemotherapy. Of this group
32 (74%) are alive after tumour resection,
chemotherapy and pulmonary resection and
29 (67%) have no evidence of disease.
Of the 38 patients without metastatic dis
ease at the time of admission 24 (63%) are
alive without evidence of disease and with
out having had postoperative metastases.
Compared with published survival rates,
these results are considerably better than
those of previously described treatment
plans.7, 32-35
The ultimate test for this method of man
agement is the control of tumour. The mean
time for development of pulmonary meta
stases after amputation for osteogenic sarco
ma has been reported to be 7.9 months.3 ’' In
a recent study at Memorial Sloan-Kettering
Cancer Center, when radiographs were taken
at 1-month intervals, the mean time for de
tecting pulmonary metastases was only 5.5
months.10 Poor survival rates in children
with osteogenic sarcoma, despite adequate
radical ablation of the primary tumour site,
are probably due to the presence of distant
microfoci of disease, mainly pulmonary, at
the time of operation.36' 37 Hence pul
monary resection and systemic chemothe
rapy using drugs with demonstrated efficacy
are needed for optimal treatment of this
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radioresistant tumour. If these means are
utilized, en bloc resection for osteogenic sar
coma appears to be a feasible alternative to
radical amputation.
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• increases the chances
of survival in acute
pancreatitis
•
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stops hyperfibrinolytic
hemorrhage
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venous injection (at a rate not to exceed 5 ml
per minute), the rest if necessary by slow infu
sion. Administration should be continued up
to 1,000,000 K.I.U. per day until the hemorrhage
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RADIATION TREATMENT OF EWING’S SARCOMA AND
OSTEOGENIC SARCOMA*
R. D. T. JENKIN, MB, FRCP[C]t
A t the Princess Margaret Hospital, Toronto, dur
ing the period 1960 to 1975, radiation therapy
was given to 59 patients with Ewing's sarcoma
without overt metastases. Over this period
treatment was modified to include, as well as
irradiation to the primary tumour, total body ir
radiation (TBI) and chemotherapy according to
various regimens. The 5-year survival rate of 38%
in 26 patients who received TBI suggests that
this may be of value.
In patients with osteogenic sarcoma preoper
ative irradiation was not found to be of value.
Recently the resection of pulmonary metastases
combined with chemotherapy has increased the
survival rate. When the primary site makes
resection impracticable, the response to ir
radiation and chemotherapy is encouraging.
Three cases so treated are described.

Entre 1960 et 1975, au Princess Margaret Hos
pital de Toronto, de la radiotherapie a ete administree a 59 patients souffrant de sarcome
d'Ewing sans signe de metastases. Durant cette
periode le traitement a ete modifie pour inclure, avec I'irradiation de la tumeur primaire,
I'irradiation corporelle totale (ICT) et divers
regimes chimiotherapeutiques. Le taux de survie a 5 ans de 38% chez 26 patients qui ont
recu I'lCT suggere que ce mode de traitement
peut etre valable.
Chez les patients souffrant de sarcome osteogenique I'irradiation preoperatoire n’a pas ete
trouvee de valeur. Recemment la resection des
metastases pulmonaires associee a la chimiotherapie a augmente le taux de survie. Quand
le foyer primaire rend la resection impossible,
la reponse a I’irradiation et a la chimiotherapie
est encourageante. Trois cas traites de cette
maniere sont decrits.

*From the department of radiation oncology, The
Princess Margaret Hospital, Toronto, Ont.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont. May 12,
13, 1977
tAssociate professor of radiology, University of
Toronto.
Reprint requests to: Dr. R. D. T. Jenkin, Depart
ment of radiation oncology, The Princess Marga
ret Hospital, 500 Sherbourne St., Toronto, Ont.
M4X 1K3.

I n both Ewing’s sarcoma and osteogenic
sarcoma, control of the primary tumour is
the first requirement if adjuvant drug treat
ment is to fulfil its potential to increase the
rate of cure by eradication of occult meta
static disease. In Ewing’s sarcoma irradia
tion of the primary tumour will provide
rapid complete control initially. In osteo
genic sarcoma response to irradiation alone
is slow and often incomplete, so that re
section is the treatment of choice, irradia
tion being reserved for the small number
of patients in whom the tumour site makes
resection impracticable.
This report will update and extend the
experience at the Princess Margaret Hos
pital, Toronto (PMH) with radiation therapy
for Ewing’s sarcoma1’3 and osteogenic sar
coma.
E w in g ’s Sarcoma

During the period 1960 to 1975, 77
consecutive patients with Ewing’s sarcoma
who had not been treated previously were
registered at PMH; 17 had overt metastatic
disease at the time the diagnosis was made.
In all 77 patients the primary tumour was
treated by irradiation. Treatment methods
evolved during the study period, and they
will be analyzed for each of four periods
of uniform treatment policy (1960 to 1964,
1965 to 1969, 1970 to 1972 and 1973 to
1975).
Treatment Groups
1960 to 1964.—During these years
treatment consisted of irradiation of the
primary tumour alone, careful follow-up
and, in the metastatic phase of the disease,
single-agent chemotherapy and local irra
diation of symptomatic sites.
The 16 consecutive patients without me
tastases at the time of diagnosis, so treated,
formed the base line for our subsequent
experience. The 5-year survival rate in these
16 patients was 25% and the 5-year re
lapse-free survival rate was 12% (Fig. 1).

November 1977

THE CANADIAN JOURNAL OF SURGERY

531

Years

Fig. 1.—1960 to 1964. Ewing’s sarcoma. Survi
val (------) and relapse-free (— ) survival rates
in 16 patients whose initial treatment was local
irradiation only. Results at 1, 3 and 5 years are
indicated.

At 1 year from diagnosis only 44% were
relapse-free.
The primary tumour was treated with a
dose of 4500 to 6000 rad in 3 to 6 weeks;2
5000 rad in 25 fractions over 5 weeks be
came our standard dose, employed to the
present time. The tissue volume irradiated
included the whole tumour and a margin
of not less than 5 cm. Ewing’s sarcoma,
while arising in bone, is mostly a large soft
tissue mass. Therefore, if the tumour was
located in a limb, the irradiated volume
included not only the whole involved bone
but all the soft tissues of that segment of
the limb. In the pelvis it is difficult to de
lineate the soft tissue mass precisely by
palpation, bone and soft tissue radiography,
or bone scanning, even when complemented
by intravenous pyelography or angi
ography. Recently computerized tomography
(CT) has proved valuable in delineating the
soft tissue mass at this site and has re-em
phasized the large fields required to pro
vide adequate irradiation (Fig. 2).
1965 to 1969.— Experience with irra
diation of the primary tumour as the only
treatment indicated that most patients with
Ewing’s sarcoma have occult metastases at
the time of diagnosis, which subsequently
become overt, usually within 18 months.
This is illustrated by the shape of the re
lapse-free curve in Fig. 1.
Impressed by the effectiveness of irradia
tion in the treatment of the primary tumour

Fig. 2 b
Fig. 2.—(a) Radiograph and (b) computerized
tomography scan o f Ewing’s sarcoma of left ilium.
Note large soft tissue mass identified on scan.

we developed a protocol in which the occult
systemic disease was also treated by irra
diation. Thirteen patients were treated ac
cording to this protocol during the years
1965 to 1969. Upon completion of primary
tumour irradiation they underwent total
body irradiation (TBI) (300 rad given in a
single treatment).2- 2 Three of these 13 pa
tients had evidence of metastases at the
time of diagnosis, although in 2 patients only
a solitary site was identified.
The 5-year survival and relapse-free
survival rates were 38 and 23% , respective
ly (Fig. 3). Among the four patients alive at
5 years were the two with a solitary meta
static site (one in bone, one in lung).
While these were relatively good results
for this tumour, 10 of the 13 patients had
relapsed within 24 months of diagnosis, so
that the initial steep slope of the relapsefree survival curve was not altered (Fig. 3).
During this period adjuvant chemo-
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Years
Fig. 3 .—1965 to 1969. Ewing’s sarcoma. Survivival ------ ) and relapse-free (-—) survival rates
in 13 patients whose initial treatment was local
irradiation followed by total body irradiation
(TBI).
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Fig. 4.—1970 to 1972. Ewing’s sarcoma. Surval (------ ) and relapse-free (— ) survival rates
in 13 patients whose initial treatment was local
irradiation. TBI and 1 year of cyclophosphamide
and vincristine.

therapy, under study elsewhere, had shown out demonstrable metastases at the time
promising early results.4 10 A new protocol of diagnosis received irradiation of the
was therefore designed in which elective primary tumour as before, although chemo
systemic treatment was with TBI, cyclo therapy was given concurrently. A number
phosphamide and vincristine.
of chemotherapy regimens were used. In
1970 to 1972.— Thirteen patients with particular, nine patients received a fourout evidence of metastatic disease at the drug program including various combina
time of diagnosis received, initially, a dose tions of cyclophosphamide, actinomycin D,
of 5000 rad in 25 fractions to the primary vincristine and doxorubicin (Adriamycin),
tumour, 300 rad TBI on completion of lo which was planned to be of 24 months’
cal irradiation and then combination chemo duration.
therapy, which began on recovery from the
Results have been disappointing. The
pancytopenia induced by TBI and continued actuarial 3-year survival and relapse-free
for 12 months. Cyclophosphamide (15 survival rates were 32 and 19% although
mg/kg) and vincristine (0.05 mg/kg to a the respective 1-year rates of 100 and 70%
maximum dose of 2.0 mg) were given as represented an improvement (Fig. 5).
alternating weekly intravenous injections.
Primary Tumour Control
Nine of these patients were treated more
than 5 years ago and four more than 4
All 59 patients included in the four treat
years ago.
ment groups described above had an ap
The actuarial 5-year survival and re parently adequate initial response to irra
lapse-free survival rates were 38 and 11%, diation at the primary site as determined
respectively (Fig. 4). These results were not by symptomatology, clinical and radiologic
obviously different from our former ex examination.
perience; in particular, the 1-year relapseThe true effectiveness of local irradiation
free rate (46% ) was not improved.
is indicated by the rate of recurrence at
During this period TBI precluded the the primary site. An isolated first relapse at
use of chemotherapy until approximately 2 the primary site or a synchronous first re
months after diagnosis. Since the initial lapse at both the primary and distant sites
slope of the relapse-free survival curve re are the forms of primary recurrence that
mained steep (Fig. 4) we elected to discon are clearly definable and obviously repre
tinue TBI and to introduce early combina sent inadequate irradiation control, so that
tion chemotherapy.
their incidence may be used to monitor the
1973 to 1975.— Seventeen patients with- effectiveness of irradiation. Recurrence at

0
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Fig. 5.-1973 to 1975. Ewing’s sarcoma. Actu
arial survival (------) and relapse-free (—-) sur
vival rates in 17 patients whose initial treatment
was local irradiation followed by 18 to 24 months
of chemotherapy with various combinations of
cyclophosphamide, vincristine, actinomycin D and
doxorubicin.

the primary site may also be seen after one
or more systemic relapses, but its impor
tance at that time is uncertain with regard
to the differentiation between true tumour
recurrence and reseeding to the primary
site. At autopsy, diffuse skeletal involve
ment is common and microscopic tumour at
the primary site is generally found. While
the incidence of a first relapse at the primary
site is clearly definable and of major clinical
importance, the true rate of irradiation
failure, while not precisely definable, will
be higher.
A first relapse, which included recurrence
of the primary tumour, was seen in 15
(25%) of the 59 patients. In 4 patients the
first relapse was at the primary site alone
whereas the other 11 patients had synchro
nous relapse at both primary and distant
sites. The prospect for relapse at the primary
TABLE I.—I ncidence of P rimary R ecurrence

of

site was not dependent on the site of the
primary tumour, at least when sites were
divided simply into those of limb or trunk
(Table I). Neither did the specific treatment
protocol appear to influence the incidence
of recurrence at the primary site, although
the patient numbers were small (Table II).
Among 35 patients with a limb tumour,
overt metastatic disease did not develop in
10. Only 1 of these 10 patients had a relapse
at the primary site, and he was subsequently
cured by resection. But of the 25 patients in
whom metastatic disease developed, the first
relapse was at the primary site in 8, although
this was synchronous with metastatic disease
in 7 of them. The greater effectiveness of
primary tumour irradiation in the patient
without occult metastases may simply reflect
a selection of patients with smaller primary
tumours, that is, with a smaller number of
tumour stem cells to be eradicated or with
less malignant tumours, rather than an indi
rect influence of the occult malignant cell
population on primary tumour radiosensitiv
ity. Our patient numbers were too small to
provide useful data on this point.
Conclusions

In Ewing’s sarcoma irradiation of the
TABLE II.—I ncidence of P rimary R ecurrence
of E wing ’s Sarcoma R elated to the T reatment
R eceived
Primary
No. of
patients recurrence

Treatment
Irradiation to tum our
alone................................
Irradiation to tum our and
total body irradiation
(T B I)..............................
Irradiation to tumour,
TB I and chemotherapy.
Irradiation to tum our and
chemotherapy................
T o tal...........................
E wing ’s Sarcoma R elated

to the

16

4

13

2

13

3

17

6

59

15

S ite of Origin

Recurrence
No. of
patients

Primary
site alone

Primary and
distant sites

Total (%)

T runk—
Lim b.......

24
35

2
2

4
7

6 (25)
9 (26)

Total

59

4

11

15 (25)

Site
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primary tumour remains the treatment of
choice. Return of normal function is rapid
and primary recurrence is uncommon un
less overt metastatic disease appears syn
chronously or earlier. A dose of 5000 rad
in 25 fractions over 5 weeks is considered
appropriate in that local morbidity is ac
ceptable even when combination chemothe
rapy is given for protracted periods. All
available methods of investigation should
be used to delineate the extent of the pri
mary tumour. Very generous tissue vol
umes should then be irradiated.
It is unclear from our experience whether
TBI is an effective systemic treatment. The
5-year survival rate of 38% for 26 patients
who received this treatment, with or with
out cyclophosphamide and vincristine, sug
gests that it may be of value. The elective
irradiation of tissues likely to be involved
with micrometastases at diagnosis therefore
remains an active area of investigation.

Vol. 20

Recent Advances

Until recently the mortality rate for osteo
genic sarcoma was about 80%. Failure of
treatment was due almost entirely to the de
velopment of, and the failure to control,
pulmonary metastases. Two advances have
changed this situation. First, it became ap
parent that multiple pulmonary resections
could salvage some patients with overt pul
monary metastases.13 In as many as 50%
of patients in whom pulmonary metastases
eventually appear, only a small number of
foci exist, so that cure by resection is prac
tical. Second, effective adjuvant chemothe
rapy with either doxorubicin or high-dose
methotrexate with citrovorum factor rescue
was developed, with a 50% chance of era
dicating micrometastases present at the time
of diagnosis.14’ 13
The combination of adjuvant chemothe
rapy with pulmonary resection when neces
sary has markedly increased the survival
rate, in osteogenic sarcoma. For example, at
O steogenic Sarcoma
the PMH the 2-year survival rate increased
from 18 to 81% when 31 patients, less
Historical Considerations
than 30 years old, treated during the period
Extensive experience with preoperative 1958 to 1970, were compared with 16
irradiation for osteogenic sarcoma demon treated during 1974 and 1975 (Fig. 6).
strated that tumour response was slow and
frequently incomplete, even at high dosage.
Current Indications for Irradiation
For example at the PMH from 1958 to
The success of doxorubicin and high1970, 27 patients less than 30 years of age
were treated by initial irradiation of a
peripheral tumour to a dose of 5000 to
6000 rad in 25 to 30 fractions. Response
was judged to be complete in 3, partial in
17 and absent in 7. The primary tumour
recurred in all 27 patients within a median
time of 3.6 months.11 Therefore, this did
not prove to be a useful palliative man
euver, while we sought to select for delayed
amputation patients in whom the risk of
development of pulmonary metastases was
small. Irradiation of the peripheral primary
tumour has therefore been abandoned, at
least in North America.
Massive irradiation immediately preoperatively has also had adequate trial. The ra
tionale was that this might be a tumour- Fig. 6.—Comparison of survival rates for 16
specific immunologic stimulus and also that patients
with osteogenic sarcoma, less than 30
old, referred postoperatively to Princess
viable tumour cells would not be liberated years
Margaret Hospital, Toronto (PMH) during 1974
at the time of resection. Results were un and
1975 for elective systemic therapy and for 38
patients treated during 1958 to 1970 at PMH.
equivocally negative.12
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dose methotrexate in the adjuvant context
required that the effectiveness at the pri
mary site of irradiation combined with
these drugs be evaluated. Since in some
patients the tumour site makes resection
impracticable, experience with this bimodal
approach is accumulating. Three patients
with primary osteogenic sarcoma in the
sacroiliac region have been treated at the
PMH in this manner.10
Case 1.— A 12-year-old girl had both a
primary tumour in the sacroiliac region and a
single secondary in the os calcis. The primary
tumour was irradiated with 6000 rad (in 30
fractions) and the secondary with 2500 rad
(in 5 fractions). This was followed over a pe
riod of 8 months by a course of doxorubicin
to a cumulative dose of 550 m g /m 2 and subse
quently by intermittent high-dose methotrexate.
She continued in complete remission more than
39 months from the time of diagnosis. The
hypoxic cell sensitizer, metronidazole, was
given during irradiation. Evidence of late
toxicity included major bone degeneration in
the irradiated area and soft tissue fibrosis.
Case 2.— A 16-year-old girl had a primary
tumour at the sacroiliac joint and a small
shadow, assumed to be a metastasis, in the left
lower lung. The primary site was irradiated
with 5000 rad (in 24 fractions). Doxorubicin
was given concurrently followed by combina
tion treatment with doxorubicin and high-dose
methotrexate. Doxorubicin given after she had
received 4200 rad caused acute enteritis. The
patient remained in complete remission more
than 11 months from the time of diagnosis.
Late toxic manifestations included an episode
of small bowel obstruction requiring laparo
tomy.

Fig. 7.—Case 3. Extent of left sacroiliac chondroblastic osteogenic sarcoma is demonstrated.
Note soft tissue pelvic component of mass and
direct invasion of, and seeding within, spinal canal.

Case 3 .— In this 23-year-old woman a
primary osteogenic sarcoma of the sacroiliac
area was recently diagnosed. Seeding within
the spinal canal was evident (Fig. 7). Local ra
diation was given to 4750 rad in 23 fractions
combined with high-dose methotrexate in the
1st and 3rd weeks of irradiation. M etronidazole
(1 to 3 g/d) was given 4 hours before irradia
tion. A severe skin reaction required that treat
ment be discontinued before 5000 rad was re
ceived as planned. It is too early to assess this
patient’s response to irradiation.

It is possible that irradiation control of
the primary tumour may have been enhanced
in these patients by the chemotherapy, since
in our earlier experience with 27 irradiated
patients less than 30 years old only 3 pa
tients had a “complete” response and this
response was of only 3 to 6 months’ dura
tion. However, the toxicity has been high.
Control of primary osteogenic sarcoma
with irradiation at high-dose-per-fraction
megavoltage combined with the radiosensi
tizer, 5 -bromodeoxyuridine, and systemic
therapy with high-dose methotrexate, doxo
rubicin, cyclophosphamide and vincristine
has recently been reported.17 The high-dose
fractions were used since there is a broad
shoulder to the cell survival curve for osteo
genic sarcoma irradiated in vitro.18
Metastatic Lung Disease

Whole lung irradiation alone to a dose of
2000 rad in 20 fractions has little demon
strable effect ^fcovert metastatic disease of
the lung. Individual lung metastases may re
spond to small-volume high-dose irradia
tion.
Elective irradiation of the lung (1500 rad
over 14 d) following control of the primary
site has been subjected to prospective ran
domized clinical trial. At the Mayo Clinic
no observable effect was found, although at
48 months approximately, 37% of all pa
tients were without pulmonary metastases.10
Conversely, in a cooperative prospective
randomized clinical trial, 41% of the electively irradiated patients (1750 rad in 10
fractions over 12 d) were free of metas
tases at 48 months compared with 26% of
those with no irradiation of the lung (P =
0.08).20' 21
Since radiation is an active agent in osteo✓
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genic sarcoma, its elective use in combina
tion with chemotherapy to eradicate occult
pulmonary metastases is currently under
active study.

Conclusions
Resection is the primary treatment of
choice in osteogenic sarcoma. There are pro
visional data indicating that, when resection
is not practical, the primary tumour may be
controlled by irradiation in combination
with effective chemotherapeutic agents and
possibly with radiosensitizers. The duration
of medical control is uncertain but appears
to be greater than that achieved with irra
diation alone.
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CURRENT CONCEPTS IN THE MANAGEMENT OF DISSEMINATED
MALIGNANT BONE DISEASE IN CHILDHOOD*
NORMAN JAFFE, MB, BCh, Dip Paed
Disseminated malignant disease should be ap
proached with the intention of curing the patient.
This requires a multidisciplinary approach. Es
sential to the successful application of multi
disciplinary treatment is the administration of
effective chemotherapy, which may achieve re
duction in both microscopic disease and overt
tumour. In Ewing’s sarcoma, the latter should be
treated also by irradiation. Limited areas of bulk
tumour that have failed to respond or have re
sponded only partially may be removed surgical
ly. Chemotherapy and radiation therapy should
be used extensively for palliation; surgery may
be required occasionally for control of pain. The
decision to treat palliatively should be reached
only after patients have received multidisciplin
ary consultation.
Les neoplasies disseminees devraient etre
abordees avec I’intention de guerir le patient.
Ceci requiert un apport multidisciplinaire. Line
chimiotherapie efficace est essentielle au succes d'un traitement multidisciplinaire. Elle peut
permettre d’enrayer aussi bien les lesions microscopiques que la tumeur macroscopique.
Dans le sarcome d'Ewing, il y a lieu de recourir
aussi a I’irradiation. Des regions limitees d'une
masse tumorale qui n’a pas repondu au traite
ment ou qui y a repondu partiellement peuvent
etre enlevees chirurgicalement. La chimiothe
rapie et la radiotherapie devraient etre frequemment utilisees comme traitement palliatif;
la chirurgie peut etre necessaire a I’occasion
pour controler la douleur. La decision d'entreprendre un traitement palliatif ne devrait etre
prise qu’apres que les patients aient repu une
consultation multidisciplinaire.

D uring the past decade, major progress has
been made in the management of several
childhood tumours.115 This derives from
the application of adjuvant chemotherapy to
*From the Sidney Farber Cancer Institute, Chil
dren’s Hospital Medical Center, and Harvard
medical school, Boston, MA.
Supported in part by a research grant (CA06516)
from the National Cancer Institute and by grant
RR-05526 from the division of research facilities
and resources, National Institutes of Health.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont., May 12
and 13, 1977.
Reprint requests to: Dr. Norman Jaffe, Sidney
Farber Cancer Institute, 44 Binney St., Boston,
MA 02115, USA.

destroy clinically undetected micrometastases and the adoption of an integrated
multidisciplinary approach to the treatment
of established disease. This paper reviews
current concepts in the management of dis
seminated malignant disease in childhood
with particular reference to osteogenic sar
coma and Ewing’s sarcoma.
G en er a l P r in c ip l e s

Histologic Diagnosis

Meticulous histologic confirmation of the
tumour is basic to planning an optimal
course of therapy and will assist in differen
tiating primary malignant tumours of bone
from metastatic infiltration from other
sources. Tumours that most frequently me
tastasize to bone include neuroblastoma,
rhabdomyosarcoma and soft tissue sarcomas.
Occasionally Ewing’s sarcoma must be dif
ferentiated from nonHodgkin’s lymphoma
and early leukemia, and osteogenic sarcoma
from fibrosarcoma and chondrosarcoma.
Assessment of Extent of Disease (Staging)

After confirmation of the existence of a
neoplasm, its full extent must be determined.
In bone diseases, investigation for this
purpose includes radiographic examination
of the chest, complete lung tomography and
fluoroscopy if indicated. Radiographic ex
amination of the skeleton has generally been
replaced by bone scintigraphy, reserving the
former for sites dictated by the scintigram.
Bone marrow examination is frequently per
formed in suspected cases of Ewing’s sar
coma or nonHodgkin’s lymphoma of bone.
Other examinations are carried out as indi
cated.
Evaluation of Previous Treatment

A fujl assessment of the treatment pre
viously administered is of critical impor
tance. This applies particularly to chemo
therapy. Occasionally patients considered
unresponsive to a specific chemotherapeutic
regimen may obtain a response when the
dose and schedule of the identical agents
are altered. This has been demonstrated
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in the weekly high-dose methotrexate pro
gram (vincristine-methotrexate-citrovorum
factor).3
Multidisciplinary Conference
Once the full extent of disease has been
established, expertise from each discipline
is elicited for the planning and strategy of
further treatment. Each patient receives in
dividual consideration, and invariably the
approach should be with “an intent to cure” .
Patients generally will fall into two major
categories: those in whom cure is possible
and those who cannot be cured.
Curable advanced metastatic disease. —
Chemotherapy in these patients forms the
vanguard of treatment. When administered
in an aggressive and systematic manner, de
struction of tumour may result in impressive
responses and it may be possible to transfer
the patient from a “palliation” treatment
status to one of “potential cure”. If a satis
factory response is achieved, one may reach
a decision to ablate the primary lesion if
this has previously not been performed.
Foci that fail to respond or foci of residual
disease, if limited, may be removed sur
gically or treated by irradiation. After a
complete remission, further treatment is with
adjuvant chemotherapy.
Palliation. — This form of treatment con
stitutes the bulk of clinical practice in pa
tients with disseminated disease since cure is
usually not attainable when the disease is
widespread. The decision to palliate should
be made at the multidisciplinary consultation.
Analgesics should then be administered judi
ciously and without restriction. Chemothe
rapy and radiation therapy are indispensable
for treating patients in this category. Fre
quently their application may reduce turnoutbulk and prolong useful life.8- »• 13 Surgery
also has a definite role in palliation. In some
instances cervical chordotomy may be
recommended. Occasionally the pain in a
swollen functionless limb is so intense that
relief may be possible only through am
putation. The family should be fully ap
prised of the goals of treatment, and ade
quate supportive care should be provided.
The general principles governing the man
agement of disseminated disease in children
are particularly applicable to osteogenic sar
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coma and Ewing’s sarcoma, in which the
evolution of new treatment programs has
produced a number of unusual complica
tions. These have required more specific
forms of management and will be discussed
in greater detail.
O steogenic S arcoma

Effective chemotherapy has induced a
change in the biologic behaviour of osteo
genic sarcoma. In the majority of patients,
micrometastases appear to have been de
stroyed and in the minority who relapse, metastases of the lungs, the most frequent
site of spread, have been reduced and de
layed.2 0 This has prompted more aggres
sive treatment to render additional patients
free of disease.5 Essentially, attempts are
made to achieve an NED (no evidence of
disease) status by the administration weekly
of a combination of vincristine and highdose methotrexate with citrovorum factor
(V-MTX-CF). Metastases that fail to re
spond are removed surgically. Radiation
therapy combined with V-MTX-CF weekly
may be administered if the tumour has been
incompletely resected. After an NED status
has been achieved, V-MTX-CF is admin
istered at 3-weekly intervals on the assump
tion that this can still be effective against
residual microscopic disease. Doxorubicin
(Adriamycin) is also prescribed for patients
who have not received this agent previously.
With this approach, 12 of 24 patients have
been rendered free of disease for periods
varying from more than 7 to more than
52 months (updated from original publica
tion"’).
The alteration in metastatic pattern has
not been limited to the pulmonary paren
chyma- During the past 2 years in seven
patients undergoing treatment with adjuvant
programs, metastases developed in iliac
nodes, ribs, femora, vertebrae or other bones.
Surgical removal of metastatic tumour was
attempted in most with gratifying results.
Radiation therapy and V-MTX-CF weekly
were also administered to some patients. In
those with lesions of the femur, internal
prostheses were used, permitting further
ambulation.5
Involvement of the vertebral bodies by
metastatic osteogenic sarcoma represents an
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emergency situation. It occurred in three
patients who had been treated with V-MTXCF for 20 to 24 months after the diagnosis
had been made and treatment initiated.
Pulmonary metastases had appeared approx
imately 8 months earlier. In view of the
limited number of pulmonary metastases,
the potential for extended survival appeared
excellent. In one patient, immediate neuro
surgical decompression to secure viability
of the spinal cord was undertaken. This was
followed by radiation therapy (3500 rad),
which was also administered to the other
two patients. In all three symptomatic im
provement and retention or restoration of
neurologic function were achieved. The
complication may be detected' incidentally
on radiographic examination or may mani
fest with pain, sudden onset of paralysis or
paresis and inability to void urine. The site
of obstruction is demonstrable by myelo
graphy. The problem will probably be en
countered with increasing frequency in the
future and will represent a major challenge.
Metastases to bone may be particularly
painful. Frequently such pain can be re
lieved by irradiation and weekly treatments
of V-MTX-CF. More recently we have ob
tained similar gratifying results with cisplatinum (50 m g/m 2) administered on 2
consecutive days every 3 weeks. In one pa
tient objective and subjective responses were
obtained. Further investigations with cisplatinum are in progress.
E w in g ’s Sarcoma

Various chemotherapeutic regimens are
effective in Ewing’s sarcoma and several
have produced complete remission.8’ •' This
provides compelling support for the use of
chemotherapy in patients with metastatic
disease. Combinations of vincristine, actinomycin D, doxorubicin and cyclophospha
mide have prolonged survival. However, in
most patients the responses were tempo
rary.8’ !) Additional or alternative modes of
therapy are indicated.
Radiation therapy is also effective in the
treatment of Ewing’s sarcoma. This is gen
erally administered as treatment of the pri
mary lesion in association with chemothe
rapy. Most investigators report a high degree
of local control. Their experience indicates
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that patients with metastatic disease should
receive a combination of radiation therapy
and chemotherapy. Chemotherapy should
be administered principally to destroy mi
croscopic tumour and, it is hoped, areas of
bulk disease wherever possible. The latter
should also be irradiated to achieve a more
durable response. Surgical ablation of resi
dual disease, if limited, or of isolated tu
mours that have failed to respond, might
also be considered.
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BONE SARCOMAS: CLINICAL EXPERIENCE*
JOSEPH G. SINKOVICS, MD, FACPt and CARL PLAGER, MD
Sarcomas of osseous origin form a heterogen
eous group of tumours with great variability in
their natural history. Irradiation is an established
etiologic factor. The possibility of oncornaviral
etiology offers a unifying concept. Patients with
osseous sarcomas respond immunologically to
their tumours. Immunotherapeutic measures
have not as yet conferred more than marginal
benefit when applied adjunctively with conven
tional therapy. Chondrosarcoma is a surgically
curable tumour still resistant to radiotherapy and
chemotherapy. Adjuvant chemotherapy with
doxorubicin or with high-dose methotrexate and
citrovorum factor rescue can suppress or eradi
cate the micrometastases of osteogenic sar
coma. Ewing's sarcoma is highly sensitive to ra
diotherapy and chemotherapy, and adequately
treated patients can now survive, clinically free
of tumour, for long periods.
Les sarcomes d'origine osseuse forment un
groupe heterogene de tumeurs ayant une gran
de variabilite dans leur etiologie naturelle. L’irradiation est un facteur etiologique reconnu. La
possibility qu'ils originent d’un virus oncorna
offre une notion d’unification. Les patients souffrant de sarcome osseux reagissent immunologiquement a leur tumeur. Jusqu'a maintenant
I’immunotherapie n'a confere que de faibles
benefices lorsque administree en appoint au
traitement conventionnel. Le chondrosarcome
est une tumeur qui peut etre guerie par la chirurgie mais qui demeure resistante a la radiotherapie et a la chimiotherapie. Une chimiotherapie d’appoint avec de la doxorubicine, ou avec
de fortes doses de methotrexate et du leucovorin au besoin, peut diminuer ou eliminer les mi
crometastases du sarcome osteogene. Le sarco
me d’Ewing est tres sensible a la radiotherapie
et a la chimiotherapie, et les patients adequatement traites peuvent survivre, cliniquement
exempts de tumeur, pour des periodes prolongees.
*From the solid tumor service (clinics) and section
of clinical tumor virology and immunology, de
partment of medicine, The University of Texas
System Cancer Center, M. D. Anderson Hospital
and Tumor Institute, Houston, TX.
Presented at the conference “Modern Concepts of
Bone Tumor Treatment”, Ottawa, Ont., May 12
and 13, 1977.
tlnvited guest lecturer of the Royal College of
Physicians and Surgeons of Canada.
Reprint requests to: Dr. J. G. Sinkovics, Section
of clinical tumor virology and immunology, M. D.
Anderson Hospital and Tumor Institute, Houston,
TX 77030, USA.

T he clinical behaviour of sarcomas of osse
ous origin is highly variable. Ewing’s sarco
ma may be multicentric in origin or may
metastasize rapidly through hematogenous
routes after its inception. The classic intra
medullary osteogenic sarcoma is notorious
for having produced pulmonary micrometas
tases by the time of its diagnosis. In contrast
the typical chondrosarcoma is characterized
by slow and localized growth and a tendency
to metastasize late in its clinical course.
E w in g ’s S arcoma

There is no doubt that adequate therapy
for Ewing’s sarcoma should not be directed
to the primary tumour only.1' - At our clin
ics, patients without clinically evident metastases presently receive radiotherapy
(> 5000 rad megavoltage in > 5 weeks) to
the primary tumour and systemic chemothe
rapy with vincristine (1.5 m g/m- on day 1,
intravenously), cyclophosphamide (200 mg/
d on days 3, 4 and 5, orally) and doxoru
bicin (Adriamycin) (60 m g/m- on day 2,
intravenously) at 28-day intervals until a to
tal dose of 450 m g/m - of doxorubicin is
reached. Thereafter doxorubicin is replaced
with actinomycin D (0.3 m g/m -’d) on days
1 to 5 within each course, but courses are
given at 8-week intervals for a total treat
ment time (including previous courses with
doxorubicin) of 2 years. Patients with meta
static disease receive radiotherapy to selected
painful bone metastases and systemic chemo
therapy with vincristine, cyclophosphamide,
doxorubicin and dimethyl-triazeno-imidazole-carboxamide (DTIC). Table 1 presents
the clinical data for 16 patients we have
treated in the past 2 years with a follow-up
of approximately 2 years. No evidence of
disease (NED) status was achieved at 2 years
in five of six patients treated as cases of pri
mary presentation. The new treatment regi
men to be implemented in 1977 will consist
of the same schedule for radio- and chemo
therapy, but between courses of chemothe
rapy immunotherapy will also be admin
istered; that is, on days 13, 17 and 24 pa
tients will receive live Chicago bacille Cal
mette Guerin (BCG) by scarification and

TABLE I.—R esults
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P atients

with E wing ’s Sarcoma T reated with
therapy, 1975 to 1977

R adiotherapy

and

C hemo 

Clinical evaluation
at 8 — 30 mo
E xtent o f disease at in itia tio n
o f treatment

No. of
patients

N E D status

P rogression o f disease

1
Primary*..................................
7§
Metastatic)..............................
“Received vincristine (VCR), cyclophosphamide (CTX) and doxorubicin (DXR) with actinomycin D
6
10

5
3J

■(Received VCR, CTX, DXR, Act D and dimethyl-triazeno-imidazole carboxamide (DTIC).
J1 patient died of DXR cardiotoxicity.
,
.
§2 patients were inadequately treated (refused or could not take more than 1 to 3 courses of chemotherapy).

intracutaneous inoculations of “viral oncolysates” prepared from an established cell
line of Ewing’s sarcoma.3 Pseudomonas
vaccine if available for this purpose will be
given preference over BCG.
O steogenic Sarcoma

The natural history of this tumour varies
according to the cell type (fibroblastic being
the least, and osteoblastic the most, malig
nant, with chondroblastic tumours running
an intermediate course) and the location and
size of the primary tumour. Osteogenic sar
coma of the facial bones carries a good prog
nosis, there being approximately 50% survi
vors at 3 years, and still over 40% survivors
at 5 years. The most frequent primary site
is the femur; primary tumours in the proxi
mal femur follow a much more malignant
clinical course than those located distally.
At the M. D. Anderson Hospital there were
no 5-year survivors among patients with
primary osteogenic sarcoma of the proximal
part of the femur, whereas the 3- and 5-year
survival rates for patients with primary tu
mours in the distal half were 23 and 12% ,
respectively.4 In addition to the classic in
tramedullary osteogenic sarcoma, periosteal,
parosteal, extraosseous and other variants
of this tumour exist; the parosteal variant
is the least malignant.
Death from osteogenic sarcoma is fre
quent because of an extremely high (over
80%) incidence of hematogenous pulmonary
metastases. Two powerful treatment modali
ties have recently reduced postamputation
mortality and achieved remission in meta
static disease; these are systemic chemothe
rapy with doxorubicin or with high-dose
methotrexate with citrovorum factor rescue.

These modalities can be applied in combina
tion, and the methotrexate regimen aug
ments the efficacy of low-dose radiother
apy. 5-0
In addition to immunotherapy in the form
of nonspecific immunostimulation, we and
others (page 494) have applied sarcoma-spe
cific immunization with x-irradiated alloge
neic (or autologous) tumour cells, sarcoma
cell lysates (including viral oncolysates), lym
phocyte mediators (transfer factor and in
terferon) and lymphocyte transfusions.10’ 11
The overall results of immunotherapy have
been disappointing, but not entirely with
out promise. For example, both transfer
factor and interferon appear to suppress
subclinical micrometastases of osteogenic
sarcoma.
The contrast between soft tissue sarcomas
and osteogenic sarcoma in terms of response
to active immunization remains unexplained.
Modest benefits derived from nonspecific
immunostimulation and sarcoma-specific
immunization to patients with soft tissue sar
comas; sarcoma-specific immunization was
carried out with either x-irradiated sarcoma
cells12 or viral oncolysates of sarcoma
cells.13 In the latter trial, patients with me
tastatic sarcomas received chemotherapy for
5 days at 29-day intervals and on days 17
and 24 they received Chicago BCG scarified
in the skin and intracutaneous inoculations
of lysed sarcoma cells prepared from estab
lished allogeneic cultures infected with the
harmless PR8 influenza A virus with the
purpose of stabilizing antigens expressed at
the cell membrane. The least number of
progressors were found in the group receiv
ing chemoimmunotherapy.13 Similar trials,
that is, immunization of patients with clin
ical or subclinical osteogenic sarcoma with
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Osteogenic Sarcoma After Amputation, 1975

to

1977

Clinical status
No. of
patients
4

Treatment

A t initiation of treatment

A t 9 — 24 mo

VCR, CTX, DXR, DTIC

N ED

N ED > 24 mo

1*

VCR, CTX, DXR, DTIC

N ED

N ED > 24 mo

1

VCR, CTX, DXR, DTIC

Pulmonary metastases

Progression

MeCCNU, Act D

Pulmonary metastases

PR, stable > 24 mo

1

VCR, CTX, TF, BCG, DXR, Pulmonary metastases
DTIC, VO

Progression

M TX , X RT

Stable

Pulmonary metastases

1

VCR, CTX, DXR, DTIC

Pulmonary metastases

Dead

1

RBD, D TIC

Pulmonary metastases

Dead

5

COnPAdr

NED

Progression

DXR, DTIC

Pulmonary metastases

Progression in 4 (1 died)
PR, then progression in If

M TX , XRT

Pulmonary metastases

PR, then progression in 1
Stable, then progression in 2
(1 died)
Progression in 1

L5 excision. Allograft, 1970
2100 rad

N ED

Recurrence 1972

4488 rad a t 22 MV

Recurrence

1
GCB

RBD, D TIC

Progression
Stable, then progression, 1976

tAIso received bacille Calmette Guerin (BCG) and viral oncolysates (VO).
P CB
“ 11 tumour of bone;M eCCNU = methylcyclohexyl-chloroethyl-nitrosourea; T F = transfer
factor; M TX = high-dose methotrexate with citrovorum factor rescue; X RT = radiotherapy; COnPAdr =
cyclophosphamide, Oncovin (vincristine), phenylalanine mustard, Adriamycin (doxorubicin)- N ED =
no evidence of disease; PR = partial remission.

x-irradiated osteogenic sarcoma cells or with
various osteogenic sarcoma cell lysates,
failed to influence the course of this disease.
Table II summarizes our clinical experi
ence in 15 patients with this tumour limited
to the past 2 Vi years. It is evident that post
amputation treatment with vincristine, cyclo
phosphamide, doxorubicin and DTIC pre
vented clinical manifestation of metastatic
disease. The Southwest Oncology Group
protocol has been applied successfully for
the adjuvant treatment of postamputation
osteogenic sarcoma and it will be presented
elsewhere (unpublished data). Once metastases became evident, the same chemothe
rapy, chemotherapy with high-dose metho
trexate and citrovorum factor rescue with
radiotherapy, and various modalities of im
munotherapy failed to gain long-lasting con
trol over the disease. One patient with
malignant giant cell tumour of bone has been
included. Brief, temporary tumour response

was noted to rubidazone, but it was less than
that required to qualify for a partial remis
sion. Of the 15 patients, 5 had no evidence
of disease more than 2 years after postampu
tation treatment, 2 were stable at 1 and 2Vi
years, 4 had progression of their disease be
tween 9 months and 2 years and 4 died dur
ing that time.
C hondrosarcoma

In a previous review of 83 patients treated
at our institution, the pelvis was the most
common primary site.1^ This tumour differs
substantially from osteogenic sarcoma in its
natural history. The peak incidence is in the
older age groups. Radical surgery has been
curative for chondrosarcoma; decades of
tumour-free survival follow for most patients
who have undergone adequate operation.
Another difference between osteogenic sar
coma and chondrosarcoma is the relative
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Clinical status and location

C hondrosarcoma, 1976

to

1977
Clinical course

Treatment

i

Well-differentiated tumour of sternum
Pulmonary metastases

Excision, 1973
BCG, VO, 1976
RBD, D TIC , 1976

2

Myxoid tumour of chest wall

Local immunotherapy, 1976 Brief remission,
1976
Progression, 1977
RBD, D TIC , 1976

3

Grade 2 tumour of humerus

Disarticulation, 1973

N E D , 1977

4

Myxoid tumour of sacrococcyx
Pulmonary and abdominal metatases, 1976

VCR, CTX, DXR, DTIC,
1976

Dead, 1976

5

Poorly differentiated tumour of left knee.
Pulmonary metastases

5000 rad, 1973
BCG, VO, RBD, DTIC,
1976

Progression, 1976

6

Myxoid tumour of right knee
Pulmonary metastases

6000 rad, 1973.
McCCNU, D TIC , 1976

Progression, 1976
Progression, 1977

7

Grade 3 tumour of L4

Excision. 5000 rad, 1976
VCR, CTX, DX R, DTIC,
BCG, VO, 1976

N ED , 1977

Disarticulation, 1976
VCR, CTX, DXR, DTIC,
1976

Progression. 1977

8

Dedifferentiated tumour of right femur
Pulmonary metastases

radiotherapeutic and chemotherapeutic resis
tance of the latter. While the response rate of
osteogenic sarcoma to doxorubicin is almost
30% , less than 15% of the chondrosarco
mas are known to have responded. In pre
dicting the clinical course of a chondrosar
coma, grading is essential. Low-grade tu
mours (those without mitotic cells) may re
cur locally if inadequately removed, but they
seldom metastasize. The 5- and 10-year sur
vival rates for patients with these tumours
are estimated to be 90 and 83%, respective
ly. Grade 3 tumours (those with more than
two mitotic cells per high-power field) dis
play a high propensity for distant metastasis
with estimated 5- and 10-year survival rates
of 43 and 29% , respectively. The moderate
ly malignant grade 2 tumours lie in between,
with a local recurrence rate of about 50% ,
but their propensity for metastasis is still
low (grading as practised at M. D. Anderson
Hospital and Tumor Institute, unpublished).
The dedifferentiated or spindle cell chondro
sarcomas carry a poor prognosis. The preli
minary impression at our institution is that
poorly differentiated chondrosarcomas re
spond better to doxorubicin than do the
well-differentiated tumours.
At present we attend eight patients with

Progression, 1977
Progression, 1977

Progression, 1977

chondrosarcoma at our clinics (Table III).
It is evident that metastatic disease in this
group of patients has failed to respond to
chemoimmunotherapy.
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EVALUATION OF INTRAOPERATIVE BIOPSY OF THE PANCREAS*
C. JAMIESON, MB, BS, FRCS[C], K. D. BURY, MD, FRCS[C1, FACS and
N. D. COLAPINTO, MD, FRCS[C], FACS
The authors carried out a retrospective review
of intraoperative biopsy of the head of pancreas
in 47 patients. Vim-Silverman needle biopsy (32
patients), or wedge biopsy (9 patients), or both
(5 patients) were used. The correct diagnosis in
the 34 patients with carcinoma was made in
7 6 % by paraffin section and in 6 5 % by frozen
section. Diagnostic accuracy was 7 7 % with
needle biopsy and 3 8% with wedge biopsy. Com
plications occurred in six patients and consisted
of pancreatitis, fistula and hemorrhage. Two pa
tients required reoperation because of hemor
rhage. The case of one patient who died of a
pancreaticoperitoneal leak at the biopsy site is
described in detail. The overall complication rate
was 15%. These results indicate that wedge
biopsy carries significant risks and frequently
does not detect carcinoma. Needle biopsy is
relatively safe and is more likely to provide an
accurate diagnosis of carcinoma.
Les auteurs ont realise une etude retrospective,
chez 47 patients, des resultats de biopsies de la
tete du pancreas prises lors d'une intervention
chirurgicale. Une biopsie a I’aiguille Vim-Silver
man (32 patients), ou une biopsie conique (9
patients), ou les deux (5 patients), ont ete utilisees. Le diagnostic correct chez les 34 patients
souffrant de carcinome a ete obtenu chez 7 6 %
par coupe a la paraffine, et chez 6 5 % par coupe
surgelee. La precision de diagnostic a ete de 7 7 %
avec la biopsie a I'aiguille et de 3 8 % avec la biop
sie conique. Des complications, consistant en pan-

*From the departments of surgery, The Wellesley
Hospital and St. Michael’s Hospital, University of
Toronto, Toronto, Ont.
Reprint requests to: Dr. N. D. Colapinto, Ste. 503,
55 Queen St. E., Toronto, Ont. M5C 1R6.
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creatite, fistule et hemorragie, sont apparues
chez six patients. Deux patients ont necessity
une deuxieme intervention pour juguler une he
morragie. On decrit en detail le cas d'une patiente qui est decedee des suites d'une fistule
pancreatoperitoneale au point de biopsie. Le
taux global de complication a ete de 15%. Ces
resultats indiquent que la biopsie conique comporte des risques significatifs et souvent ne permet pas de deceler un carcinome. La biopsie a
I'aiguille est relativement sOre et elle est plus
susceptible d'assurer un diagnostic precis de
carcinome.

I ntraoperative biopsy of the pancreas re
mains controversial, with disagreement
among surgeons as to the value and dangers
of different methods of biopsy.1'" Often it
is difficult at operation to distinguish be
tween carcinoma and chronic pancreatitis
when a hard localized mass is found in the
head of the pancreas. Some experienced sur
geons are prepared to resect such a mass
without histologic confirmation that it is a
carcinoma;1"'1- in less than 2% of such in
stances do they mistakenly resect a benign
lesion. Most surgeons would probably re
sect benign lesions in error more often if
they did not first obtain a biopsy. If a carci
noma of the pancreas was considered unresectable at operation, the patient and his
family would benefit from an accurate diag
nosis and prognosis, but biopsy in this
situation probably would not alter the
method of management and therefore would
be an unjustified risk. Some surgeons be-
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lieve that biopsy is never indicated.3
Because of this unresolved controversy
we carried out a retrospective study of our
recent experience with intraoperative biopsy
of the head of the pancreas.
P atients

and

M ethods

In this analysis we reviewed all intraoper
ative biopsies of the head of pancreas per
formed by different surgeons at two Toronto
teaching hospitals during the 10-year period,
1966 to 1975. Cases involving biopsy of
surrounding lymph nodes, and lesions of the
ampulla, tail or body of the pancreas were
excluded.
In 35 of the 47 patients the indication for
surgery of the pancreas was obstructive
jaundice. The other patients underwent
biopsy because carcinoma was suspected, an
abdominal mass was present, or because a
mass was found in the pancreas during an
unrelated abdominal procedure.
The biopsy was taken either by needle
(Vim-Silverman) or as an incisional wedge
(Table I). Most patients had more than one
biopsy. Some underwent repeated biopsy
until a positive diagnosis was obtained; one
patient required 10 needle biopsies. In those
in whom the needle was used the average
number of biopsies was 2.3. All material ob
tained by biopsy was examined by frozen
section at the time of the operation and by
paraffin section later. Each biopsy specimen
was interpreted by several different patho
logists.
In addition to biopsy, 28 patients under
went some type of biliary-enteric bypass,
with or without gastrojejunostomy, and 7
patients underwent pancreatectomy; 12 pa
tients had biopsy only. One patient died as
a result of biopsy. This case is reported in
detail because it illustrates some of the prob
lems that may occur with biopsy of the
pancreas.
TABLE I.—B iopsy
T y p e o f bio p sy

of

Case R eport
A 63-year-old woman was admitted for in
vestigation of obstructive jaundice and weight
loss. Septic shock developed as a result of
suppurative cholangitis. At laparotomy, the
gallbladder was dilated and edematous, the
common bile duct was dilated and anterior
to it a discrete firm nodule was found in the
head of pancreas. Purulent bile was drained
from the duct and two small stones were re
moved. The distal duct was patent. Biopsy of
the pancreatic nodule was performed with a
direct approach and a wedge ( 9 x 6 mm) was
excised. Histologic examination of the speci
men indicated only inflammation and fibrosis.
Cholecystectomy and choledochoduodenostomy were performed. The patient made an ex
cellent recovery. Four weeks after operation
she was readmitted with ascites, but she had no
evidence of peritonitis and was otherwise in
good health. We suspected there was a com
munication between the pancreatic duct and
the peritoneal cavity at the biopsy site. Our
plan was to treat the patient with intravenous
alimentation, to perform retrograde pancreato
graphy followed by a pancreaticojejunostomy
over the biopsy site. However, she deteriorated
rapidly. In spite of peritoneal lavage she died
3 days later of sepsis, peritonitis and respira
tory failure. Peritonitis was confirmed at au
topsy, but there was no evidence of pancrea
titis. The biopsy site had not healed. When
injected with radioapaque dye, the distal pan
creatic duct appeared dilated and a proximal
stricture was seen (Fig. 1). The biopsy site
communicated with the pancreatic duct, distal
to the stricture (Fig. 2). Histologic examination
confirmed that this stricture was a small car
cinoma. It is unlikely that this small deep
lesion would have been identified by biopsy;

P ancreatic T umours
N o . o f p a tie n ts

Vim-Silverman needle
32 (7 transduodenal)
biopsy (alone)
9 (2 transduodenal)
Wedge biopsy (alone)
Needle and wedge biopsy 5
1
Unknown
Total

547

47

Fig. 1.—Postmortem pancreaticogram with am
pulla cannulated. Proximal to stricture pancreatic
duct is dilated.
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Fig. 2.—Pancreas opened along duct displays
stricture (lower arrow). Upper arrow indicates un
healed biopsy site.

nevertheless, it was responsible for the sur
rounding pancreatitis and probably contributed
to the complication by obstructing the pan
creatic duct.
R e su l t s

Accuracy
Two of our 47 patients had probable car
cinoma. If they are included with the 32 pa
tients in whom pancreatic carcinoma was
confirmed, the overall accuracy in diagnos
ing carcinoma on paraffin section was 76% ,
compared with 65% by frozen section.
Needle biopsy appeared to be more accurate
than wedge biopsy (Table II). There were
no false-positive reports.
Complications
Patients who underwent pancreatectomy
following biopsy were excluded from those
considered at risk from biopsy complica
tions. Six patients had clinically significant
complications that could be attributed to
the biopsy itself, and all but one of these
patients had multiple complications (Table
TABLE II.—A ccuracy of I ntraoperative B iopsy
of P ancreas in 34 P atients with C arcinoma
Diagnosis made by
Type of biopsy
(iand no. of
patients*)

Needle (30)
Wedge ( 8)

Frozen
section,
no. (and %)

Paraffin
section,
no. (and %)

20 (67)
2 (25)

23 (77)
3 (38)

22 (65)

26 (76)

*Some underwent both needle and wedge biopsy.
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III). Three patients had severe hemorrhage
from the biopsy site; two required reopera
tion to arrest the bleeding. Pancreatitis de
veloped in these three patients; in one the
condition was associated with pseudocyst
and fistula, and in another with a subsequent
fistula. Pancreatitis and cutaneous fistulas
developed in two other patients. All fistulas
eventually closed spontaneously, although
one did not heal for 4 months. In another
five patients, bleeding and enterocutaneous
fistulas were probably caused by the asso
ciated procedures rather than by the biopsy
itself. The incidence of complications was
low after needle biopsy alone (2 of 32), but
was high after wedge biopsy alone (3 of 9).
There were no complications in the nine
patients who underwent transduodenal nee
dle biopsy.
D iscussion

The diagnostic accuracy of pancreatic
biopsy and the resulting complications vary
widely in published reports. Errors in diag
nosis are more often due to inaccurate sam
pling than to mistaken interpretation. Inter
pretation of small pancreatic biopsies is not
easy. The pathologist must look for peri
neural infiltration and subtle cytologic
changes in order to recognize well-differen
tiated lesions. When malignant tissue is
obvious on the surface of the pancreas, only
a small wedge is needed. Since wedge biopsy
is usually used only in this situation, the
relative accuracy and resulting complica
tions of different biopsy methods may be
influenced.
TABLE III.—C omplications of I ntraoperative
B iopsy of P ancreas

Type of
biopsy

No. of patients
with
complications/
out of total

Vim-Silverman
needle

2/32

Wedge

3/9

Both wedge
and needle

1/5

Type of
complication

Hemorrhage and
pancreatitis
Fistula and
pancreatitis
Hemorrhage,
pancreatitis
and fistula
Pancreatitis
Fistula and
pancreatitis
Hemorrhage,
pancreatitis,
fistula and
pseudocyst
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Athough theoretically needle biopsy
leaves only a small tract, our results suggest
that there is still a small risk of subsequent
development of fistula or pancreatitis. Such
complications probably originate when the
duct is obstructed by carcinoma and the
needle establishes a pathway of escape for
the pancreatic secretions. The secretions may
leak into the gland parenchyma causing pan
creatitis, and into the peritoneal cavity creat
ing a fistula. A needle placed anywhere in
the pancreas has an excellent chance of
entering the ductal system at some point.3
Although wedge biopsy resulted in a high
incidence of complications in our series,
George, Brown and Gilchrist8 reported 47
successive wedge biopsies with no complica
tions. They stressed the importance of avoid
ing the main pancreatic duct when perform
ing a wedge biopsy. Wedge biopsy was also
found to be safe by Lightwood, Reber and
Way;0 they reported a 3% morbidity rate
and 87% accuracy with this method, but
they reported three complications and two
deaths after 22 needle biopsies, and their
accuracy was only 50% . Fewer than half of
the biopsies reported in that study were of
the head of the pancreas, and the results
therefore may not be comparable to ours. It
is interesting that their complication rate
with wedge biopsy was the same whether the
biopsy was deep or superficial; this suggests
that other factors such as dissection or mani
pulation of the pancreas may be responsible
for some complications. Hemorrhage is a
danger with both techniques; although it
may occur more often as a result of wedge
biopsy, it is more easily recognized and con
trolled. Another potential hazard of biopsy
is traumatic implantation of tumour in an
otherwise curable lesion, but this remains
theoretical.
The operative findings in cases of carci
noma of the head of pancreas may be similar
to those of chronic pancreatitis. Features
that are more typical of carcinoma are a
dilated common bile duct, a discrete mass
that is firm or hard, and a palpable dilated
pancreatic duct.1".!* These findings, sup
plemented by biopsy, will usually give a
definitive diagnosis. An additional diag
nostic technique is injection of the pan
creatic duct with radiopaque dye; in pa
tients with carcinoma, a typical gap be
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tween the smoothly dilated duct and the
duodenum is revealed.12
Each situation must be dealt with indivi
dually. If there are no hepatic or lymphnode metastases to biopsy, a decision must
be made as to whether biopsy of the pan
creas is justified. If there are unquestionable
features of carcinoma there is no point in
attempting to obtain a histologic diagnosis,
since the lesion would be resected regardless
of the results of biopsy. Material from a
large superficial tumour may be obtained
safely by taking a wedge biopsy with a scal
pel, carefully avoiding the main ducts. A
deeper mass is more safely biopsied with a
needle. Tru-Cut (Travenol Laboratories
Inc.) disposable biopsy needles are sharper
than Vim-Silverman needles and easier to
use in hard masses. If the mass is appro
priately located, the needle should be in
serted through both walls of the duodenum
to reduce the risk of fistula.
Recent reports13' 13 of needle aspiration
biopsy with immediate cytologic interpreta
tion have shown a high degree of accuracy
with no complications. A standard dispos
able 20-mL syringe with a 21-gauge needle
is used, and the needle is gently moved up
and down in the mass while suction is ap
plied. The suction is then released and the
needle withdrawn. The syringe is detached
from the needle, filled with air, reattached
and used gently to blow the collected fluid
and cells in the needle onto a glass slide.
After fixing and staining, interpretation can
be made in the same time it takes to perform
a standard frozen section. The needle may
be reinserted several times, without danger,
to sample different areas.
In assessing the value of pancreatic biop
sy there are other considerations. Cure is
rare, and the operative mortality after resec
tion of pancreatic carcinoma is high. There
fore the benefits of a positive biopsy leading
to resection are minimal. In comparison,
death following pancreatectomy, without
biopsy, for a lesion that is found to be benign
is a tragedy. On the other hand, relatively
curable lesions such as a penetrating carci
noma of the ampulla may not be resected if
a biopsy is not obtained because they are
mistakenly thought to be pancreatic carci
noma.

meiamuciL
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In a retrospective review of 47 patients,
intraoperative pancreatic biopsy success
fully identified 76% of the patients with
carcinoma of the head of pancreas. The over
all complication rate was 13% . Complica
tions included pancreatitis, pseudocyst, fis
tula and hemorrhage. One patient died after
a wedge biopsy during which the pancreatic
duct was entered resulting in a pancreatico-peritoneal leak. Vim-Silverman needle
biopsy was more accurate and safer than
wedge biopsy; further improvement could
probably be obtained by the use of aspira
tion needle biopsy. Pancreatic biopsy at
operation, if applied with discretion, is a
valuable procedure in the management of
pancreatic masses.
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RUPTURE OF THE DIAPHRAGM RESULTING
FROM BLUNT TRAUMA IN CHILDREN*
LALIT K. SHARMA, MB, MS, FRCS.t RICHARD F. K E N N E D Y , MD, CM, FRCS[C]t
and WALTER D. H ENEG HAN, MB, BCh, FRCP[C]§
Rupture of the diaphragm due to blunt trauma is
rare in the pediatric age group. This article de
scribes six such cases. This life-threatening con
dition should be suspected in the case of any
serious thoracoabdominal trauma, even in the
presence of negative radiographic findings on
initial evaluation. In the very sick child, horizon
tal beam, lateral radiographs of the chest and
abdomen have been extremely useful in estab
lishing the diagnosis. The suspicion and investi
gation of associated diaphragmatic injury will
result in earlier diagnosis and treatment.
La rupture du diaphragme consecutive a un
traumatisme contondant est rarement observee
chez les patients d'age pediatrique. Cet article
decrit six tels cas. Cette atteinte menagant
le pronostic vital devrait etre envisagee dans
tous les cas de traumatismes thoracoabdominaux serieuses, meme lorsque les resultats radiographiques sont negatifs a I'examen initial.
Chez I’enfant tres malade les radiographies laterales, par faisceau horizontal, du thorax et de
I'abdomen ont ete extremement utiles a I'etablissement du diagnostic. Le doute et la recherche
d’une blessure diaphragmatique associee en
permettront le diagnostic et le traitement plus
rapides.

of the diaphragm due to blunt
thoracoabdominal trauma is now a wellestablished surgical problem. While several
large series of cases have been reported in
adults.1' 2 there are few reports of cases in
the pediatric age group.3'3
R upture

* Presented at the annual meeting of the Canadian
Association of Pediatric Surgeons, Quebec City,
P.Q. Jan. 21, 1976.
tC hief resident in surgery, Dr. Charles A. Jane
way Child Health Centre, and Memorial Univer
sity of Newfoundland, St. John’s, Nfld.
tChief of pediatric surgery, Dr. Charles A. Jane
way Child Health Centre; clinical associate pro
fessor of surgery, Memorial University of N ew 
foundland.
§Chief of radiology, Dr. Charles A. Janeway
Child Health Centre; clinical associate professor
of radiology, Memorial University of Newfound
land.
Reprint requests to: Dr. R. F. Kennedy, Chief of
pediatric surgery, Janeway Child Health Centre,
Newfoundland Dr., St. John’s, Nfld. A 1A 1R8.

Analysis of 106 cases of blunt thoracoab
dominal trauma admitted to the Dr. Charles
A. Janeway Child Health Centre between
January 1966 and December 1974, dis
closed six cases of diaphragmatic rupture. A
critical analysis of these cases forms the
basis of this paper. To our knowledge this
is the largest number of cases in the pedia
tric age group to be reported in a single
series.
Table I summarizes the age and sex of
the six patients, the mode of trauma and
clinical presentation, and the site of dia
phragmatic injury.
Three types of presentation in adults with
diaphragmatic rupture have been described
in the literature; delayed, interval and acute.
These types are also seen in children as illus
trated by the following reports.
C ase R epo r ts

Delayed Presentation
Case 1.— A 9-year-old boy, while riding on
a sleigh, ran into a slow-moving truck. On ad
mission to a district hospital he was observed
as a case of blunt abdominal trauma. N o ab
normality was detected on the initial radio
graphs. The possibility of diaphragmatic
injury was not considered at this time and he
was discharged apparently in good condition.
One month after the accident he was read
mitted with acute dyspnea and vomiting. Chest
radiographs in the anteroposterior and lateral
positions were taken, but the patient died be
fore any treatment could be given. At autopsy
a tear in the left dome of the diaphragm was
found. The left pleural cavity was filled by a
dilated stomach, which was twisted and gan
grenous.
Interval Presentation
Case 2.— A 13-year-old boy was knocked
down by a car. On admission he was uncons
cious, shocked, dyspneic and had multiple
long-bone fractures. A supine radiograph of
the chest led to the initial diagnosis of pul
monary contusion with infrapulmonary pleural
effusion and probable splenic injury. A trache
ostomy was performed. For 4 days the pa
tient’s condition was quite stable. On the 5th
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TABLE I. Age , Se x , M ode
Patient
no.
i
2

3

Age,
yr
9
13

7

4

of

Sex
M
M

T rauma

and C linical P resentation in
of the D iaphragm

Mode of
injury
Sleigh riding,
hit truck
Pedestrian,
hit by truck

5d

M

Pedestrian,
hit by truck

Shock. Stable,
then vomiting

F

Pedestrian,
run over by
bus

Dyspnea,
persisting
shock

5

14

M

Pedestrian,
hit by car

Dyspnea,
shock, para
plegia

6

5

M

Pedestrian,
hit by truck

Dyspnea,
shock, retinal
hemorrhage

day he again became suddenly shocked and
dyspneic. A radiograph of the chest indicated
diaphragmatic injury on the left side (Fig. 1).
At laparotomy a tear was discovered in the left
dome of the diaphragm; the lacerated spleen
was lying in the left hemithorax along with the
splenic flexure of the colon. The patient made
an uneventful recovery.
In this example of interval presentation the
patient suffered severe multiple injuries, but
injury to the diaphragm was not initially de
tected. It was only on the 5th day that acute
cardiorespiratory symptoms led to the dis
covery of the extent of his injuries.
Acute Presentation
Case 3 .—The rear wheels of a bus passed

S ix P atients

Presenting
Interval from
signs and
trauma to
symptoms
presentation
Acute dyspnea,
1 mo
vomiting
Dyspnea,
shock. Stable,
then recurrent
dyspnea and
shock

Vol. 20

2h

with

Site of
rupture
Left

R upture

Result
Dead

Left

Alive

1h
3d

Left

Alive

30 min

Right

Dead

5h
?

Left

Dead

1h

Left

Alive

over a 4 Vi year-old girl. On admission she was
shocked, dyspneic and cyanosed, but she was
fully conscious. Chest radiographs revealed
multiple rib fractures and contusion of the
right lung with pneumothorax but no evidence
of pneumoperitoneum. Drainage through an
intercostal tube relieved the cyanosis, but the
shock persisted. Repeat investigation with
horizontal beam lateral radiography of the
chest and abdomen revealed a pneumoperito
neum that had not been detected on the earlier
films. It was concluded that the pneumoperi
toneum was caused by pleural air entering
through a rent in the right diaphragm, or by
perforation of a hollow abdominal viscus. At
laparotomy a large tear was found in the right
dome of the diaphragm along with extensive
laceration of the right lobe of the liver. This
patient died 56 hours after admission. Death
was attributed to extensive traumatic injury to
the lungs and to respiratory failure.
It is interesting that this child sustained the
rare injury to the right dome of the diaphragm.
The value of repeated radiographs, particularly
the use of horizontal beam lateral radiography
of the chest and abdomen, in the diagnosis of
diaphragmatic injury in a seriously ill child
is apparent from this case.
D iscussion

Fig. 1.—Case 2. Anteroposterior chest radio
graph on 5th day after injury reveals collapsed
left lung with colonic shadow in left chest and
shift of mediastinum to right.

When blunt diaphragmatic injury is caused
by an automobile accident in an adult the
patient is usually the driver of a vehicle or
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the front-seat passenger. It is striking that
five of our six patients were pedestrians.
Most had sustained major crushing injury to
the thoracoabdominal region (Table II).
Therefore we do not concur with Radhakrishna, Dickinson and Shaw4 that raised
intra-abdominal pressure is the sole cause
of diaphragmatic tear. Our own experience
is in agreement with that of Hill6 that any
major blunt thoracoabdominal trauma can
cause a diaphragmatic tear.
Five of our six patients sustained injury
to the left diaphragm. The close proximity
of the large right lobe of the liver may dis
tribute the force evenly on the diaphragm
and thus protect the right dome. 7 Lucido
and Wall8 believe that the common site of
injury (the left posterolateral leaflet) is a
potentially weak area owing to embryologic
fusion. Others7 could not substantiate this
theory. Bekassy and colleagues,!l using adult
cadavers, subjected both leaves of the dia
phragm to increasing pressure and con
cluded that the left side was weaker than
the right but that the difference was not
statistically significant.
The diagnosis of diaphragmatic injury in
cases of major thoracoabdominal trauma,
especially in the presence of multiple in
juries, is difficult. Carter, Guiseffi and Felson10 have described acute, interval and
delayed presentations in adults. The acute
phase is dominated by the associated in
juries and damage to the diaphragm may
escape notice unless the diagnosis is sus
pected in every case. The possibility should
be considered even when initial radiographs
do not disclose such an injury. In three of
our six patients there was no finding sug
gestive of diaphragmatic injury at the ini
tial clinical and radiologic examinations. In
interval and delayed presentations the out
standing signs and symptoms are those of
TABLE II. —Associated I njuries
Injury
Central nervous system..............
Thoracic trauma (ribs and lungs)
Injury to abdominal viscera.......
Spleen...................................
Liver.....................................
Kidney.................................
Colon...................................
Fracture of long bones and pelvis
Spine and spinal cord injury. . . .

No. of cases

3
4
5
2
1
1
1

2
1
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gastrointestinal disease and strangulation.
The physical findings as outlined by Bowditch 11 are still applicable — “prominence
and immobility of the left chest, displace
ment of the cardiac dullness to the right,
diminished or absent breath sounds on the
left and tympanic percussion noted over the
left chest”.
The essential radiologic indications of
diaphragmatic injury as summarized by Car
ter, Guiseffi and Felson1 0 and Arbulu, Read
and Berkas,1- are as follows: elevation of
the left diaphragm, arch-like shadow above
the diaphragm, shifting of the mediastinal
structures and presence of fluid levels in the
affected hemithorax. Peck1:! has described
the radiologic features present in the rare
injury to the right leaf of the diaphragm. We
suggest that supine radiographs of the chest
and abdomen and a horizontal beam lateral
radiograph of chest and abdomen are essen
tial in all cases of blunt thoracoabdominal
trauma in children. Barium meal, induction
of pneumoperitoneum1 4 and liver scan
ning15 are all helpful in the diagnosis of
diaphragmatic injury. Laparoscopic evalua
tion is not practical in these sick patients.
The treatment of diaphragmatic disrup
tion is surgical repair at the time of diagnosis.
The choice between a thoracic and abdomi
nal approach should be decided on the basis
of the associated injuries in each case.
In children who have sustained blunt tho
racoabdominal trauma, the suspicion of
associated diaphragmatic injury, whether it
arises early or late, will lead to earlier diag
nosis and treatment for these seriously in
jured patients.
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DAVIS & GECK SURGICAL ESSAY AWARD
FOR RESIDENTS
Davis & Geek annually awards $1000.00 to the surgical resident submitting the best
paper on a surgical topic to the Canadian Journal of Surgery. This award is intended
to promote scientific and literary excellence among Canadian surgeons in training.
The conditions of entry for the 1978 award are the following: —1. Candidates shall be currently engaged in a recognized surgical residency program
leading to eligibility for the Fellowship of the Royal College of Physicians and
Surgeons of Canada in one of the surgical specialties (cardiovascular and thoracic
surgery, general surgery, neurosurgery, obstetrics and gynecology, ophthalmology,
otolaryngology, orthopedic surgery, plastic surgery and urology).
2. The material to be submitted shall be in the form of a manuscript relating to work
in which a surgical resident is or has been the prime or major investigator.
Prior oral presentation at a Royal College meeting or a Surgical Forum meeting
will not be a disqualification, but prior publication as a formal paper in a
journal will. The paper should relate to any field of surgical interest. The manu
script must conform to the style requirements of the Journal and must not
exceed 3000 words of text and six tables and/or six figures. Coauthors are
permitted on the understanding that the candidate shall be the first author and
that only the first author shall be eligible for the award.
3. Entries must be received in the office of the Journal no later than June 30, 1978.
Each entry must be submitted to E. M. Cooperman, MD, FRCP[C], at the
office of the Canadian Journal of Surgery, PO Box 8650, Ottawa, Ont.
K1G 0G8, with a letter stating that the paper is being submitted as an entry
for the Davis & Geek Surgical Essay Award.
4. All papers submitted shall be the property of the Canadian Journal of Surgery
unless returned to the author without publication.
All papers submitted will be judged by an independent committee comprising at
least one member of the editorial board of the Journal, one fellow of the Royal College
of Physicians and Surgeons of Canada, and one representative of The Canadian Medical
Association, together with other fellows invited to serve at the discretion of the three
permanent members of the committee. For the purpose of judging, the candidates will
be anonymous. The judges’ decision shall be final.
The name of the successful candidate and the title of the paper will be announced
in the November 1978 issue of the Journal.
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EPIDERMOID CYSTS OF THE SPLEEN*
S LAN, MD, FRCS[C], L.-P. LEJEUNE, M D, FRCS[C], D. DILENGE, M D, FRCP[C]
and P. M ADARNAS, MD, FRCP[C]
The authors report three cases of epidermoid
cyst of the spleen. A squamous cell lining was
found in all three. One patient had a history of
antecedent trauma, and in the surgical specimen
the gross and histologic features were compatiible with splenic damage. No hematologic alter
ation was recognized on presentation. Angio
graphy and spleen scanning were valuable aids
in the diagnosis. All three patients were well 1
year after operation.
Les auteurs signalent trois cas de kystes epidermoides de la rate. Dans les trois cas on a
retrouve un revetement de cellules squameuses.
Un patient presentait des antecedents de traumatisme, et les caracteristiques macroscopiques
et histologiques du prelevement a la chirurgie
etaient compatibles avec une lesion splenique.
Aucune modification hematologique n’a ete observee. L’angiographie et la scintigraphie de
la rate ont contribue au diagnostic. Les trois
patients se portaient bien 1 an apres I'operation.

B e t w e e n Jan. 1, 1969 and Dec. 31, 1975,
259 splenectomies were performed at the
Centre Hospitalier Universitaire in Sher
brooke. In three cases from this series the
pathological diagnosis was epidermoid cyst.
The relative rarity of this entity and its
debatable pathogenesis and clinicopathologic
significance justify this report.
Splenic cysts lined by squamous epithe
lium constitute a variable proportion of the
different pathologic types of cyst found in
the spleen, depending on the geographic area
of their occurrence. In parts of the world
where hydatid disease has a high prevalence,
the hydatid cyst is the predominant lesion. In
the United States and Canada, the propor
tion of cysts lined by squamous epithelium
is relatively high although such cysts are un
common. Ferris, Dockerty and Heldon1
found only one case in the Mayo Clinic se
ries from 1911 to 1956. Cave, Garvin and
Doohen2 discovered 51 cases in an extensive
review of the literature. Five additional
♦From the departments of surgery, radiology and
pathology, faculty of medicine, University of
Sherbrooke, Sherbrooke, PQ.
Reprint requests to: Dr. P. Madarnas, Department
of pathology, Centre Hospitalier Universitaire,
Sherbrooke, PQ J1H 5N4.

cases were reported in a 32-year review of
the surgical specimens from the University
of Minnesota hospitals.3
In the cases we describe the diagnosis of
splenic cyst was made preoperatively by
means of plain radiographs, angiograms or
spleen scans.
C ase R e p o r t s

Case 1.—A 3 3-year-old woman had a his
tory of recurrent urinary tract infection, and a
2-month history of polyuria, polydipsia and
weakness. She was admitted for investigation
and control of diabetes. On routine physical
examination the spleen was palpable 2 cm
below the left costal margin. The liver was not
palpable and no other mass was felt. The
spleen scan indicated the presence of a cyst
(diameter, approximately 7 cm) in the supero
lateral half of the organ. Angiography (Fig.
1) revealed hypovascularity in this region. The
regularity of the surrounding splenic tissue
further supported the diagnosis of a cystic le
sion. Laboratory data on admission included
the following: hemoglobin value 10.9 g/dL,
hematocrit 34.3%, leukocyte count 4.9 x
109/L (normal differential), platelet count 250
x 109/L, erythrocyte sedimentation rate 10
m m /h and blood glucose value 350 mg/dL.
An uncomplicated splenectomy was per
formed from which the patient made a straight
forward recovery. The patient’s diabetes was
controlled by insulin.
The enlarged spleen was deformed by a uni
locular cystic structure (Fig. 2a). The wall
varied from paper-thin to 0.4 cm in thickness
in the trabeculated areas. After evacuation of
the clear fluid content, the specimen weighed
225 g. The inner lining of the cyst was made
up of keratinized stratified squamous epithe
lium with prominent intercellular bridges
(Fig. 2b). Hemosiderin-laden macrophages and
iron deposits were identified in the outer wall
and the adjacent splenic tissue, which was un
dergoing atrophy. Germinal centres and thy
mic-dependent lymphoid hyperplasia were
prominent in the white pulp. The red pulp was
unremarkable.
Case 2.—A 19-year-old woman was admitted
complaining only of an occasional sharp pain
in the left shoulder. She had had one previous
hospital admission 1 year earlier when she
had had mild jaundice 1 month after an in-
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Fig. 3a

Fig. 3b
Fig. I .—Case 1. (a) Selective arteriography of
celiac axis (2) permits good visualization of
splenic artery (1), which appears elongated and
pushed downward by displacement of spleen
whose inferior limit reaches L4 level (arrows).
This displacement is caused by hypovascularized
mass, which seems to occupy upper portion of
spleen (3=right hepatic artery; 4=gastroduodenal
artery), (b) Regularity of lower contours of mass
(arrows) is displayed; it appears embedded within
the splenic parenchyma.
fluenza-like episode. At that time an enlarged
spleen was detected. She was discharged with
out medication after 2 weeks. The jaundice
was presumed to be due to hypersensitivity to
an oral contraceptive agent (norgestrel-ethinylestradiol). F or the 7 months before the present
admission she had been aware of a mass in
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Fig. 2. Case 1. (a) Cross-section of spleen
and of uniloculated cystic mass. Inner surface
shows hyalinized trabecular bands, (b) Stratified
nonkeratinizing squamous epithelium with promi
nent intercellular bridges, (hematoxylin and eosin,
reduced by 50% from x 400).
the left upper quadrant, particularly when she
was in the erect position, and 6 months before
admission she had experienced an episode of
epigastric pain lasting 1 day.
On physical examination two spider angio
mas were noticed. On palpation the liver was
not enlarged but the spleen was palpable 7.5
cm below the left costal margin. Angiography
indicated a possible cystic lesion. The spleen
scan was normal. The hemoglobin value was
13.2 g/dL , hematocrit 40.4%, leukocyte count
7.5 x 109/L , and platelet count 226 x 10VL.
Splenectomy was performed from which
the patient made a smooth recovery.
The spleen was enlarged and severely de
formed by a lobulated but unilocular cystic
mass. The thickness of the wall varied from
0.1 to 0.4 cm in the irregularly trabeculated
areas. The cyst contained clear colourless
fluid with small amounts of white flaky ma
terial. The inner surface was lined by squa
mous epithelium with focal areas having a
prominent stratum granulosum and showing
superficial keratinization. The adjacent splenic
pulp contained hemosiderin deposits and
showed evidence of pressure atrophy. Hyper
plasia of the white pulp with prominent ger
minal centres and thymic lymphoid hyper
plasia were evident. The red pulp was normal.
Case 3 .— A 35-year-old man was seen in
the outpatient department with a 6-month his
tory of dry cough. In a motor vehicle accident
13 years before he had sustained fractures of
the left 6th and 7th ribs; no visceral trauma
was detected and he had been treated conser
vatively.
On physical examination, the blood pres-
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sure was 110/80 mm Hg, and the pulse was
60/min. No abnormality was found on chest
examination. The spleen was not palpable. A
chest radiograph disclosed a calcified mass
(diameter, 7 cm) in the left upper abdominal
quadrant. The hemoglobin value was 16.2 g/
dL and the leukocyte count was 6.1 x 109/L
(normal differential). The platelet count was
310 x 107L, and the SMA 12 biochemical
profile was normal. Angiography revealed the
opacity to be situated at the splenic hilum
(Fig. 3); the spleen itself did not appear en
larged.
When splenectomy was performed dense ad-
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hesions were found between the spleen and
the parietal peritoneum. The postoperative
course was uneventful.
The intact spleen weighed 217 g. It was de
formed by a spherical, rigid, calcified cyst
(Fig. 4) whose wall was up to 0.6 cm in thick
ness. It contained a clear colourless fluid. The
decalcified sections showed a scanty cellular
lining which, in focal areas, appeared as stra
tified squamous epithelium (Fig. 4b). Within
the splenic tissue, remote from the cyst, there
were several irregular fibrous areas with pro
minent hemosiderin deposits and siderotic
impregnation of the collagen resembling that
seen in Gamma nodules. The white pulp dis
played a noticeable thymic lymphoid hyperpla
sia with inconspicuous germinal centres. The
red pulp was unchanged.
D iscussio n

Epidermoid cysts, by definition, are lined
by stratified squamous epithelium.4, 3 Since
many of these cysts are found in children
without a history of antecedent trauma,
their origin from embryonic rests is strongly
favoured.5 The embryologic situation of the
spleen within the dorsal mesogastrium sug
gests a possible origin from ectopic esopha
geal epithelial tissue. An alternative sug
gestion is that the squamous epithelium rep
resents a metaplastic change of endothelium
or mesothelium.2’ 7' 8
The pathological changes in the three spe
cimens described here are similar. All three
cysts had a stratified squamous epithelial
lining. The scanty lining in the third speci
men may have been the result of pressure

Fig. lb
Fig. 3.—Case 3. (a) Routine chest radiograph re
veals calcified cystic mass (arrows) in area of
spleen, (b) Selective arteriography shows elon
gated splenic artery (arrows) with displacement
of its branches, which seem to enwrap calcified
mass. Spleen does not appear enlarged or de
formed.

Fig. 4.—Case 3. Cross-section of normal-sized
spleen, with focal whitish scars, showing thick and
calcified hilar cystic mass, (b) Area of nonkera
tinizing stratified squamous epithelium resting on
collagenized fibrous tissue (hematoxylin and eosin,
reduced by 58% from x 400).
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atrophy. The origin of this cyst may have
been the cavitation of a previous hematoma
as suggested by the history of trauma. Ex
cept in this case, where hemosiderin deposits
and broad bands of irregular fibrous tissue
within the spleen suggested an earlier trau
matic episode, no intrinsic splenic pathology
was found.
The patients were kept under observation
for at least 1 year and had no evidence of
the development of hematologic abnormali
ties other than those expected after splenec
tomy. Thus, for alleviation of symptoms,
avoidance of complications and accurate
histologic diagnosis, splenectomy is the pro
cedure of choice in all cases of epidermoid
cyst of the spleen.9,10
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IN T E ST IN A L OBSTRUCTION D U E TO A DEFECT IN T H E OMENTUM
JOHN A. McCREDlE, MB, MCh(Belf), FRCS(Edin), FRCS[C], FACS*
An unusual cause of instestinal obstruction is
described in a 46-year-old woman thought be
fore operation to have Crohn’s disease. The
right colon and terminal ileum had passed
through a defect that had developed sponta
neously in the greater omentum and had re
mained in that position for at least 1 year.
The bowel was reduced and the multiple defects
in the omentum were repaired.
On decrit chez une femme de 46 ans une cause
inhabituelle
d’obstruction
intestinale.
Avant
I operation la maladie de Crohn etait suspectee.
Le colon droit et I’ileon terminal avaient fait
saillie a travers une dechirure apparue spontane-

*Associate professor of surgery and therapeutic
radiology, University of Western Ontario, London,
Ont.
Reprint requests to: Dr. J. A. McCredie, D epart
ment of surgery, Victoria Hospital, 375 South
St., London, Ont. N6A 5A5.

ment dans le grand epiploon, et etaient demeures dans cette position depuis au moins 1 an.
L’intestin a ete remis en place et la region de
I'epiploon presentant des defauts multiples a
ete reparee.
I n t e r n a l hernias are an uncommon cause

of intestinal obstruction. They may occur
in the paraduodenal and paracecal regions,
at the root of the mesentery of the sigmoid
colon and in the pelvis and diaphragm.1
Bowel has also passed through the foramen
of Winslow into the lesser sac2 and through
defects in the mesentery of the terminal
ileum3 and transverse mesocolon.4 We re
port a case of recurrent subacute intestinal
obstruction due to passage of bowel through
a hole that developed spontaneously in the
greater omentum. The patient was con
sidered preoperatively to have Crohn’s
disease.
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Fig. 1.—Radiograph shows narrow segment in
terminal ileum considered before operation to be
due to Crohn’s disease.

Fig. 2.—Right colon and terminal ileum have
herniated through hole in greater omentum. Bowel
is firmly adherent to stretched-out margins of
defect.

Fig. 3.“ After reduction of hernia, thickened
margins of defect are visible.

Fig. 4.—Specimen resembles doughnut in shape
and size. Diameter of defect was larger when
occupied by herniated bowel.

Fig. 5.—Attentuated regions can be seen in
greater omentum. Intestinal obstruction was due
to passage of bowel through one of these regions.

Fig. 6.—Greater omentum after repair of trans
lucent thinned-out regions.
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C ase R e p o r t

A 46-year-old woman was admitted to hos
pital in July 1975 with a clinical diagnosis of
small bowel obstruction. Radiographic studies
included a flat plate of the abdomen and gas
trointestinal series with follow-through; the re
sults were normal. She continued over a period
of 1 year to have recurrent bouts of colicky,
midabdominal pain associated with nausea and
distension. The attacks lasted for 1 to 2 days.
She was re-admitted to hospital in June 1976
with a similar attack that settled spontaneous
ly. The gastrointestinal series now showed a
narrow segment in the terminal ileum consis
tent with that seen in Crohn’s disease (Fig. 1).
The patient had not had any abdominal injury
or abdominal operations. At laparotomy an
8-cm hole was found in the right of the greater
omentum and through this defect had passed a
mobile cecum, ascending colon, right half of
the transverse colon and the terminal 12 cm of
ileum (Fig. 2). The omentum at the circum
ference of the defect was thickened to form a
rolled edge about 3 cm in thickness. There
were firm adhesions between the bowel that
had herniated through the opening and the
margins of the defect. The adhesions were
divided and the bowel was retracted (Fig. 3).
The defect in the greater omentum was excised,
furnishing a specimen that resembled a dough
nut in appearance and size (Fig. 4). On hold
ing up the greater omentum several attenuated
translucent regions were seen (Fig. 5). Sutures
were inserted to obliterate these defects (Fig.
6). The patient has not had any recurrence of
symptoms.
D is c u s s io n

In this patient the right colon and termi
nal ileum herniated through a defect that
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developed spontaneously in a thin greater
omentum. The bowel must have occupied
this position for at least 1 year because the
patient had symptoms during this time and
there were firm adhesions between the
margins of the defect and the bowel. The
margins at the circumference of the defect
had become thickened (up to 3 cm) prob
ably as a reaction to the repeated trauma
from powerful peristalsis of the bowel with
in the ring.
The occurrence of a defect in the rela
tively avascular part of the mesentery of
the terminal ileum (Treves’ field) is well
documented. The defect is thought most
often to be congenital in origin and less
frequently due to injury, spontaneous atro
phy or chronic inflammation.3 One that
occurs in the transverse mesocolon, general
ly to the left of the middle colic vessels,
is considered by Tanner4 to result from
atrophy in most instances. In one case
described by Tanner where there was a
hole in the transverse mesocolon, the bowel
left the lesser sac through a defect in the
lesser omentum; in another patient the
bowel passed through a defect in the great
er omentum. The literature contains no
report of intestinal obstruction due to a
defect in the greater omentum alone.
R eferences
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Another surgeon
is about to use one of
the wor cfe finest
surgica blades....
... .this happens
thousands of times
everyday!
It happens because the blades are by Swann-Morton,
the people who meet the highest requirements in surgical knives.
We need say very little about our superiority.
The world's surgeons have proved it for us!
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1977 DAVIS & GECK SURGICAL ESSAY AW ARD

Dr. A. G. de la Rocha received the 1977 Davis & Geek Award at the Victoria Hospital, London,
Ont. on Sept. 27.

The award was presented by Mr. John W. Ployart (second from left) of the Cyanamid Corpo
ration on behalf of Davis & Geek. Dr. C. Barber Mueller (left), co-editor of the Canadian
Journal of Surgery and Mr. John Stavroff. (right), local representative for Davis & Geek,
were also present.

The editorial board and the editors of the Journal wish to thank Davis & Geek for providing
this award, and extend their congratulations to Dr. de la Rocha and their thanks to all those
who participated in the competition.

(Requirements for the 1978 award appear on page 556 of this issue.)
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CORRESPONDENCE
SIMPLE DEVICE TO PREVENT DISRUPTION OF CENTRALLY
PLACED INTRAVENOUS CATHETERS
To the editor: The earliest observation of
the fatal potential of intravenous air was de
scribed by the Italian naturalist Redi in
1667.1 Recently the use of central venous
lines in the care of critically ill patients has
increased.2- 3 The period of greatest risk,
which occurs during the insertion of the
catheter, can be reduced by placing the pa
tient in the Trendelenburg position.
Air embolism has been reported following
Fig. 3.—Device for securing connections, (a)
accidental disconnection of the central ven Orifice
for intravenous (IV) needle, (b) Orifice
ous pressure (CVP) catheter at the hub.4' 6 for IV extension tubing.
In the past 3 years we have experienced at
least three instances of this mishap, despite
attention to precautionary measures to se
cure the connection. This prompted the in
vention of a simple device to prevent such
disruption of CVP catheters. The device can
be used with any intravenous catheter con
nection.
In our hospital, using aseptic technique
and subclavian puncture, we insert the
catheter (length, 20 cm) through a 14-gauge
needle. The needle is then connected to the
manometer by intravenous (IV) extension
tubing (Fig. 1). Fig. 2 shows the site of dis
Fig. 4.—Device in position, (a) Entry site of IV
tubing, (b) Exit site of IV needle.
ruption of the central line.
Fig. 3 illustrates the simple device, which
is constructed of stainless steel so that it The IV extension tubing must be compressed
can be repeatedly sterilized and used. At in order to place it in its orifice, thereby se
one end of the device is an orifice into which curing it in position (Fig. 4) and preventing
is fitted the needle end of the connection. At disruption of the IV connection. It can be
the other end is an orifice of smaller diame modified both in length and diameter of
ter to accommodate the IV extension tubing. orifices to fit different connections. If de
sired, tapes can be used to make the con
nections even more secure.

Fig. 1.—Standard intravenous line.

B rian P. D. C o lq u h o u n , m b , fr c s ( e d in ),
FACS
Department of surgery,
University Hospital,
Saskatoon, Sask.
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Fig. 2.—Disruption of line at connection.
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TOTAL REPLACEMENT ARTHROPLASTY OF ELBOW IN
RHEUMATOID ARTHRITIS
To the editor: The painful, stiff and unstable
rheumatoid elbow poses a therapeutic dilem
ma that has not yet been resolved, and, for
this reason, the article by Harder and Beau
champ (Can J Surg 20: 234, 1977) at first
glance appears timely. Their early results
with complete synovectomy and total pros
thetic replacement were good; in eight of
nine elbows mobility was improved and pain
relieved. But nine cases from which to draw
valid conclusions are rather few and may
give a falsely optimistic view of the diffi
culties of surgery and the possibility of
postoperative complications.
W. A. Soutar, in reporting 30 total elbow
replacements (/ Bone and Joint Surg [Br]
59: 99, 1977), noted that although the early
results were good, there was a slow dete
rioration over 5 years, the major problems
being instability due to loosening of the
humeral stem, severe comminuted fractures
of eroded bone and gross instability of the
elbow if ever the prosthesis had to be re
moved. Hinge prostheses are especially
prone to these complications, because the
hinge itself has no means for absorbing ro
tational movement or movement in the co
ronal plane, and these stresses are trans
mitted to the bone-cement interface. Soutar
no longer recommends this type of arthro
plasty. In Harder and Beauchamp’s series
of cases, the longest interval from operation
to final evaluation of their patients was
only 2Vi years and the shortest was 2
months. One is reminded of Harold Crowe’s
remark that his feeling about this was that
the authors hadn’t yet had time enough to
find out what trouble they could get into.
The painful, stiff and unstable rheuma
toid elbow defies efforts to find a definitive
solution. Pending the development of a
more satisfactory prosthesis, synovectomy
is still the best that the surgeon can offer,
and it has the additional advantage that
further surgery is possible, should it become
necessary.

J o h n V. F o w l e s , m b , f r c s [ c ]
CARE/M EDICO
18, ave docteur Conseil,
Tunis,
Tunisia.

To the editor: Dr. Fowles’ comments are
timely. Of our initial group of patients
treated by total elbow replacement of the
hinge type as reported in the Canadian
Journal of Surgery, none has yet required re
exploration of the elbow because of loosen
ing or fracture. At present the interval from
surgery ranges from approximately 2Vi to
5 years. One patient has clinical evidence
of loosening of the humeral component, but
function of the arm remains satisfactory.
It is my unsubstantiated impression that
attention to two details at the time of the
procedure may be particularly important: if
removal of cancellous bone in the medullary
canal is thorough, permitting intimate con
tact of the methylmethacrylate cement with
cortical bone, and if the methylmethacrylate
is inserted well beyond the tip of the stem
of the prosthesis, the considerable stress
exerted on this area may be sufficiently well
distributed to reduce the danger of the toggle
effect, which causes eventual breakthrough
at the tip of the stem.
It is recognized that, as in the case of knee
hinge prostheses, a fully constrained joint
is far from ideal. We therefore continue to
restrict the hinge arthroplasty to a small
number of patients with extensive elbowjoint destruction.
It is hoped that a semiconstrained pros
thesis, perhaps one along the lines of that
designed by F. C. Ewald, will prove suffi
ciently superior that fully constrained elbow
joints with their inherent limitations will
need to be used only in cases in which soft
tissue supporting structures and inadequate
bone stock allow no alternative.
D. H. H a r d e r , m d , f r c s [c ]
Department of orthopedic surgery,
Royal Columbian Hospital,
New Westminster, BC.
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OBITUARY
HOMMAGE AU DOCTEUR JACQUES TURCOT

C’est avec peine que nous apprenions le
deces subit du docteur Jacques Turcot, survenu en ce samedi saint, le 9 avril 1977.
Tous ceux qui connurent Jacques Turcot,
pour avoir oeuvre a ses cotes soit comme
resident, soit comme patron, ne pouvaient
faire autrement que d’etre atteres par le de
part inattendu d’un collegue estime. La
condition physique remarquable du docteur
Turcot en trompa plus d’un; seuls ses proches purent depister l’atteinte lethale quelques jours seulement avant l’echeance.
Pour tous les chirurgiens qui se sont
entraines a l’Hotel-Dieu de Quebec, le sou
venir du docteur Jacques Turcot restera
comme un monument. II n’avait pas son
pareil et aucun autre patron ne lui ressemblait. De contact exigeant, le docteur Turcot
s’imposait cependant par sa force de caractere, sa competence et son dynamisme. Chirurgien minutieux et habile, anatomisme
par formation, le professeur Turcot ne pouvait accepter la mediocrite ou le laisseraller. II n’etait satisfait que par l’excellence
du geste chirurgical.
Tout au long de sa carriere d’ailleurs, sa
chirurgie se caracterisa par la precision du
geste, la delicatesse anatomique et le savoirfaire chirurgical. L’assurance de son jugement se doublait d’une sagacite acquise par
l’experience.
Forme a l’ecole de l’Hotel-Dieu par les
chirurgiens Vezina, Roy et Petitclerc, au
Memorial Hospital for Cancer and Allied
Diseases de New York, puis a la Mayo
Clinic de Rochester, Jacques Turcot ne mit
que tres peu de temps pour s’imposer. Sa
reputation depassa rapidement les limites
hospitalieres. Ses debuts furent marques a
l’enseigne de la science et de l’innovation.
Fils et petit-fils de medecins, le docteur
Jacques Turcot suivit les traces que ses peres souhaitaient et rarement il a du les
decevoir. En 1946 le service de chirurgie
organisa un cours de chirurgie a l’HotelDieu de Quebec et le docteur Turcot en fut
l’un des fondateurs et Fame directrice. Cette

ecole de chirurgie a forme plus de 80 chi
rurgiens generaux.
Le chirurgien se doublait d’ambition universitaire, et rapidement il gravit les echelons
academiques, devint secretaire du departement de chirurgie, puis directeur en 1972.
Pour lui, l’enseignement et le soin au patient
etaient deux entites inseparables.
Sur les scenes nationale et internationale,
Jacques Turcot represente surement le chi
rurgien canadien-fran§ais le plus connu et
le plus estime. La liste des nominations acceptees par le docteur Turcot, au niveau
des divers organismes professionnels tant
provincial que canadien et americain, temoigne de ses qualites exceptionnelles.
Parrni plusieurs, je n’en mentionnerai que
trois:gouverneur de l’American College of
Surgeons, membre de la James IV Associa
tion of Surgeons et president du College
royal des chirurgiens et medecins du Canada
(1968-70). C’est a cette periode que sa car
riere atteint son apogee.
Son influence sur Involution de la medecine canadienne s’est egalement faite
sentir particulierement au niveau du Centre
R- Samuel McLaughlin, centre de dosimetrie mis sur pied par le College royal pour
l’enseignement et les examens de specialites.
C’est en temoignage de son oeuvre que
!e Gouvernement canadien lui decemait, en
1974, le titre d’officier de l’Ordre du Ca
nada. C’etait reconnaitre, en la personne
du docteur Jacques Turcot, un chirurgien
universitaire de grande classe et un humanisme de grande tradition.
Jacques Turcot n’est plus. Les chirur
giens de l’Hotel-Dieu de Quebec et les
anciens residents du cours de chirurgie garderont toujours de lui le souvenir d’un
chirurgien exigeant, competent et fier d ’etre
ce qu’il etait. Son contact permit, a plus
d’un, une remise en question dans l’apprentissage du role de chirurgien et de profes
seur. Jacques Turcot restera a plus d’un
titre un exemple a suivre.
Louis D ionne ,

md
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THE ANAESTHESIOLOGIST’S HAND
BOOK. 2nd ed. Donald G. Catron. 201 pp.
IHust. University Park Press, Baltimore,
1976. $8.95, paperbound. ISBN 0-83910956-3.
This handbook is aptly named since it fits
very conveniently into the pocket of most
operating room gowns.
In his preface Catron describes the book as a
collection of references “intended for use by
busy practitioners and students as an on-thespot review of problem situations” and I be
lieve it fulfils its stated purpose.
It is not a “how to” handbook, rather it is
a “why”. It lists the basic fundamentals of
knowledge that any competent anesthetist must
understand. Cross-references are given and, in
general, the reader will find answers to most
questions in a straightforward and systematic
manner.
The doses given are somewhat confusing
because the author has not been consistent, but
has used metric and imperial measures inter
changeably. Some important areas are not
given sufficient emphasis; for example, the
treatment of hypertension is not brought up
to the standards of 1975 — the year of the
most recent reference quoted. In fact, the
references are rather limited in number.
Despite these minor criticisms, the reader
will find this a useful book to have at hand
when a few spare moments are found to re
fresh the mind. A comprehensive index is
provided.

the difficulties encountered in arterial and
venous injections of human cadavers and
briefly describe how they have overcome these
problems. The technical detail, however, is in
sufficient to guide others with similar in
terests.
The book is technically of good quality. The
text is brief; the bibliography is scanty. The
legends to the illustrations are clear and wellwritten. The dissections are excellent, the vessels
clearly shown, and the photography is very
good.
Although it is intended for orthopedic sur
geons, neurosurgeons and neurologists, the
book has certain drawbacks which will limit
its appeal to clinicians. It is entirely devoted
to descriptive anatomy; there is no attempt to
relate the anatomical distribution of vessels to
vascular disease as a clinical problem. Al
though the intramedullary arterial and venous
patterns are well shown, they are not correlated
with the ascending and descending pathways
and the various spinal nuclear groups. The au
thors illustrate the variation in size of radicular
arteries at different segments, but they do not
analyze the variety of patterns they must have
found in their numerous dissections.
Despite its excellent technical quality, this
book will only be of limited use to the readers
for whom it was intended.
D. M. R obertson
Department of pathology,
Queen’s University,
Kingston, Ont.

P. G oodhall
Associate anesthetist-in-chief,
Department of anesthesia,
Women’s College Hospital,
Toronto, Ont.

THE BLOOD SUPPLY OF THE VERTE
BRAL COLUMN AND SPINAL CORD IN
MAN. H. V. Crock and H. Yoshizawa. 130
pp. Illust. Springer Verlag New York Inc.,
New York, 1977. $38.50. ISBN 0-38781402-7.
This book is an atlas of colour and black-andwhite photographs, and a few radiographs, of
dissections of the blood supply to the spine
and spinal cord. The authors did their dissec
tions on cadavers in which the arterial and
venous systems were injected. They emphasize

CAHIERS D’ENSEIGNEMENT DE LA
S.O.F.C.O.T. 4. Conferences d’Enseignement. Sous la direction de J. Duparc. 186
pp. Illust. Expansion Scientifique Franyaise,
Paris, 1976. $24.84, broche. ISBN 2-70460875-X.
L’impression generate qui se degage de ce
cahier de conference d’enseignement d’orthopedie nous parait tres favorable. Sa publica
tion semble s’adresser au niveau post-gradue
des residents a l’entrainement en orthopedie
et represente possiblement un attribut complementaire pour d’autres residents se dirigeant
dans des disciplines chirurgicales connexes a
l’orthopedie impliquant la traumatologie. Cette
revue peut, a la fois, s’appliquer a des etudiants de l’ecole de Medecine s’interessant
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particulierement a la traumatologie; soit a des
orthopedistes desirants a la fois rafratchir leurs
connaissances fondamentales ou faire revalua
tion, a leurs termes, de leur technique chirurgicale. Nous avons note que ce volume est
tres bien documente sur la litterature internationale tout en degageant une vaste expe
rience personnelle de la methodologie frangaise. Cependant il est a noter que cette revue,
tout en recouvrant en detail une forme de traitement, une hypothese de travail ou une revue
d’un systeme, ne couvre qu’en partie le probleme mentionne et, de ce fait meme, ne peut
etre consideree que complementaire a un texte
de base fondamentale faisant l’etude compa
rative de toutes les autres possibilities de traitement.
Plus particulierement, nous aimerions discuter l’article ecrit par Y. Gerard du service
de clinique d’orthopedie et traumatologique
de Reims sur l’enclouage percutane des frac
tures diaphysaires des membres. Les principes
ainsi que la technique de l’enclouage a foyers
fermes de la diaphyse femorale nous semblent
tres bien ecrits, d’une precision et d’un appli
que qui font certes preuve d’une experience
clinique en traumatologie des plus excellentes.
Le tout est fait de fagon concise et precise,
montrant a la fois les indications, les contreindications et les dangers d’une telle technique
au cours des diverses phases de la procedure
ainsi que les moyens d’eviter toute complica
tion. Quant aux resultats, nous notons qu’ils
sont comparables a toutes les autres series publiees, soit sur le continent Nord Americain,
soit en Europe, se servant de techniques similaires. Nous remarquons avec satisfaction un
taux d’infection tres minime dans toutes les
series mentionnees, ce qui denote un jugement
clinique et une technique qui est a la hauteur
de la reputation de ce centre. Pour ce qui est
des indications de l’enclouage intra-medullaire
de fagon fermee, nous posons certaines reti
cences lorsqu’il s’agit d’une fracture multifragmentaire ou, selon nous, il n’y a pas pro
duction d’une fixation interne rigide, et dans
certains cas qui, selon notre experience, necessitent une exposition de trait de fracture avec
encerclage du fragment isole, en evitant toutefois une devitalisation exageree des tissus mous.
Cependant il est a noter que les resultats mentionnes sont tres acceptables. Pour ce qui est
des cas particuliers, lorsqu’il s’agit d’une frac
ture poly-fragmentaire, nous favorisons plu
tot un traitement orthopedique pur par ex
tension continue. Selon nous un enclouage
fait par un petit tuteur metallique intra-me
dullaire ne nous semble pas essentiel pour maintenir une angulation adequate des fragments.
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Une immobilisation dans un appareil de Tho
mas, apres avoir mis celui-ci dans une posi
tion adequate dependant du niveau du trait de
fracture et de la deformite qui peut etre prevue a cause de l’attachement musculaire, nous
permet de conserver un alignement adequat
ainsi qu’un raccourcissement minime. Nous
abondons dans le meme sens que l’ecole frangaise au fait qu’une reduction ouverte par
plaque et vis peut produire une devitalisation
exageree de l’os, incitant ainsi a la pseudarthrose et aux incidences septiques, sans toutefois permettre une fixation interne assez rigide
pour rendre le patient immediatement ambu
lant. Nous favorisons plutot, des que la con
solidation est partiellement amorcee apres en
viron 5 ou 6 semaines, l’application d’un platre prothese qui, a la fois, permet de conserver
la mobilite du genou amorcee dans l’appareil
de Thomas et une mise en charge plus rapide
de fagon a augmenter l’osteogenese. Ceci nous
semble un compromis tres acceptable permettant a la fois un bon controle de l’alignement
et de la rotation, une preservation de la motilite du genou et de la cheville, un taux d’in
fection nil, un raccourcissement minime du a
l’amorce deja avancee de la consolidation, un
retour de la fonction beaucoup plus rapide que
le traitement conservateur, et un taux de con
solidation plus rapide par le fait de la mise
en charge.
En ce qui a trait aux fractures ouvertes un
taux d’infection de 6% nous semble prejudiciable au patient. Nous abondons dans le sens
de l’article qui montre un taux de complica
tions septiques comparables pour l’enclouage
secondaire. La methode par plaques vissees
rajoutant la devitalisation des tissus mous aux
traumatismes initiaux nous semble aussi prejudiciable au patient. Comme alternative, nous
suggerons plutot la methode orthopedique pure
par extension continue, pour une periode limitee d’environ 4 a 6 semaines, jusqu’a for
mation d’un cal osseux assez abondant pour
pouvoir placer le patient dans un platre pro
these par la suite.
La discussion sur I’enclouage percutane intra-musculaire du tibia nous semble aborder un
probleme excessivement controverse; bien que
la technique ait ete abondamment discutee,
nous ne favorisons que tres rarement cette
methode vu l’incidence relativement elevee de
pseudarthrose, soit 2.5% dans les cas de frac
tures fermees et 4% dans les cas de fractures
ouvertes, avec un taux d’infection de 8% dans
les fractures ouvertes. Le traitement conser
vateur par la methode du platre de Sarmiento
nous semble une alternative des plus valables
avec une mise en charge presque immediate, un
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taux d’infection nil et des taux de pseudarthrose certainement comparables aux resultats
obtenus dans cette serie.
Pour l’enclouage de l’humerus, nous abondons dans le sens de cet article demontrant
que l’humerus est un os qui se prete beaucoup mieux a un traitement orthopedique
simple. L’osteosynthese cependant est possible
et tres efficace, surtout lorsqu’il s’agit de frac
tures pathologiques, avec un retour de la
fonction des plus adequates.
Nous aimerions souligner en terminant l’article du Theomine qui revoit avec une tres
grande precision les fractures de la main et
leur traitement a la fois conservateur et chirurgical; nous ne pouvons que souscrire avec
enthousiasme a ce magnifique document de
precision, concision et realisme. Notre expe
rience montre aussi le peu d’indication de la
fixation interne par ce systeme de plaques et
vis tel que decrit dans le systeme Suisse.
P. O. N adeau
Chirurgien-orthopediste,
Hopital du Saint-Sacrement,
1050 Chemin Ste-Foy,
Quebec, PQ.
CEREBRAL DURAL SINUSES AND THEIR
TRIBUTARIES. Jefferson Browder and
Harry A. Kaplan. Edited by Robert H.
Wilkins. 120 pp. Illust. Charles C Thomas,
Publisher, Springfield, IL, 1976. Price not
stated.

The authors of this book are highly respected
for their contributions to the understanding of
the vascular system of the brain. This mono
graph, although small in size, is a treatise on
the anatomy of the cerebral venous circula
tion; Browder and Kaplan have provided a
meticulous anatomical description of normal
specimens and their variants. The book is
written in a clear, concise style and is easily
understood.
The book is organized into 12 chapters; each
chapter deals with a different region and
structure within the cerebral venous system.
Old and new anatomical concepts are con
trasted and presented in appropriate places
throughout the text. Chapter 12 is especially
interesting; it deals with recently recognized
tumours of the cerebral dural sinuses and their
possible association with benign increased in
tracranial pressure. The finding of 68 such
lesions gathered from their 950 specimens is
of special interest.
Most of the illustrations are photographs of
vinylite casts taken from selected parts of the
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sinuses and their tributaries; the quality is
excellent. The remaining illustrations are in
the form of schematic drawings; these are
clear but of only average quality.
This book is highly recommended, especially
for neurosurgeons; it will also be of value to
residents, medical students and practising
physicians in all of the neurologic specialties.
E. V entureyra

Department of surgery,
Children’s Hospital of Eastern Ontario,
Ottawa, Ont.
COUPES SERIEES DU CORPS HUMAIN.
Anatomie-radiologie-Scanner. G. Guerinel,
L. Chevrot et M. Mattel. 287 pp. Illust.
Masson, Paris, 1977. $108.90. ISBN 2-22546464-2.

11 s’agit d’un atlas presentant les dessins de
coupes seriees du corps humain obtenues par
serigraphie (“scanner”) et comparees avec la
realite anatomique controlee sur cadavre. Voici
un magnifique volume cree tout specialement
pour les radiologistes de pointe et pour les
medecins interesses a ce nouveau moyen d’investigation. Dans une premiere partie les au
teurs font une etude theorique de la tomodensitometrie (TDM), (computed tomography, CT)
depuis la prise de I’image jusqu’a sa concretisation par l’ordinateur, en exposant quelque
peu les indications de la technique; dans la
seconde partie de l’ouvrage ils cofnparent en
couleur et en noir et blanc l’image des coupes
obtenues par TDM et la realite anatomique
de la tete, du tronc et des membres.
L’illustration est excellente et la nomencla
ture est en fran?ais et selon l’appellation internationale.
Ce serait le premier volume frangais du
genre, ce qui temoigne de la clairvoyance de
ses auteurs.
Bien que le livre soit destine a une clientele
de radiologistes, il apporte aux anatomistes une
dimension de variabilite individuelle associee a
une precision mathematique.
G. M arceau

Faculte de medecine,
Universite Laval,
Quebec, PQ.
CLOT. James J. Tullis. 572 pp. Illust. Charles
C Thomas, Publisher, Springfield, IL, 1976.
$39.50.

The subject of blood coagulation is reputedly
difficult and contentious. The obfuscation in
some of the current books and review articles
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on the subject has unfortunately helped to DIRECTIVES AUX CONTR1BUANTS
promote this viewpoint.
This book is well produced; it is of modest Toute communication initiale doit etre adressize and contains excellent, current references. see aux Coredacteurs, CP 8650, Ottawa, Ont.
Apart from two chapters, the book is written K1G 0G8 sous la mention: “Le journal canadien de chirurgie”.
by one author.
The first section deals with the physiology
and biochemistry of coagulation; subsequent Manuscrits. Les texts originaux des articles
sections deal with defects of clotting and et des autres communications y compris un
nombre limite de rapports sur des cas spehemostasis and the clinical implications of ciaux
etre rediges en double exemsuch defects. The author properly gives equal plaire, doivent
en
frangais
ou anglais, et accompagnes
emphasis to bleeding disorders and conditions d’une lettre demandant
leur publication dans
associated with hypercoagulability; too fre le Journal. Veuillez les dactylographier
une
quently, in other books, this information is seule face d’une feuille normal avec sur
double
fragmented. He has wisely included only interligne et grandes marges.
limited details of specific technical procedures. Illustrations. Les illustrations telles que des
The controversial areas of theory and practice photographies
cliniques, des rain coagulation have been presented in a bal diographies, desd’appareils
photomicrographies, des graanced manner.
et des digrammes doivent etre fourThroughout the book the reader is left with phiques
nies
sous
la forme d’epreuves sur papier glace
the impression that the author is fully aware sans montage,
les bordures intactes, d’un format
of his subject; he has not merely garnered the ne depassant pas 12 x 17 cm. Chaque illustra
impressions of other workers. The author’s tion doit etre munie d’une legende dactylostated intent was to bridge the gap between graphiee sur une page separee du texte de
research and practice; he has achieved his l’article. S’il s’agit d’une photomicrographie,
le contraste et l’echelle de l’agrangoal. This book will be useful to residents and expliquez
dissement.
lettres qui servent a identifier
specialists in either laboratory or clinical medi les elementsLes
illustration doivent etre d’u
cine. The reading will bring profit and pleasure ne dimensiond’une
suffisante
afin de demeurer visi
to those who choose to look into it.
bles lorsque les necessites de l’impression imposent une reduction de l’image fournie. II
T. G. J ones
ne faut pas qu’on puisse identifier un patient
grace a une illustration a moins qu’il n’y ait
Department of laboratory medicine,
expressement consenti par ecrit; faute de per
Ottawa Civic Hospital,
mission
les- traits de sa physionomie doivent
Ottawa, Ont.
etre obliteres. Les illustrations en couleur ne
seront publiees qu’aux frais de leur auteur.
ENDOCRINE SURGERY. A HANDBOOK Si l’illustration provient d’une autre source que
OF OPERATIVE SURGERY. Edward Pa- celle de l’auteur, il convient d’obtenir tant de
que de l’editeur de l’ouvrage dont elle
loyan and A. M. Lawrence. 269 pp. Illust. l’auteur
est tiree, l’autorisation de s’en servir aux fins
Year Book Medical Publishers, Inc., Chica de
la publication.
go, 1976. Price not stated.
II faut en les etablissant se conformer
The busy surgeon is in need of a short author Tables.
au
format
rectangulaire du Journal et les
itative account of endocrine surgery. The ob rediger sur des
jective of the authors, an endocrine surgeon table par feuille.feuilles separees du texte, une
and a medical endocrinologist, was to meet this
References. Celles-ci doivent etre citees dans
need; they have succeeded.
au moyen d’un chiffre et groupees
The book covers the subjects of parathyroid, le texte
l’ordre a la fin de votre article en vous
thyroid, pancreatic and adrenal gland surgery. dans
a la maniere de faire adoptee par
The current state of the art in each field is conformant
ce
Journal.
references a des periodiques
clearly and dogmatically presented by two doivent etreLesconformes
a celles qu’adopte
workers who are actively engaged in the field. Vlndex Medicus.
In each section the embryology, anatomy and Un resume qui ne doit pas depasser 125 mots
physiology are described; this is followed by a doit accompagner chaque article sur une page
discussion of the pathology associated with separee.
specific clinical syndromes, and their medical
and surgical treatment. There are many clear
line drawings illustrating anatomical points A titre d’approbation, un exemplaire du maredige sera envoye aux auteurs mais
and details of surgical procedures. The careful nuscrit
non
les
epreuves.
arrangement of the text and illustrations, the
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clear print and the convenient size of the book,
make it a pleasure to read. In addition, specific
topics are easily found.
There are no references in the book and only
a brief summary of controversial points is in
cluded. Nevertheless, considering the overall
economy of words, the text is surprisingly
complete.
Few surgeons have a sufficient volume of
endocrine surgery to restrict themselves to this
subspecialty. General surgeons who, from time
to time, are confronted with these problems,
will find this book a source of much useful
information.
H. T. G. W illiam s
Professor and chairman,
Department of surgery,
University of Alberta,
Edmonton, Alta.
HISTOPATHOLOGIE O.R.L. ET CERVICOFACIALE. F. Leroux-Robert et J. de Brux.
390 pp. Illust. Masson, Paris, 1976. $50.71.
ISBN 2-225-45793-X.

Dans l’avant-propos, les auteurs attirent l’attention sur l’importance de la clinique dans l’interpretation histopathologique d’une lesion. II
s’ensuit que chaque pathologie est accompagnee d’une partie clinique, dans laquelle nous
trouvons frequemment un rappel embryologique; puis, l’histopathologie nous est expliquee.
Les pathologies les plus courantes et, quelques
fois meme les plus rares, y sont discutees et
illustrees de photos histologiques. Comme les
auteurs le mentionnent, les references les plus
importantes y sont rapportees; leur choix dans
l’ensemble m’apparait juste.
Les discussions cliniques sont interessantes
pour l’anatomopathologiste, mais la pathologie
y est souvent trop courte; il est probable aussi
que le chirurgien prefererait y trouver plus de
details cliniques. Les microphotographies a
petit grossissement sont de mauvaise qualite;
la majeure partie des photos sont cependant a
moyen et fort grossissement et de bonne qua
lite. II n’existe pas suffisamment de macropho
tographies ou de photographies cliniques; le
detail clinique ayant sa place dans le livre, il
me semble que certaines microphotographies
auraient dues etre sacrifices.
Dans l’ensemble, il s’agit d’un livre honnete
et agreable a lire; le tout resulte probablement
d’un habile dosage de clinique d’histopathologie. Le livre se veut l’experience de deux
pcrsonnes et les discussions apparaissent done
plus comme le resultat de l’experience que
comme une revue de la litterature. Le livre
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nous apparalt surtout oriente vers le clinicien
qui aimerait revoir son histopathologie.
G . P . D io n n e

Pathologiste,
National Defence Medical Centre,
Ottawa, Ont.
LE TRAITEMENT DES METASTASES OSSEUSES. Rapport Presente au 78e Congres
Frangais de Chirurgie. Edited by J. Duparc
and J. Decoulx. 274 pp. Illust. Masson, Pa
ris, 1976. Price not stated, paperbonnd. IS
BN 2-225-45529-5.

Most publications on cancer deal with the treat
ment of primary malignant neoplasms. But the
management of patients with metastases re
mains the most common problem facing the
practising physician. Bone metastases are dis
abling; they are the source of the most severe
pain, they compromise integrity of the skeletal
system resulting in serious loss of function
and are often responsible for neurologic com
plications that arise when vertebral metastases
impinge on the cord.
This book is oriented to surgeons. It sup
ports and emphasizes the need for a more posi
tive and enterprising approach to the treatment
of bone metastases since far too often a pessi
mistic attitude prevails in relation to the sur
gical treatment of such metastases. One impor
tant chapter deals with vertebral metastases;
both operative and nonoperative management
are discussed, for the most part from the sur
geon’s viewpoint.
The first few chapters deal with oncologic
generalities as they relate to bone involvement.
Diagnosis and nonsurgical treatment are well
summarized and presented in an informative
but not exhaustive manner. The most important
part of the book describes the different forms
of surgical treatment with details on the new
advances of cement fixation and prosthetic re
placements. It is interesting to read about the
attempt to standardize prosthetic hardware re
placements. In this type of surgery many dif
ferent types and sizes of prostheses are neces
sary. Often they must be custom made and it
is unrealistic to expect most general hospitals
to store them.
The authors describe the various surgical
techniques required to deal with bone meta
stases in various locations. The reader is re
ferred to an excellent bibliography for accu
rate details of the technique. The authors have
summarized the clinical results from several
centres and the advice in every chapter is
substantiated in this way.
This book is an excellent reminder that in
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medicine, it is as important to improve the
quality of life as to prolong it.
A. T rias
Department of orthopedic surgery,
University of Sherbrooke,
Sherbrooke, PQ.
LA HANCHE EN CROISSANCE. Jean Ga
briel Pous, Alain Dimeglio, Jose Adrey and
others. 216 pp. Illust. J. B. Bailliere, Paris,
1976. $30.00. ISBN 2-7008-0009-5.

“The growing hip” is a basic textbook on or
thopedic problems of the hip in children; it is
designed for specialists including the ortho
pedic surgeon, pediatrician, physiatrist and
physiotherapist who are confronted with these
problems.
After a short introduction, the growth of the
hip is described from its embryology to com
plete maturation. In the following sections the
authors describe congenital, developmental and
traumatic conditions. The final chapter illus
trates surgical techniques currently employed
in the management of orthopedic problems in
children.
This book fulfils its aim as an excellent
teaching text. The problems are discussed
clearly and completely; the discussion is up to
date. The authors include most current tech
niques and methods — not only ones they
favour. Chapters are well introduced; impor
tant points are emphasized in heavier print,
in order to draw the attention of the reader.
Sketches and radiographs are plentiful and are
of excellent quality.
This book is an important contribution to
the field of disorders in the growing hip; it
is highly recommended to those working in
this area.
R. G allien

La Clinique de Chirurgie Orthopedique
du Qu6bec,
220 est, Grande-Allee,
Quebec, PQ.
LA MALADIE DE CROHN RECTO-COLIQUE. M. Julien et J. Vignal. 141 pp. Illust.
Masson, Paris, 1976. $12.83, broche. ISBN
2-225-45210-5.

Cette monographie est une etude anatomoclinique retrospective de 192 dossiers de malades presentant une maladie de Crohn rectocolique, traites dans differents hopitaux frangais. Les diagnostics histologiques et topographiques ont tous ete verifies. Le traitement
de tous ces malades fut chirurgical. Les dif-
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ferentes donnees furent analysees sur ordinateur.
Les grands chapitres comportent une etude
pathologique, epidemiologique, clinique radiologique, endoscopique, therapeutique et pronostique de la maladie. Les complications,
particulierement les complications ano-rectales
et le diagnostic differentiel font l’objet de cha
pitres particuliers. Toutes les donnees ainsi
recueillies sont comparees a celles de grandes
series publiees dans la litterature anglo-saxonne
et scandinave. La bibliographic est d’ailleurs
tres abondante. Certains points particuliers
demandent quelques remarques. Les auteurs
affirment la place preponderante de la pathologie dans le diagnostic. Ils ne se prononcent
pas sur l’existence de colites granulomateuses
differentes de la maladie de Crohn et de la
colite ulcereuse. L ’examen macroscopique peroperatoire aurait plus de valeur que l’histologie
des tranches de section pour determiner
l’extension de la resection. Les auteurs preconisent la conservation du rectum le plus pos
sible. Leurs resultats therapeutiques apres chi
rurgie sont difficilement comparables, a cause
du jeu de recul. Finalement, ils insistent, avec
raison sur la valeur de l’hyperalimentation
parenterale comme nouvelle therapie adjuvante.
Le volume comporte de plus, de bonnes
reproductions de cliches radiologiques, des
photos de pieces pathologiques et histologi
ques et de nombreux tableaux. II s’agit done
d’un resume des travaux presentes au 78e
congres frangais de chirurgie. Ces resumes sont
plus complets que ceux que l’on publie avant
les congres des associations nord-americaines.
Cependant, l’ouvrage n’a de valeur que comme
etude prealable a 1’assistance a ce congres.
R. C ote
Hopital du St. Sacrement,
1050 Chemin Ste-Foy,
Quebec, PQ.
THE IMMUNOLOGY OF MALIGNANT
DISEASE. 2nd ed. Jules E. Harris and Jo
seph G. Sinkovics. 606 pp. Illust. The C. Y.
Mosby Company, Saint Louis, 1976. $45.90.

This book fulfils two roles: first, it presents a
comprehensive review of the latest advances in
the area of immuno-oncology and second, it
provides an excellent source (more than 5600)
of pertinent references. The complex subject
matter is dealt with in depth, but it is clearly
presented. The book is not concise and is not
recommended for bedtime reading. It demands
the reader’s complete attention. But it is an
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excellent reference textbook and, as such,
should have broad appeal.
The book is divided into five chapters; each
leads logically to the next. The first chapter is
devoted to a review of the current state of hu
moral and cellular immunology and the role
that T and B cells play in the regulation, mod
ulation, suppression and enhancement of the
humoral and cell-mediated immune responses.
I imagine that the authors felt compelled to in
troduce the reader to the entire breadth of im
munology before leading him or her into the
more forbidding and less understood areas of
clinical and immuno-oncology. Although to
day it is not possible to cover the whole field
of immunology in a single chapter, the authors
have, with some success, attempted to do this.
An immunologist would have no trouble fol
lowing the sequence of topics and train of
thought developed in this chapter. However,
nonimmunologists may find it rather heavy
reading.
Chapter 2 deals at length with the immuno
logy and tumours in experimental animals. The
data are presented in great detail and the casual
reader may at times feel lost. Certain basic
concepts, such as immunologic surveillance,
are discussed here and in several other chap
ters. It would seem reasonable to repeat im
portant concepts as they apply to a variety of
topics.
Chapters 3 and 4 deal with the immune de
ficiency states associated with malignant dis
eases and the methods used to suppress the
immune response. The immune states are dis
cussed in great depth. Special emphasis is
placed on the subjects of Hodgkin’s disease,
the leukemias and multiple myeloma. Parts of
chapter 4 deal with the chemical suppression
of the immune response in patients undergoing
organ transplantation and the immunosup
pressive therapy for autoimmune diseases; these
subjects might, at first glance, appear to be
out of place in this book. However, several of
the chemotherapeutic drugs used in the treat
ment of allografted patients and patients with
autoimmune diseases are identical to those
used in patients with malignant disease. I sus
pect that these subjects were included to em
phasize this fact.
The fifth and final chapter of the book con
sists of a systematic presentation of the various
human malignant diseases, their etiology, patho
genesis and clinical picture and the role of
immunotherapy in modifying the natural
course of these diseases.
I have two minor reservations about this
book. First, the authors have not included
enough of their own subjective but expert
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analysis of the data and second, the bibliogra
phies appended to each chapter, while com
prehensive, are too long. The majority of read
ers who are less familiar with the field would
appreciate a short list of important references
at the end of each chapter.
In summary, Harris and Sinkovics have tried
to condense all of contemporary immunology
and present it in a form comprehensible to
clinical oncologists. They have included in their
discussions the role of viruses in oncogenesis
and the evidence in favour of immunotherapy
as a form of treatment. This book should be on
the highly recommended reading lists of all
clinical oncologists and basic scientists work
ing in the field. Unfortunately the price of this
book may deter medical students and residents
from purchasing it; the prevailing attitude is
that the half-life of any medical textbook is
shorter than the time required to read it.
The reader should not expect to wade
through this book in short order. However,
the rewards in terms of information gleaned
from it are directly related to the effort put
into reading it. I believe that the book will
serve as a primary standard reference book for
a good number of years.
M. R ichter
Department of pathology,
Ottawa Civic Hospital,
Ottawa, Ont.
MOTOR DISORDERS OF THE ESOPHA
GUS. Robert D. Henderson and John O.
Godden. 231 pp. Illust. The Williams & Wil
kins Company, Baltimore; Burns and MacEachern Limited, Don Mills, Ont., 1976.
$24.75. ISBN 0-683-03947-4.

With the development of modern manometric
techniques much new information on normal
and abnormal esophageal function has accu
mulated in the medical literature. This mono
graph is a timely presentation of this knowledge
and its application to clinical practice. After a
brief review of the structure and function of
the esophagus, the authors describe the ap
proach to investigation and management of
common motor disorders.
The presentation is well balanced including
sections on hiatus hernia and achalasia that
take up more than half the text. The informa
tion is well classified and is easily read. Case
histories are used frequently to illustrate im
portant points and a large number of goodquality radiographs and sketches are used to
correlate structure and function. Although
much of the material is from Henderson’s own
data (both published and unpublished), an ade-
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quate review of the literature and an accom
panying bibliography are presented with each
chapter. On the various controversial issues
Henderson clearly states his personal prefer
ences.
There are some minor criticisms. In attempt
ing to develop an orderly concept of patho
physiology the issues have sometimes been
oversimplified. In chapter 2, for example, sec
ondary and tertiary peristaltic activity of the
normal variety is confused with that associated
with disordered motor activity. Cinefluorography, generally regarded as an important diag
nostic tool, is mentioned only briefly. Undue
emphasis is placed on the role of the abdominal
segment of esophagus in preventing reflux. The
authors believe that a long intra-abdominal
tube prevents reflux in the absence of a lower
esophageal sphincter; this view is contradicted
by the available data and is certainly not shared
by workers in the field.
On the whole, in attempting to describe a
rational approach to the investigation and
management of esophageal problems, the auth
ors have achieved their objective. Anyone in
terested in esophageal disease will find the
book both interesting and useful.
T. A. K han
Assistant professor of surgery,
University of Manitoba,
Winnipeg, Man.

CRITIQUE OF ITEM 609 (SESAP II)
The roentgenogram is typical of osteogenic
sarcoma. There has been a great effort to
improve the survival rate of patients with
osteogenic sarcoma by using various forms
of irradiation and chemotherapy alone or
in combination with a variety of surgical
procedures. No such methods or combina
tion of methods have proven to be as suc
cessful as radical surgical ablation, such as,
in this case, hip disarticulation in order to
remove the entire femur. Hemipelvectomy
offers no advantage over hip disarticulation
but does add significantly to operative risk
and complications. pB]
Reference

6 0 9 /1 . Friedman MA, Carter SK; The the
rapy of osteogenic sarcoma: Current status
and thoughts for the future. J Surg Oncol
4:482-510, 1972.
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OUTLINE OF ORTHOPAEDICS. 8th ed.
John Crawford Adams. 472 pp. Illust.
Churchill Livingstone, Edinburgh; Longman
Canada Limited, Don Mills, 1976. $13.50,
paperbound. ISBN 0-443-01167-2.

This book is a classic in the field of medical
summaries. It is another text in the tradition
set by Bailey’s “Short Practice of Surgery”
that so many of us relied on in the anxious
days before the final examinations. Unfortu
nately the subject of fractures is not included,
but a companion volume by the same author
entitled “Outline of Fractures” is available.
The subject of orthopedics is developed from
a historical introduction. The language is clear
but not clipped; it is interesting but brief.
Simple diagrams are used to explain the patho
genesis of conditions such as osteomyelitis.
Diagrammatic presentations, line drawings and
radiographs are used effectively to explain,
in a step-wise fashion, subjects that other
wise would be complicated for the novice.
Normal and abnormal radiographs are pub
lished side by side to illustrate the lesion under
consideration. Subheadings are in bold type
and less important information is presented
in small print. References and the bibliogra
phy are appropriately left to the end of the
book.
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This text is accurate, clear and to the point.
It will continue to be of special value to the
medical student and to those who are un
familiar with the field of orthopedics.
E. M. Cooperman
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